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§1 colorectal cancer: ePidemiology and 
Prognostic factors
Colorectal cancer is the second most common malignancy in women and the third 
most common in men. In the Netherlands, approximately 10,000 people are diagnosed 
for colorectal cancer each year and about 30% of these tumors originated from the 
rectum (www.IKCnet.nl). In the Western world, the incidence of colorectal cancer is 
increasing due to changes in lifestyle. The incidence of both colon and rectal cancer is 
higher in men than in women 1,2. Food intake rich in meat and fat and low in fiber is an 
important risk factor for the development of colorectal cancer. In addition, decreased 
physical activity, smoking and high alcohol consumption play an important role in the 
epidemiology of this disease 3,4. The connection between lifestyle and colorectal cancer 
epidemiology is clearly illustrated by the increased incidence of this malignancy in Third 
World countries adopting the Western lifestyle. 
About 4,000 patients die of colorectal cancer per year in the Netherlands (www.
IKCnet.nl). The 5-years overall survival is approximately 50-60%. Factors prognostic 
for outcome after treatment of colorectal cancer can be roughly divided in tumor-and 
treatment-related factors. Some tumors are more aggressive than others; this is, at least 
partly reflected in tumor stage, type and differentiation grade as well as in molecular 
features (paragraph 2 and 3). However, treatment is one of the most important factors 
for prognosis. With the right treatment, even aggressive tumors can sometimes have 
an excellent prognosis. On the other hand, if small, potentially harmless tumors are not 
adequately treated their prognosis can become terrible poor (paragraph 4).  
§2 Pathology of colorectal cancer 
Pathologically, tumors can be characterized by stage, type and grade. Staging of 
colorectal tumors has a long history and is still based on the system devised by Cuthbert 
Dukes in the 1930’s. He described the 2 main components; invasion depth and nodal 
status. In later years, the distant metastases were added as a third component and 
this formed the basis of the current tumor, node, metastasis (TNM) systems of the 
international union against cancer (uicc) 5. Combinations of these three components 
are grouped in 4 stage categories, having each a different prognosis. The TNM system 
is one of the most classic tumor-related prognostic factors (Figure 1).
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Figure 1: Representative survival curves for each TNM stage (I-IV) illustrating the differences in cumulative 
relative survival (CRS) between the different stages of colorectal cancer. The CRS rates of each stage 
of colorectal cancer were kindly provided by the Comprehensive Cancer Centre South, Eindhoven, the 
Netherlands and were calculated for the period 1995-2004.
In addition to the TNM stage, patients’ prognosis might also depend on the tumor 
type. There are several histological tumor types with different prognoses. The majority 
of colorectal carcinomas (approximately 90%), are classified as adenocarcinomas. 
The remaining 10% are mucinous carcinomas. Furthermore, there are some very 
rare epithelial tumor types (less than 1%) such as signet ring cell carcinomas, 
adenosquamous carcinomas and undifferentiated carcinomas. According to the World 
Health Organization (WHO) guidelines a tumor is classified as mucinous when the 
proportion of the mucinous component is ≥ 50%. This mucinous component usually 
consists of mucinous lakes that either contain tumor cells or are sterile. Sometimes, 
mucinous carcinomas with signet ring cell dedifferentiation can be observed. These 
signet ring cells contain intracellular mucin that pushes the nucleus to the cell 
membrane, thus resembling a signet ring. A carcinoma containing signet ring cells 
not arising from dedifferentiation of a mucinous carcinoma is called a de novo signet 
ring cell carcinoma and can be recognized by the absence of mucinous lakes 6. The 
prognosis of an adenocarcinoma, mucinous and signet ring cell carcinoma, with 
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similar tumor stages, ranges from good to poor respectively 7-9. A third important 
tumor-related prognostic factor is tumor grade. Tumor grade is traditionally classified 
as undifferentiated, poorly, moderately or well differentiated according to the WHO 
guidelines. The classification of the tumor grade is based on the percentage of gland 
formation. Poorly or undifferentiated tumors have a poorer prognosis than moderately 
or well differentiated tumors. Dedifferentiation of tumor cells at the invasive front, also 
referred to as tumor sprouting or budding 10,11 is associated with increased tumor spread 
and poor prognosis 12,13. On a molecular level, tumor budding is accompanied by loss of 
adhesion molecules and an increased expression of metalloproteinases 14,15.
§3 genetic Background of colorectal cancer
Carcinogenesis of colorectal cancer is a very complex mechanism that is largely 
influenced by the genetic background. In general, the development of sporadic 
colorectal cancer is traditionally described by two different pathways; the gatekeeper 
and the caretaker pathway (Figure 2). 
Figure 2: The two most common pathways involved in tumor development with their sporadic and most 
common hereditary variants. The flagged arrows indicate the accelerated process of carcinogenesis in 
the hereditary variants. HNPCC: Hereditary Non-Polyposis Colorectal Cancer, FAP: Familial Adenomatous 
Polyposis.
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Ninety to ninety-five percent of cancers arising in the colon or rectum have no defined 
hereditary basis and are called sporadic tumors. Approximately 85% of these tumors 
have been developed trough the gatekeeper pathway (white filled arrows, Figure 2). 
This pathway is initiated by mutations in the gatekeeper gene adenoma polyposis coli 
(APC), located on the long arm of chromosome 5 16. APC is a tumor suppressor gene 
and the most important function of the APC protein is to control the Wnt signal 
transduction pathway 17,18. In addition, this protein has also been described to interfere 
with the microtubule formation causing increased mitotic abnormalities 19,20 explaining 
that carcinogenesis via the gatekeeper pathway often results in aneuploid tumors. 
Chromosomal deletions (loss of heterozygosity), amplifications and translocations are 
frequently observed. This chromosomal instability regularly affects the Kirsten-RAS 
(K-RAS) 21 oncogene and the tumor suppressor genes mothers against decapentaplegic 
homolog 4 (Drosophila) (SMAD- 4) 22 and p-53 21,23.
The second pathway of cancer development is primarily initiated by mutations in the 
mismatch repair genes (MMR genes) and is also referred to as the caretaker pathway. 
About 15% of sporadic tumors arise due to disfunctioning of caretaker genes. Examples 
of these genes are human MutL homologue 1 (hMLH1), human MutS homologue 2 (hMSH2), 
human MutS homologue 6 (hMSH6) and human post-meiotic segregation ( hPMS2). 
Normally, the MMR proteins repair errors of 1 to 3 base mismatches that occurred 
during DNA replication 24. However, mutated or epigenetically changed caretaker genes 
will result in genetic instability leading to an increased rate of carcinogenesis (black 
filled arrows, Figure 2). Short tademly repeated DNA sequences are very susceptible to 
errors in replication 24. Increased hypermutatability (due to stand slippage) of markers 
with these short tandem repeats, also referred to as micro satellite instability (MSI), 
reveals the presence of genetic instability caused by disfunctioning caretaker genes. 
Examples of hypermutated functional genes, involved in cell growth and survival that 
also contain these tandemly repeat sequences are type II transforming growth factor-beta 
receptor (TGFβRII), Bax and Caspase-5 25-27. The inactivating mutations in these genes 
have an important impact on carcinogenesis. In contrast to the gatekeeper pathway, 
tumors with deficient caretaker genes are generally diploid with no significant gross 
chromosomal changes but subtle sequence alternations. In addition, aberrant gene 
silencing by means of methylation (e.g. methylation of the MLH1 gene) is commonly 
observed in tumors that have developed following the caretaker pathway 28,29. A 
poor differentiation grade, extensive infiltration of lymphocytes and the presence of 
extracellular mucin are morphological characteristics that can be appreciated in tumors 
exhibiting MSI 30,31.
Only 5-10%, of colorectal cancers arise due to underlying germline mutations. In the 
case of an inherited mutation, the process of carconigenesis will occur at an increased 
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rate (Figure 2) because only one mutation, in the normal allele, is required for loss 
of function, as described by the two-hit theory 32. Hereditary variants of both the 
gatekeeper and caretaker pathways can be found. Patients with familial adenomatous 
polyposis (FAP) have a germline mutation in the gatekeeper gene APC. Hereditary 
non-polyposis colorectal cancer (HNPCC, or Lynch syndrome) is caused by germline 
mutations in one of the caretaker genes mlh-1, msh-2, msh-6 or pms-2.
Recent studies have shown that these different pathways of carcinogenesis not only 
result in different tumors with genetic profiles but also affect prognosis. For example, 
patients with MSI tumors have a more favorable prognosis but are less likely to benefit 
from chemotherapy 33-35. However, investigations on the gatekeeper pathway have 
shown that this type of carcinogenesis seems to have less prognostic potential.
§4 treatment of colorectal cancer
§4.1 surgery
Surgery is the mainstay of treatment for both colon and rectal cancer. The surgical 
approach of colon cancer is aimed not only on achieving wide margins of resection (a 
proximal and distal margin of at least 5 cm) but also on harvesting regional lymph nodes 
located in the mesocolon. If a tumor is located in the cecum, ascending colon, hepatic 
flexure or the transverse colon, a right hemicoloctomy, including a dissection of the 
mesenteric lymph nodes, will be performed. Tumors located in the splenic flexure or the 
descending colon are treated with a left hemicolectomy. Tumors in the sigmoid colon 
are operated on with a segmental (low anterior) resection. Colon cancer can be treated 
with open surgery but can also be safely treated laparoscopically 36,37. Laparoscopic 
surgery of rectal carcinoma is under investigation and is currently not routinely applied 
in clinical practice but is still in the experimental phase.
The rectum requires a different surgical approach than the colon because of the 
anatomy and location in the pelvic area, beneath the peritoneal reflection. Traditionally, 
this kind of surgery was difficult to perform and, as such, resulted in a large number of 
local recurrences. A major step forward with respect to surgery of rectal cancer is the 
introduction of the total mesorectal excision (TME) surgical technique. This technique 
was described by Heald in 1986 and aims to remove as much mesorectal fat as possible 
by sharp dissection following the mesorectal fascia (the “holy” plane, Figure 3) 38. The 
introduction of TME surgery resulted in a decrease in local recurrence rates of 40/50% to 
<10% because more tumors could be completely excised by this technique 39-41. Tumor 
location determines whether a low anterior resection (LAR) or an abdominoperineal 
resection (APR) should be performed (Table 1). A LAR is performed in case of middle 
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and upper rectal cancer in which the tumor is located 5-15 cm from the anal verge. If the 
tumor is located more distally (0-5 cm from the anal verge), an APR will be required, 
amputating the anal sphincter and forming a permanent colostomy. Traditionally, 
many rectal cancers were treated with an APR resection, however, improved imaging 
techniques and surgical expertise enabled successful local, sphincter saving excisions 
using the LAR surgical approach. In addition to retention of the anal sphincter, local 
recurrence rates are lower and survival rates are higher after a LAR procedure compared 
to patients who underwent APR 42,43. In case of small (T1, N0) superficially growing, well 
or moderately differentiated rectal tumors, TME surgery is not required. Instead, the 
tumor can be dissected by transanal endoscopic microsurgery (TEM) (Table 1). 
A very important treatment-related factor in rectal cancer related to surgery is the 
circumferential margin (CRM). The CRM is the shortest distance (in mm) between the 
circumferential resection plane and the tumor (Figure 3). The circumferential margin 
is assessed microscopically. A specimen with tumor ≤ 1 mm from the inked margin is 
considered as having a positive CRM. The value of CRM assessment in rectal cancer 
was first demonstrated by Quirke et al in 1986 44 and has been confirmed by numerous 
other studies over time. The colon is for the most part surrounded by the serosa, 
which is less easily penetrated by tumor cells than the mesorectal fat. The anatomy 
of the colon is such that a circumferential margin is generally not present but surgical 
resection planes of the cecum, descending colon and ascending colon can be quite large 
compared to other parts of the colon. The prognostic implications of retroperitoneal 
surgical resection margin (RSRM) involvement of colon segments that are partially 
fused to the peritoneum are limitedly studied. However, Scott et al demonstrated that 
RSRM involvement was present in 19 of 228 right hemicolectomies and was correlated 
with advanced tumor stage and a high incidence of synchronous and metachronous 
distant metastasis 45. In conclusion, circumferential margin involvement is a well 
established treatment-related factor with profound prognostic value in rectal cancer 
but the prognostic implications of RSRM involvement in colon cancer is currently under 
investigation and is not well established (yet). 
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Figure 3: Schematic drawings of a sagittal 
section (A) and transversal section (B) through 
the rectum, illustrating the “holy” plane (dotted 
lines). A: the white line indicated the level of the 
transversal section depicted in panel B. B: the 
boxed area indicates region for circumferential 
margin assessment. Abbreviations: D: dorsal, 
V: ventral  T: tumor.
§4.2 (neo)adjuvant therapy
Traditionally, adjuvant therapy was applied to selected cases of colorectal cancer after 
surgery. Chemotherapy has some effect on colon cancer, but the effects on rectal cancer 
were long in doubt. Currently, colon cancer patients are eligible for postoperative 5-
fluorouracil (5-FU) based chemotherapy if positive lymph nodes (stage III) are found 
in the resection specimen (Table 1). But in the case of high-risk stage II colon (T4, poor 
differentiation grade, perforation, obstruction, angioinvasion and/or less than 10 lymph 
nodes investigated) adjuvant chemotherapy should be under serious consideration 
(www.oncoline.nl).  
Radiotherapy is only possible in rectal cancer. Trials in Sweden in the 1990s have 
General introduction
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demonstrated that the use of short-term neoadjuvant radiotherapy causes improved 
local control and survival 46 and is more effective than postoperative radiotherapy 47. 
The beneficial effects on patients prognosis by preventing local recurrence is a major 
advantage of preoperative radiotherapy. In addition, preoperative radiotherapy has 
been shown to be more effective than postoperative radiotherapy with a similar dose, 
which could be explained by the fact that well-oxygenated cells are more sensitive to 
radiotherapy than hypoxic cells 48.
Another major advantage of neoadjuvant treatment is the achievement of tumor 
down-staging, facilitating the resection of advanced rectal tumors. Down-staging is 
dependent on fraction sized and the total irradiation dose applied. These two factors 
largely determine the overall treatment time (time between start of irradiation and 
surgery). The overall treatment time of short-term radiotherapy (approximately 10 days) 
is too short to achieve down-staging since the overall treatment time to achieve this 
should be at least 4 weeks 49,50. Therefore, optimal neoadjuvant treatment of advanced 
rectal cancer consists of long-term radiotherapy with or without chemotherapy.
Patient prognosis can be improved and over-treatment can be reduced if patients are 
selected for the appropriate neoadjuvant or adjuvant treatment. Rectal cancer can 
roughly be divided in three categories with each a different treatment strategy; small 
well differentiated tumors, mobile tumors (T1-T3) and locally advanced rectal cancer 
(LARC). 
However, the term LARC is not clearly defined. Definitions range from patients who 
received long-term neoadjuvant radiotherapy (RT) or radiochemotherapy (RCT), to 
patients with positive lymph nodes, advanced cT3 or cT4 or patients with a threatened 
or invaded CRM. The population of patients with LARC described in the present thesis 
is defined as patients with a rectal carcinoma with an invaded or threatened CRM (a 
predicted CRM of less than 2 mm on MRI). A clear definition of LARC and application 
of the proper therapy regimen is crucial since it improves the outcome of this specific 
patient population.
Small (T1, N0) superficially growing, well or moderately differentiated rectal tumors 
only require limited surgery. However, if after inspection of the TEM specimen the 
margins appear to be involved or lymphangio or vascular invasion is detected, patients 
will nevertheless receive short-term radiotherapy followed by TME surgery (www.
oncoline.nl).  Mobile (T1-T3, N0/N+) rectal tumors receive short-term preoperative 
radiotherapy (5X5 Gray) followed by surgery within 5 days after completion of 
radiotherapy. This therapy became the standard regimen in the Netherlands after the 
Dutch TME trial which demonstrated that the addition of preoperative radiotherapy to 
standardized TME surgery could decrease local recurrence rates from 8.2% to 2.4% 51. In 
20
case of tumor fixation (non-mobile tumors), short-term radiotherapy followed by TME 
surgery is not sufficient. This subpopulation of rectal tumors, also referred to as locally 
advanced rectal cancer (LARC), require extensive preoperative radiochemotherapy 
(RCT) consisting of long-term radiotherapy (45-50 Gy in fractions of 1.8-2 Gy) combined 
with 5-FU based chemotherapy (Table 1). The aim of this more aggressive regimen is to 
increase local control. 
TABLE 1. OVERVIEW OF THE CURRENT TREATMENT GUIDELINES FOR 
COLORECTAL CANCER IN THE NETHERLANDS
Tumor 
type
Tumor stage Tumor 
location
Surgical 
approach
(Neo)adjuvant therapy
co
lo
n Stage I/II na Open or 
laproscopic
none
Stage III or high risk 
stage II*
na adjuvant 5-FU) based chemotherapy
re
ct
um
T1/N0 well to moderately 
differentiated, absence 
of lympangio or vascular 
invasion
na TEM none
Mobile: T1/T3, N0/N+
0-5 cm from 
anal verge
APR Neoadjuvant short term RT (5X5 Gy)
5-15 cm from 
anal verge
LAR
Advanced, fixed rectum 
tumors (T4, N0/N+)
LAR, APR, 
ASR or PE
Neoadjuvant long term RCT (45-50 
Gy in fractions of 1.8-2 Gy combined 
with 5-FU) based chemotherapy
*High risk stage II is defined as tumors having at least one of these characteristics: T4, poor differentiation 
grade, perforation, obstruction, angioinvasion and/or less than 10 lymph nodes investigated. Abbreviations: 
TEM: transanal endoscopic microsurger APR: abdominoperineal resection, LAR: low anterior resection, 
ASR: abdominal-transsacral resection, PE: pelvic exenteration, RT: radiotherapy, RCT: radiochemotherapy, 
5-FU: 5- fluorouracil, na: not applicable. Source: www.oncoline.nl.
§5 PredictiVe factors for resPonse to 
(neo)adjuvant therapy 
Tumor response to (neo)adjuvant therapy affects treatment outcome. Predictive 
factors for therapy response are often tumor-related factors that can predict the extent 
of tumor response. Foreseeing the modifying effects of therapy on the clinical outcome 
has several advantages such as prevention of under and over-treatment. However, in 
order to use these predictive factors in clinical practice, these markers will have to be 
taBLe 1. overvIeW oF the Current treatMent GuIdeLIneS 
For CoLoreCtaL CanCer In the netherLandS
TUMOR 
TyPE
c
ol
on
r
ec
tu
m
TUMOR 
STAGE
Stage I/II
Stage III or high- 
risk stage II*
 
na
TUMOR 
LOCATION
na
SURGICAL
APPROACH
Open or
laproscopic
(NEO) ADJUVANT THERAPy
none
adjuvant 5-FU) based
 chemotherapy
T1/No well to 
moderately
differentiated,
absence of 
lympangio or
vascular invastion
Mobile: T1/T3,
No/N+
Advanced, fixed
rectum tumors
(T4, No/N+)
0-5 cm from
anal verge
5-15 cm from
anal verge
TEM
APR
LAR
Neoadjuvant short-term RT
(5x5 Gy)
LAR, APR,
ASR of PE
Neoadjuvant long-term RCT (45-50 
Gyin fractions of 1.8-2 Gy combined 
with 5-FU) based chemotherapy
*High-risk stage II is defined as tumors having at least one of these characteristics: 
T4, poor differentiation grade, perforation, obstruction, angioinvasion and/or less than 
10 lymph nodes investigated. Abbreviations: TEM: transanal endoscopic microsurger 
APR: abdominoperineal resection, LAR: low anterior resection, ASR: abdominal-transsa-
cral resection, PE: pelvic exenteration, RT: radiotherapy, RCT: radiochemotherapy, 5-FU: 
5-fluorouracil, na: not applicable. Source: www.oncoline.nl
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very sensitive and specific. And despite much effort, only very few predictive factors, 
also referred to as markers, are currently used as diagnostic tools for routine testing. 
HER-2 /neu (HER2, ERBB2) is for example currently used as a marker to predict the clinical 
benefit from trastuzumab (Hercpectin) in patients with metastatis breast cancer 52,53.
At a biological level, there are numerous candidate markers involved in different cellular 
processes related to therapy resistance and are therefore interesting candidate markers 
for studying tumor response. Important categories are (Figure 4):
1  Drug influx and efflux pumps.
2  Detoxification processes.
3  Modifications of the drugs target.
Figure 4: Schematic drawing of different cellular processes related to therapy resistance. These precesses 
are numbered 1 to 3. 1: drugs influx and efflux pumps, 2: detoxification processes, 3: modifications of the 
drugs target. All these processes influence apoptosis.The different apoptosis regulating proteins studied 
in this thesis are also depicted. White arrow: pro-apoptotic effect, black arrow : anti-apoptotic effect. 
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P-glycoprotein is a well known example of a transmembrane transporter. Other 
examples of pumps with functions similar to that of P-glycoproteine are multi resistance 
protein (MPR-1) and lung resistance related protein (LRP). These pumps influence the 
intracellular levels of the active drug. Resistance can occur when these transmembrane 
transporters pump the active drug out of the cell. However, other pumps are often needed 
for transportation of larger drug particles into the cell 54,55. When the chemotherapeutic 
drug has arrived in the tumor cells, detoxification processes in the cell by for example 
a member of the enzyme detoxification family of the glutathione s-transferases (GSTs). 
These enzymes have been described to break down several types of drugs and decrease 
the effective drug levels 56,57. Modifications of the drug target also influences drug 
efficiency. 5-FU, the major component of chemotherapy regimens for colorectal cancer, 
inhibits the enzyme thymidylate synthase (TS). TS is a central enzyme in DNA synthesis 
and its protein expression is affected by three different functional polymorphisms in 
the untranslated regions (UTRs) of the gene. Sensitivity to 5-FU based therapy might 
be largely influenced by the intra-cellular levels of the TS protein. Tumors with higher 
protein levels have been described to be associated with a poorer response to 5-FU than 
tumors with lower TS protein levels 58,59. Eventually, the downstream effect of almost all 
chemotherapeutic agents is the triggering of apoptosis (programmed cell death). This 
event is regulated by the interplay of different proteins (Figure 4), such as p53, (the name 
p53 is in reference to its apparent molecular mass of 53 kDa) cyclooxygenase-2 (Cox-2), B-
cell lymphoma 2 (Bcl-2), Bcl-2–associated X protein (Bax) and mammaryserine protease 
inhibitor (maspin). All these factors have pro- or anti apoptotic properties and can 
therefore affect the apoptotic balance and finally apoptosis 60-64. The fact that some of 
these factors also influence each other, e.g.Cox-2 and Bcl-2, makes this delicate interplay 
only more complex. Moreover, the proteins that are depicted in Figure 4 are obviously 
only a small representation of all proteins involved in the regulation of apoptosis. 
§6 future staging of colorectal cancer
As described in the former paragraphs, patients’ outcome after diagnosis of colorectal 
cancer depends on several different factors. The total population of patients with this 
malignancy will have an intermediate outcome (Figure 5A). Application of traditional 
staging will split this group into good and relatively poor prognosis (5B). Evaluation of 
treatment-related prognostic factors will lead to further refinement of prognosis (5C), as 
has been described in this thesis. In the future, factors predictive for therapy response will 
finally lead to a very detailed refinement in foreseen outcome (Figure 5D); when every 
patient can receive optimal individualised treatment (tailor made therapy). Accurate 
estimation of tumor invasion depth, N status and CRM involvement by imaging techniques 
is becoming increasingly important in order to provide this
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Figure 5: Developments in colorectal cancer staging. A: Outcome of the total population, B: Differences in 
outcome based on a tumor-related prognostic factor, C: Differences in outcome based on a tumor-related 
factor combined with a treatment-related prognostic factor, D: Addition of a predictive factor, such as 
biomarkers, results in a refined prediction of patient outcome: tailor made therapy.
§7 outline of this thesis 
In this thesis pathological and biological aspects of colorectal cancer are discussed, 
focussing on improving staging and treatment. The present thesis consists of two 
major parts. The first part (chapter 1-3) deals with the pathological aspects of colorectal 
cancer treatment and the second (chapter 4-8) with the biological aspects.  For this 
purpose, 3 different patient populations were used. 
The first population consists of patients with mobile rectal (T1-T3) cancer that were 
included in the Dutch TME trial. These patients were randomized for either TME surgery 
alone or short-term radiotherapy (5X5 Gy) followed by standardized TME surgery. The 
conclusions that could be drawn based on studying this population are described in 
chapter 2, 4, 5 and 6.
The second population consists of patients with locally advanced rectal cancer (advanced 
T3 and T4) that had a threatened circumferential margin. All patients received long- 
term radio(chemo)therapy comprising of 50.4 Gy in 1.8 Gy fractions and 5-FU based 
chemotherapy. Studies based on this population are described in chapter 3 and 8. 
Finally, patients with stage III colon cancer were investigated (chapter 7). These Patients 
received adjuvant 5-Fluorouracil (5-FU) based adjuvant chemotherapy.
In chapter 1 the future of tumor staging is discussed, with special emphasis on the use 
of treatment-related factors in staging of rectal cancer. This critical comment is based 
on the data described in chapter 2. In this chapter, we compared the traditional staging 
system with a new developed system including circumferential margin status, in two 
independent populations. In chapter 3 we investigated the best way to evaluate the 
therapy-effect in locally advanced rectal cancer. 
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The first chapters dealing with the biological aspects, chapter 4 and 5 describe the role 
of adhesion molecules (epithelial cell adhesion molecule, E-cadherin and β-catenin) in 
tumor progression and shed some light on genetic mechanisms of tumor differentiation. 
chapter 6 describes the investigations on the prognostic and predictive value of Cox-
2 in patients with rectal cancer distinguishing between patients who did and did not 
receive radiotherapy. Technical aspects of determining the predictive value of TS in 
patients with colon cancer are mentioned in chapter 7. Finally the potential value of 
apotosis for the prediction of response to long-term radio(chemo)therapy is evaluated 
in chapter 8. 
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Chapter 1 
Treatment of rectal cancer has radically changed over the last decade. The introduction 
of the surgical technique Total Mesorectal Excision (TME) worldwide has resulted in 
a decline of local recurrence rate, due to the fact that more tumors were completely 
excised, along with regional metastatic disease in the mesorectal fat. In addition, the 
role of neoadjuvant treatment either by radiotherapy or by radiochemotherapy has 
been established over the last 10 years. In Europe, overwhelming evidence has been 
gathered from large randomized trials (TME, SRCT, CR07) 1-3, with a total number 
of 4427 patients showing that for primarily resectable rectal cancer short-term pre-
operative radiotherapy (5x5 Gy) resulted in local recurrence rates lower than 5%, 
especially in combination with TME surgery. For locally advanced tumors, long-term 
radiotherapy (approximately 50 Gy) in combination with neoadjuvant chemotherapy is 
the treatment of choice 4,5.
The combination of the above mentioned changes in therapy results in improved 
prognosis of patients with rectal cancer, especially with respect to local recurrence, but 
these advances have not yet been included in staging of rectal carcinoma. In fact, these 
innovations in therapy call for a change in approach of staging. Due to the application 
of neoadjuvant therapy both the function of staging systems as well as the factors used 
for staging have changed, which complicates the current practice.
Initially postoperative pathological staging was used for the prediction of prognosis as 
well as for the indication of adjuvant therapy. Nowadays, clinical staging determines 
whether and which preoperative therapy should be applied and postoperative staging 
is used to evaluate the effects of therapy in addition to the above mentioned goals. The 
consequence of these changes is a divergence between cTNM and pTNM. Moreover, the 
current pTNM is essentially different from the pTNM of last century. Still, the staging 
system for rectal cancer uses the same rules as Cuthbert Dukes proposed in 1932 6. 
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IMpaCt oF neoadjuvant therapy
Long-term radiotherapy and chemoradiation schemes are aimed at tumor down-
staging, to facilitate complete surgical removal. Pronounced changes in tumor histology 
are observed in the operation specimen, indicative of tumor response or regression. In 
many of these cases the pT stage is lowered compared to the initial cT stage, but it is 
not clear which of these two is the best predictor for prognosis. The current guidelines 
of the AJCC/TNM staging systems 7,8 acknowledge preoperative treatment by adding 
the prefix y, but the clinical consequences are not clear. 
The ypT stage can be used as a measurement for tumor down-staging, however, 
after removing locally advanced tumors, tumor remnants might be left behind in the 
surrounding tissue, resulting in inadequate determination of T stage. Moreover, there 
is a large variability between the pT3 tumors with regard to tumor load. Alternatively, 
response can be indicated by determining the grade of tumor regression. Various 
systems have been suggested to grade tumor regression 9-11, but the majority is not 
able to demonstrate a relation with prognosis. In addition, reproducibility of regression 
grading is poor 12,13.
Since the goal of long-term neoadjuvant therapy is the facilitation of surgical removal, we 
suggest inclusion of surgery related factors in the staging after this kind of treatment. 
surgical factors in the 21st century
The recognition of TME as a superior surgical technique is preceded by the recognition 
of circumferential margin (CRM) involvement as the best prognostic factor, not only 
for local recurrence, but even for development of metastases, as well as for survival. 
A recent review with data of over 17,500 patients 14 demonstrated that the prognostic 
value of an involved CRM for local recurrence is even stronger after neoadjuvant therapy 
(hazard ratio 6.3 (95%CI 3.6 -16.7) versus hazard ratio 2.2 (95% CI 1.5 -3.2) without 
neoadjuvant therapy).
A positive CRM after surgery can be caused by various factors; the most important of 
which are suboptimal quality of surgery, aggressive tumor growth, therapy resistance 
and inadequate preoperative imaging. The quality of surgery is analyzed by the 
assessment of plane of resection. This is correlated with both local recurrence and 
overall survival and its value has recently been confirmed in another large multicenter 
trial 15. The finding that CRM involvement can predict the development of distant 
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metastases as well as survival may suggest that aggressive tumor growth is most 
important 16. However, the fact a positive CRM due to poor quality surgery is correlated 
with survival as well 16, indicates that for prognosis the cause of margin involvement 
does not seem to matter 16. 
staging systems: Where should We go?
In the era of neoadjuvant therapy, the existing staging systems are suboptimal. There 
is a need for the implementation of treatment-related factors, which will improve both 
staging and prognostification 17. The result of treatment is one of the most relevant 
features for predicting final outcome, therefore modern staging systems should take 
both tumor and treatment factors into account. The incorporation of these factors 
should of course be evidence based. Before we can propose a new staging system, we 
have to address the following questions: Which factors can reliable predict prognosis? 
Are these factors generally applicable? Can these factors be assessed in a reliable and 
simple way? Is there a combination of factors that adequately divides patients in large, 
homogeneous groups with highly divergent survival curves?
Which factors can reliable predict prognosis?
First we have to question the value and reliability of established tumor factors as 
invasion depth and lymph node status in the current situation. As mentioned above, the 
reliability and relevance of ypT is questionable. The presence of lymph node metastases 
after neoadjuvant therapy is still a major prognostic factor 18-20. However, an unknown 
number of node negative patients will have had positive nodes that are sterilized by 
neoadjuvant therapy. Therefore, ypN0 consists of a heterogeneous group of patients 
who were initially node negative and patients whose metastatic tumors responded 
well to treatment. Although the meaning of ypN0 might be different from pN0, the 
prognostic impact is still there. Although a multivariate analysis of 182 patients 21 
suggests that after neoadjuvant therapy CRM is more important for prognosis than 
lymph node involvement. Since neoadjuvant therapy is mainly aimed on local control, 
we can, at current, leave the presence of metastatic disease (TNM IV) out of this 
discussion. 
Treatment-related factors are CRM, tumor regression and quality of surgery. The results 
of tumor regression grading are variable and no consistent relation with prognosis has 
been demonstrated. Moreover, 4 different studies including a total number of 490 
patients demonstrate superiority of CRM-assessment above regression grading 13,22-
24. Quality of surgery evaluation in two independent randomized trials demonstrates 
prognostic value for both local recurrence and survival 15,16. However, CRM involvement 
is more important than plane of surgery 16.
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Finally, there are many biomarkers described, but none of them have reached the 
standard assessment of rectal cancer specimens and therefore remain beyond the 
scope of this comment.
are these factors generally applicable?
Although in most cases of rectal cancer preoperative neoadjuvant therapy will be applied, 
some patients will be operated right away. The new staging should be applicable in all 
situations. Tumor invasion, lymph node metastases, CRM involvement and quality of 
surgery can be evaluated with and without neoadjuvant therapy and in any laboratory 
of pathology. One could argue that this is the case for tumor regression as well, and 
that without therapy there will be no regression. As a result, although the absence of 
regression after therapy may be a bad sign, the absence of regression without therapy 
has no meaning at all.
can these factors be determined in a reliable and simple way?
The stage of the tumor is relatively simple determined provided that an adequate 
sampling of the tumor area is performed. Especially for the determination of ypT0 
(complete regression) a standardized protocol is required. Careful examination of the 
resection specimen will reveal possible involvement of the circumferential margin and 
presence of lymph node metastasis. Detailed protocols are available 25,26. 
Determination of tumor regression is much more difficult and reproducibility studies 
show kappa values as low as 0.30 13. One of the reasons is that there is no consensus 
about the definitions that should be used, apart from the definition of complete 
response. Disappointingly, up to now none of the reported studies used this definition.
Is there a combination of factors that adequately divides patients in large, 
homogeneous groups with highly divergent survival curves?
In a recent study 27 based on the data from a randomized clinical trial 1 we demonstrated 
in a multivariate model that CRM rather than pT stage is important for the prognosis 
of rectal cancer. This is true for patients without preoperative treatment as well as for 
patients treated with short-term preoperative radiotherapy. Based on these findings 
we designed a staging system, including both CRM (treatment-related factor) as well 
as nodal status (tumor-related factor) (Figure 1). Using this system we created highly 
divergent survival curves, with a small group of patients with a poor prognosis (n = 93 
(7%), 36% 5-year survival) and a large group of patients with a good prognosis (n = 743 
(57%), 92% 5-year survival). We confirmed our findings in an independent dataset, 
derived from another randomized trial 28 (Figure 1b). In this group of patients (with 
short-term and long-term neoadjuvant therapy) the new staging system performed 
significantly better than TNM.
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Figure 1: Hazard ratio and 
95% confidence interval of 
TNM staging versus a new 
staging method which is 
based on a combination 
of nodal staging (N) and 
circumferential margin 
status (NCRM). (A) TME 
trial (n = 1530; follow-up 
67 months). (B) Polish 
rectal cancer trial (n = 316; 
follow-up 48 months). y: 
pre-operative treatment, p: 
pathologic.
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conclusion
In modern staging of cancer there should be an important place for treatment-
related factors, since the result of treatment is one of the most important prognostic 
factors. For rectal cancer we demonstrated that in the era of neoadjuvant therapy 
free circumferential resection margins are more important than the classic factor of 
invasion depth, and that incorporation of this factor in staging systems leads to better 
prognostification and selection of patients.
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Background
Staging of cancer is based on the TNM system. This valuable system only takes tumor-
related parameters into account, but in the era of refined surgery and preoperative 
therapy treatment-related factors are of equal importance. By   rectal cancer as a 
model we explored the hypothesis that a combination of tumor- and treatment-related 
parameters will result in improved prognostication. 
Patients and methods
Standardized clinicopathological and histological factors considered predictive for 
survival were studied in eligible patients treated in a trial for rectal cancer (n = 1324). 
These factors were analyzed in relation to survival using log-rank tests, Kaplan-Meier 
curves and Cox regression both individually and in combination, the latter including 
TNM staging. A second dataset from an independent trial (n = 316) was used for data 
validation.
results
Multivariate analysis identified nodal status (p=0.001) and circumferential margin 
(p=0.001) involvement as most important prognostic factors for survival. Combination 
of these factors formed an improved staging system (node status and circumferential 
margin NCRM) compared to the present TNM-staging with respect to 5-year cancer-
specific survival. The results were confirmed in our independent patient population.
conclusions
NCRM staging of rectal cancer results in a broad range of survival rates and favorable 
patient grouping. Our data give strong evidence that a staging system combing 
tumor- and treatment-related factors provides better prognostic information than 
the classic TNM system, which is based solely on tumor-related factors. Similar results 
might be obtained in other types of cancer where quality of treatment is important for 
outcome.
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introduction
Staging of cancer patients is an important tool for the selection of patients for 
adjuvant treatment. Ideally, stage grouping results in homogeneously divided groups 
incorporating patients with similar prognoses. The most important staging system 
is the TNM system that is used worldwide for treatment selection in many tumor 
types. The strength of this system is that is easily applicable and well defined. Another 
important feature is the regular adaptation due to new data, leading to the 6th edition 
in 2002.1 In general, the factors included in the TNM system are purely tumor-related. 
Currently, in many patients neoadjuvant treatment is given, which may alter stage-
related outcomes. We hypothesize that treatment-related factors might be relevant 
for identification of high-risk patients.
Recent developments in the treatment of rectal cancer include total mesorectal excision 
and the switch from postoperative to preoperative radiotherapy. The combination 
of these modalities reduced local recurrence risk significantly.2 One of the major 
prognostic factors in rectal cancer is involvement of the circumferential margin (CRM), 
3,4 which is an important surgery-related factor. This factor is not only prognostic for 
local recurrence, but also for the development of distant metastases.3 Therefore, this 
might be an important factor in the selection of patients for adjuvant therapy. The 
current TNM staging system does not take this parameter into account.
We decided to explore the hypothesis that a staging system that includes both tumor 
and treatment-related prognostic factors results in improved prognostication. These 
treatment-related factors should be easily identifiable and uniform in order to eliminate 
interpretation variation in pathological practice.5 The development of a staging system 
should be evidence-based, developed from multicenter randomized trials, and be 
tested by multivariate analysis. 
In the current study we used the patient population of a large multicenter randomized 
trial to develop a system with increased prognostic value, based on both tumor-and 
treatment-related factors. A second dataset from an independent trial was used for 
verification. Our approach can be regarded as a model for other types of cancer where 
preoperative treatment is given and where quality of surgery determines outcome 
significantly.
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methods
study population
Data from patients from the radiotherapy (RT) + Total Mesorectal Excision (TME) trial,6 
which was a large multicenter trial, are the basis of this study. This trial compared TME 
surgery and preoperative short-term radiotherapy with TME surgery and has been 
described extensively.2 Informed consent was obtained from all included patients and 
the medical ethics committees of all participating hospitals have approved the trial. 
Patient selection
For the current study, the data of the eligible Dutch patients in the trial (n = 1474 from 
83 Dutch hospitals) as described earlier were analyzed.6 Patients were excluded from 
the analysis for the following reasons: no resection (n = 37), macroscopic resection 
locally not complete (n = 5), distant metastases at operation, TNM stage IV (n = 91) and 
no tumor at operation (n = 15). For the final analysis 1324 patients could be evaluated. 
In case of cancer-specific survival analysis, cause of death was unknown in 7 patients. 
These patients were excluded for this analysis. The median follow-up period at the time 
of the analysis was 67.2 months.
independent test population
Data from patients from the Polish rectal cancer trial were used as an independent 
test population.7 This trial compared short-term preoperative radiotherapy (5 x 5 Gy) 
followed by TME with chemoradiation (50.4 Gy, 5-fluorouracil and leucovorin) followed 
by TME. 316 patients were included with a median follow-up period of 48 months.
treatment and diagnostic procedures
The short course of preoperative radiotherapy 8 and the surgical technique 9 are 
described extensively elsewhere. In brief, the main principles of this technique involve 
sharp dissection within the true pelvis around the integral mesentery under direct 
vision, envelopment of the entire midrectum and preservation of the hypogastric 
plexus. The majority of patients were treated with low anterior resection (69%). 
Pathological procedures were performed as have been described by Quirke et al.10,11 
Special attention has been given to the examination of the circumferential resection 
margin.3 A margin of 1 mm or less was considered positive. In addition, all cases were 
reviewed by the Pathology Review Committee.12
data collection and statistics
All case record forms were sent to the central data office at the Department of Surgery 
of the Leiden University Medical Center in the Netherlands. The data were checked and 
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entered in a database and analyzed with the SPSS package (SPSS 11.0 for Windows, 
SPSS Inc., Chicago, IL, USA). Relations between various parameters were analyzed using 
χ2 -methods and Mann-Whitney nonparametric testing procedures. Univariate survival 
analyses of time to cancer-related death were performed using the Kaplan-Meier 
method, with the time of surgery as the entry date. Differences in observed survival 
between groups were tested for statistical significance using log-ranks tests. Factors 
were included in the multivariate analysis if the p-value of the univariate analysis was 
less than 0.10. Multivariate analysis was performed using the Cox proportional hazards 
regression model. A p-value of 0.05 or less was considered statistically significant.
The performance of the prognostic systems was evaluated by the integrated Brier 
score.13 The integrated Brier score is a measure comparing the actual survival outcomes 
of individuals with the predictions based on a prognostic system, accounting for 
possible censoring. The integrated brier score of the whole group (using the Kaplan-
Meier estimates as a prediction) was used as an estimate of the total variance; the 
integrated Brier score taking into account the prognostic system was used an estimate 
of the residual variance. This leads to the percentage of variance explained. A prognostic 
system is better when within a prognostic group individuals are more homogeneous 
(residual variance is smaller) and as a consequence the percentage of variance explained 
is higher.
results
univariate analysis
Patient-, treatment- and tumor-related factors as well as histologic factors were 
analyzed in relation to cancer-specific 5-year survival (Table 1). 
Patient-related factors (age and gender) did not influence survival. Both surgery-related 
factors, distal and circumferential margins, were strongly associated with survival. 
Although only a small group of patients presented with a positive distal margin (n = 13), 
survival in this group was very low at 38%, compared to 78% in the negative margin 
group (p < 0.0001). Quality of surgery, as measured by the completeness of mesorectal 
excision or plane of resection, was not taken into account due to the large number of 
missing data in the whole series.14
The size of the tumor was not a relevant factor for cancer-specific survival. As expected, 
the classic factors of invasion depth and lymph node status were relevant. Tumor 
location (i.e. distance from the anal verge) showed a decreased survival for the low 
rectal carcinomas (74% vs 78% and 82% for the mid- and upper rectum, p = 0.009).
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Histological factors such as differentiation grade (2-tiered), growth pattern, lymphoid 
reaction and eosinophilic infiltrate also were significant predictors of cancer-specific 
survival in the univariate analysis, which was also reported by Nagtegaal et al.15 This 
shows the validity of our material.
multivariate analysis
Factors included in the multivariate analysis are depicted in Table 2. The most relevant 
significant factors were circumferential margin involvement and lymph node status 
(in both cases p < 0.0001), with a relative risk of 1.7 for cancer-related death in case 
of positive CRM and a relative risk of 5.3 in case of more than 3 positive lymph nodes 
(N2). Furthermore, the location of the tumor was important, as well as distal margin 
involvement. Invasion depth showed a difference in cancer-specific survival between 
the tumors limited to the bowel wall (T1, T2) and those that invaded the surrounding 
fat (T3). In theT4 group only 37 patients were present, accounting for a non-significant 
decrease in cancer-specific survival. Of the histologic factors, only the presence of 
eosinophilic infiltrate and lymphoid reaction seems to protect against cancer-related 
death.
node status and circumferential margin staging
With the results of the multivariate analysis, an improved staging system based on 
the combination of lymph node status (N) and CRM was developed (NCRM). The 
categorization of this system was based on the number of adverse factors; NCRM 0 
(0 adverse factors: N0CRM
-), NCRM 1 (1 adverse factor: N0CRM
+ or N
1
CRM-), NCRM 2 
(2 adverse factors: N2CRM
- or N
1
CRM+), NCRM 3 (3 adverse factors: N2CRM
+). The N1 
status is counted as 1 adverse factor and N2 as 2 adverse factors. This staging system 
was compared with TNM and Jass’ staging 16 with respect to the cancer-specific 5-year 
survival rate (Figure 1) and the distribution of patients. TNM and Jass’ staging could not 
be performed in 2 and 23 patients, respectively, because of missing data.
In the total population, the 5-year cancer-specific survival of different TNM stages 
ranged from 95% for TNM I to 58% in the TNM III group. For Jass’ staging these 
percentages ranged from 90% in stage-group I to 49% in stage-group IV. The NCRM 
staging showed an even larger variation in prognosis, from 92% in the best group (no 
adverse factors, N0CRM
-) to 36% in the worst group (3 adverse factors, N2CRM
+) (data 
not shown). In addition to a better discrimination for prognosis, the NCRM staging 
system also identifies more low-risk patients (Table 3). NCRM identifies 57% of patients 
with more than a 90% 5-year survival rate, TNM 33% and Jass’ 25%. 
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Figure 1: Kaplan-Meier curves for 
cancer-specific survival, (A): TNM 
staging, (B): Jass’ staging and (C): 
NCRM staging. NCRM 0 (0 adverse 
factors: N0CRM
-), NCRM 1 (1 adverse 
factor: N0CRM
+ or N1CRM
-), NCRM 2 (2 
adverse factors: N2CRM
- or N1CRM
+), 
NCRM 3 (3 adverse factors: N2CRM
+). 
For each category the percentage of 
patients is given. 
Finally, we tested the new system in the separate randomization arms of the trial, 
to evaluate whether the system is valid in both previously untreated patients and in 
patients with short-term preoperative radiotherapy treatment before surgery. In both 
arms the difference in prognosis was larger in the NCRM staging compared to both the 
TNM and Jass’ systems. The number of low-risk patients was high in both arms, 55% in 
the surgery only group and 58% in the preoperative radiotherapy group (Table 3).
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Cox regression was used to compare the prognostic value of NCRM with the prognostic 
value of TNM. Starting with TNM, the addition of NCRM improves the model 
significantly (χ2 = 50.5, p < 0.001). The addition of TNM when starting with NCRM is 
also significant (χ2 = 16.8, p < 0.001), suggesting that NCRM is a better classifier, but 
that TNM has some additional predictive value in this data. The better performance of 
NCRM is confirmed using the percentage of variance explained: TNM 11.4% compared 
to NCRM 16.9%.
independent test group
To validate our proposed classification system we applied the system to an independent 
test population. Figure 2 shows the survival curves for both classification systems in 
the independent test group. The survival rates for the total independent test group are 
depicted in Table 4. In concordance with our own population, the percentage of variance 
explained was higher in NCRM than TNM staging; 18.7% vs 13.6%, respectively. The 
analysis was repeated in the different randomization arms of the trial and both gave 
similar results.
discussion 
In the diagnosis and treatment of cancer, staging is of utmost importance. Prognosis 
of patients can be predicted based on tumor stage and the choices of adjuvant therapy 
are largely dependent on these stages. The most commonly used staging system is the 
TNM. On basis of the data of the Dutch TME-study, we developed an improved staging 
system based on nodal status and circumferential margin involvement (the NCRM). 
Multivariate analysis of 1324 Dutch patients included in the TME trial showed that lymph 
node involvement was the most important prognostic factor for 5-year cancer-specific 
survival, followed by involvement of the circumferential margin. Combination of these 
two factors leads to a 4-stage system, reflecting the number of adverse factors. 
Staging by the proposed NCRM system is transparent and easily applicable by 
pathologists. Inclusion of invasion depth as a third factor did not improve the staging 
(data not shown). Moreover, its inclusion would only make the system more complicated. 
The difference compared to other staging systems is the integration of a treatment-
related factor (circumferential margin involvement). The replacement of tumor depth 
by CRM involvement is the most distinctive feature of NCRM staging when compared 
with TNM staging. Both CRM and nodal involvement are partly depended on the 
depth of tumor invasion, but provide additional information. This explains why tumor 
invasiondepth has lesser prognostic impact on survival than the components of the 
NCRM system. TNM staging is based solely on tumor-related factors, while Jass’
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Figure 2: Kaplan-Meier curves for cancer-specific 
survival in the independent test population. (A) TNM 
staging and (B) NCRM staging. For each category the 
percentage of patients is given.
staging also takes histology of tumor microenvironment into account.16 However, the 
factors that are indicative of tumor microenvironment (growth pattern and lymphoid 
reaction) were not significant in this study on multivariate analysis. Moreover, 
the application of Jass’ staging in this setting may be complicated by the effect of 
neoadjuvant therapy on lymphoid reactions.17 Finally, another shortcoming of Jass’ 
staging is the complexity of the system, which reduces its reproducibility due to 
subjective interobserver-variation.18
An accurate estimation of prognosis for survival is a basic tool for the selection of 
patients for adjuvant therapy. The identification of high-risk patients to date has 
been difficult. Adjuvant chemotherapy has not resulted in a survival benefit in rectal 
cancer,19,20 probably due to the high local recurrence rates in those studies. For patients 
with colon cancer the effect of adjuvant chemotherapy is only proven in TNM III,21 
although it has been suggested that also high-risk TNM II patients should be treated. 
Selection of these patients is not easy. The power of the NCRM is based on a more 
discriminative grouping of patients, with a more pronounced separation of cancer-
specific outcomes, for the population as a whole as well as for the 2 randomization 
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groups tested separately. Thus, the system is most appropriate for the staging of 
resectable rectal tumors treated with short-term preoperative radiotherapy, followed 
by TME resection. Several studies confirmed preoperative therapy to be more effective 
than postoperative irradiation.22,23 As a result of this, preoperative radiotherapy in 
combination with surgery has become the preferred treatment for primary resectable 
rectum carcinoma in Europe and in many centers in North America, potentially making 
the NCRM broadly applicable.
For locally advanced rectal carcinoma, various long-term radiotherapy and radio-
chemotherapy regimens are used. These approaches result in tumor down-staging 
and downsizing, which may affect both circumferential margin- and lymph node 
involvement.7,19,24-26 In a study of 61 patients with locally advanced rectal carcinoma treated 
with long-term radiochemotherapy (45 Gy, bolus 5-fluorouracil) both circumferential 
margin involvement and lymph node metastases were the most important factors for 
cancer-specific survival in a multivariate model.27 The importance of the circumferential 
margin was confirmed in another study of 200 locally advanced rectal carcinoma 
patients treated with either long-term radiotherapy (44 Gy) or radiochemotherapy 
(with 5-fluorouracil).28 After preoperative hyperfractionated accelerated radiotherapy 
of 104 patients with locally advanced rectal cancer, 43% demonstrated tumor down-
staging. None of the patients showed complete regression.29 In this study, both 
pathologic lymph node stage and CRM were independent prognostic factors for 
disease free survival. These results, in combination with the results in our independent 
test population, although relatively small, strongly suggest that the NCRM staging is 
also applicable to patients treated with long-term radio (chemo)therapy.
The current study implicates that a staging system based on both a tumor-related factor 
and a treatment-related factor is superior to TNM staging, which is solely based on 
tumor-related prognostic factors. We encourage further testing and validation of NCRM 
staging in large populations of patients with rectal cancer. The role of cancer treatment 
is of paramount importance for obtaining good long-term results. Tumor treatment 
nowadays is almost as important as tumor characteristics and this phenomenon should 
be considered in the design of a new generation of staging systems. 
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Purpose
After preoperative (radio)chemotherapy (RCT) histological determinants for prognostifi-
cation have changed. It is unclear which parameters, including assessment of tumor 
regression, are the best indicators for local recurrence and survival.
Patients and methods
A series of 201 patients with locally advanced rectal cancer (LARC) (cT3/T4, M0) 
presenting with an involved or at least threatened circumferential margin (CRM) on 
preoperative imaging (less than 2 mm) were evaluated using standard histopathological 
parameters and four different histological regression systems. All patients received 
neoadjuvant radiochemotherapy (RCT) or radiotherapy (RT). The prognostic value of 
all factors was tested with univariate survival analysis of time to local recurrence (LR) 
and overall survival (OS).
results
LR occurred in only 8% of the patients with a free CRM compared to 43% in case of 
CRM involvement (p<0.0001). None of the four regression systems was associated with 
prognosis, not even when corrected for CRM status. However, we did observe a higher 
degree of tumor regression after RCT compared to RT (p<0.001). Absence of tumor 
regression was associated with increasing invasion depth and a positive CRM (p=0.02 
and p=0.03 respectively).
conclusion
Assessment of CRM involvement is the most important pathological parameter after 
RCT. Although tumor regression increases the chance on a free CRM, in cases with 
positive resection margins prognosis is poor irrespective of the degree of therapy 
induced regression.
Value of CRM in LARC
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introduction
 
For patients with locally advanced rectum carcinoma (LARC), surgery alone is often not 
curative. In case of cT4 tumors or a threatened circumferential margin (CRM; less than 2 
mm on preoperative imaging) in cT3 tumors, long-term neoadjuvant radio(chemo)therapy 
(RCT) is required. This will result in down-staging and increased local control 1-4.  The 
histopathology of specimens obtained after this kind of preoperative therapy is 
markedly different compared to untreated cases. Various stages of histological tumor 
regression may be present, often resulting in changed morphology.   
Histological changes after the RCT regime range from absence of any treatment effect 
to a complete response with no residual tumor identified. One of the first systems 
for grading histological regression focused on patients with esophageal carcinoma 
who were treated with RCT 5. Their results showed that after multivariate analysis, 
only grading of tumor regression was a significant predictor for disease free survival 
5. Subsequently, this system was modified by Dworak et al. for grading regression in 
the rectum 6. Currently, several different methodologies for measuring the degree of 
histological tumor regression after RCT in rectal cancer have been described 6-10 but 
none has become universally accepted. Reproducibility seems to be a key factor. 
The objective of our study is to evaluate which factors determine outcome in patients 
with LARC after RCT, focusing on the contribution of histological tumor regression 
grading and the CRM. Tumor regression after RCT was measured using four different 
methodologies and evaluated for prognostic impact with respect to overall survival 
(OS) and local recurrence (LR). CRM was evaluated according to Quirke et al. 11,12. 
Additionally, prognostic implications of clinicopathological and histological parameters 
were determined.
methods
Patient selection
The patient population consisted of a consecutive series of patients with LARC with 
biopsy proven adenocarcinoma. All patients received multimodality treatment at 
the Catharina hospital between 1994 and 2005 13. Patients were referred from all 
over the Netherlands based on the assumption of the referring surgeon that a free 
CRM was unlikely to be obtained without neoadjuvant treatment. Until August 2005, 
201 patients with stage cT4 or cT3 and a predicted CRM of less than 2 mm have been 
treated. Confirmation of the tumors proximity to the CRM and the absence of distant 
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metastasis (M0) on MRI were crucial for enrolment. Median follow-up was 22.8 months 
(range 0-124 months). Approval for the study was given by the local ethical committee 
of the Catharina hospital. 
therapy
Preoperatively, patients received different treatment regimens, considered state of the 
art at the time of treatment. Long-term radiotherapy (RT) (n= 74) involved a total dose 
of 50.4 Gy in 1.8 Gy fractions, 5 times a week. Two RCT schedules have been used. 
The MAyO schedule, hereafter mentioned as interrupted schedule (n=102), comprises 
concurrent radiotherapy and chemotherapy (RCT): a total irradiation dose of 50.4 Gy, 
1.8 Gy per fraction during 5 weeks synchronously with 5-FU (350 mg/m2) and leucovorin 
(20 mg/m2) in irradiation week 1 and 5. The radiation scheme of the continuous RCT 
regimen (n=25) compromises 45 Gy in fractions of 1.8 Gy during 5 weeks. On every 
radiation day 820 mg/m2 capecitabine was administered twice and 50 mg/m2 oxaliplatin 
was given at the first irradiation day of each week. 
surgery 
The objective in both cT3 and cT4 tumors was to obtain a radical resection (negative 
CRM). Especially in cT4 tumors, the CRM encompassed surrounding structures: i.e. 
prostate vesicle, vaginal wall, pelvic floor, uterus, sacrum etc. The CRM was considered 
negative if the outer margin of the en bloc specimen was negative.
In case of all treatment schedules, surgery was performed 6 to 8 weeks after the 
last radiation date. All patients underwent resection by experienced and designated 
colorectal surgeons (HJTR, GAPN), who routinely perform total mesorectal excision 
(TME) surgery. The extended surgical procedures used were; abdominoperineal 
resection (n=98), low anterior resection (n=91), abdomio-transsacral resection (n=9) 
and exenteration (n=3). The TME principle was adhered to in all cases, even in extended 
resections 14.
histopathological assessment
Surgical specimens were assessed according to the protocol of Quirke et al. 11,12. The 
most important issue is assessment of the CRM. In order to determine the CRM, 
the lateral resection margin of the fresh specimen was inked and subsequently the 
specimen was fixed in formalin for 48 hours. Blocks of the tumor in relation to the inked 
CRM were collected. Measurements of the margin were performed microscopically. A 
specimen with tumor ≤ 1 mm from the inked margin was considered as having a positive 
CRM. Classification of tumors was performed using the WHO guidelines; a tumor was 
considered mucinous when the proportion of the mucinous component was ≥ 50%. 
Tumors were graded according to histological differentiation into well, moderately and 
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poorly differentiated based on the poorest differentiated part of the tumor excluding 
the invasive front 15. Growth patterns were assessed as circumscribed or infiltrating 16. 
Evaluation of the tumor biopsies included assessment of tumor type and differentiation 
grade.
histologic regression grading
Histological therapy-induced tumor regression was assessed according to four different 
grading systems described by Dworak 6, Scott 7, Bouzourene 8 and Rödel 9. All four 
regression systems semi-quantitatively asses the relative proportion of residual tumor 
to stromal fibrosis. The following descriptions characterized the different regression 
grades of the regression systems used: Dworak grade 0: no regression detectable, 
grade 1: dominant tumor mass with obvious fibrosis and/or vasculopathy, grade 2: 
dominantly fibrotic changes with few tumor cells or groups (easy to find), grade 3: very 
few (difficult to find microscopically) tumor cells in fibrotic tissue with or without mucin 
and grade 4: no tumor cells, only fibrotic mass or mucin. Scott minimal: less than 1/3 
tumor regression, moderate: 1/3-2/3 tumor regression, good: more than 2/3 regression, 
maximal: no primary tumor remaining. Bouzourene TRG 5: tumor shows no signs of 
regression, TRG 4: residual tumor cells outgrowing the fibrosis, TRG 3: more tumor cells 
than TRG2 but fibrosis still predominates, TRG 2: rare residual cancer cells scattered 
throughout the fibrosis, TRG 1: absence of residual cancer and fibrosis extending 
through the different layers of the rectal wall. Rödel 0: no regression or < 25% of tumor 
mass, 1: 25% to >50% tumor regression, 2: complete regression.
When no tumor could be found macroscopically, sufficient tumor blocks were sampled 
in order to establish a complete response. In the present series, 21 patients had a 
complete response. The mean number of block samples collected from the fibrotic 
area was 9 (median 7, range 3-22). Figure 1 shows representative examples of different 
degrees of tumor regression. These microscopic images were digitalized using a Zeiss 
AxioSkop 2 Plus microscope with a Sony 950P camera attached to it. Images were 
digitized using 5x or 40x Plan-Neofluar objectives (Carl Zeiss MicroImaging). A-cellular 
mucin was considered as absence of residual tumor. The degree of tumor regression 
was determined semi quantitatively by two pathologists (JHJMvK and ITG) who were 
blinded for patients’ clinical outcome. In addition, the amount of necrosis and the 
presence of calcifications were scored as alternative parameters for regression. 
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Figure 1: Representative slides stained with H&E of different degrees of tumor regression observed after 
radio(chemo) therapy in patients with locally advanced rectal cancer (LARC). A: No sign of regressive 
changes, the fibrosis present is probably intrinsic to tumor development (original magnification: 50x). 
B: Marked fibrosis but large masses of vital tumor can still be observed (original magnification: 50x). C: 
Predominately fibrotic changes with smaller tumor masses (original magnification: 50x). D: Extensive 
tumor regression with few small clusters of tumor cells (arrow) scattered through the fibrotic area (original 
magnification: 50x). The boxed area in D is depicted with a higher magnification as an insertion in this 
panel. Three small clusters of tumor cells can be appreciated (original magnification: 400x). 
statistical analysis
Data were analyzed with the SPSS package (Statistical Product and Service Solutions 
11.0 for Windows, SPSS inc., Chicago, Illinois, USA). Univariate survival analyses of 
time to death were performed using the Kaplan-Meier method with the time of surgery 
as the entry date. Differences in observed survival between groups were tested for 
statistical significance using log-ranks tests. Chi-Square tests were used to determine 
correlations between categorized variables. Multivariate analysis was performed using 
the Cox proportional hazards regression model (Backward elimination (conditional)). 
P-values of ≤ 0.05 were considered as statistically significant. 
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results
pre-treatment patient characteristics
The majority of the patients was male (61%); median age was 63 years (range 35-86 
years). Clinical T stage was cT4 in 59% and cT3 in 41% of the patients. Slightly more 
CRM involvement was present in cT4 tumors (25% versus 17%, p = 0.13). There was no 
difference in outcome between cT3 and cT4 tumors (local recurrence 12% versus 19%, p 
= 0.31, metastases 22% versus 29%, p = 0.50, overall 5-year survival 58% versus 47%, p 
= 0.22).  Since there was no significant difference in outcome we combine both groups 
for further analysis. 
Correlations between pre-treatment factors and regression
The 3-tier Rödel system was used to demonstrate correlations between the degree of 
regression and pre- and post-treatment factors (Table 1). The Rödel system consists 
of the lowest amount of categories and therefore avoids subgroups containing small 
numbers of patients. Furthermore, this system showed significant correlation within 
the framework of a randomized trial 9. 
A strong association between treatment regimen and tumor regression was found 
(Table 1). The degree of tumor regression was significantly higher after RCT (12 % Rödel 
2) compared to RT (8% Rödel 2, p<0.001). Regression was more pronounced in tumors 
showing poor differentiation in their pre-treatment biopsy (p=0.03). Tumor regression 
was not influenced by preoperative cT stage.
post-treatment clinicopathological and histological factors and prognosis
CRM involvement, lymph node status and tumor stage were strongly associated with 
both local recurrence (LR) and overall survival (OS) (Table 2). CRM involvement was the 
strongest predictor of LR (43% versus 8%, at 24 months, p< 0.001) and OS (58% versus 
80%, p= 0.004) (Figure 2). 
LR rates increased and OS rates decreased with the number of lymph nodes involved 
(p=0.001). Mucinous histology and poor differentiation were both associated with poor 
prognosis. Although lymphangio invasion was not associated with LR, it did predict 
poor OS (40% versus 75%, p= 0.04).  All the analyses were repeated for the different 
treatment regimens, but this did not reveal different results. However, the groups are 
too small for fir conclusions per regimen.
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Table 1. Correlations between tumor regression and pre- and post-treatment factors
Factor Category Rödel 0 Rödel 1 Rödel 2 p-value 
Pr
e-
tre
atm
en
t
Therapy Radiotherapy 53 (72%) 15 (20%) 6 (8%) <0.001
48 (38%) 64 (50%) 15 (12%)
Clinical T 
stage
cT3 38 (46%) 32 (38%) 13 (16%) 0.12
cT4 63 (53%) 47 (40%) 8 (7%)
Differentiation 
grade
Good/
Moderate
56 (58%) 31 (32%) 10 (10%) 0.03
Poor/ 20 (36%) 29 (52%) 7 (12%)
Po
st-
tre
atm
en
t*
ypT stage ypT1,T2 5 (29%) 12 (71%) 0.02
ypT3, T4 96 (59%) 66 (41%)
ypN stage ypN0 65 (50%) 49 (37%) 17 (13%) 0.38
ypN1 24 (51%) 19 (40%) 4 (9%)
ypN2 12 (52%) 11 (48%) 0 (0%)
ypTNM Stage I 5 (36%) 9 (64%) 0.16
Stage II 51 (62%) 31 (38%)
Stage III 36 (55%) 30 (45%)
CRM Negative 71 (52%) 66 (48%) 0.03
Positive 30 (70%) 13 (30%)
Type 75 (55%) 62 (45%) 0.50
Mucinous 19 (53%) 17 (47%)
Differentiation 
grade
Good/
Moderate
62 (56%) 49 (44%) 0.40
Poor/ 39 (59%) 27 (41%)
Growth 
pattern
Circumscript 17 (68%) 8 (32%) 0.20
Diffuse 83 (56%) 64 (44%)
Lymphoid 
reaction
None/Few 56 (55%) 45 (45%) 0.20
Moderate 32 (57%) 24 (43%)
Extensive 12 (80%) 3 (20%)
Eosinophilic 
infiltrate
None 71 (55%) 57 (44%) 0.19
Moderate/
Extensive
29 (64%) 16 (36%)
Lymphangio 
invasion
No 94 (58%) 69 (42%) 0.54
Yes 6 (54%) 5 (45%)
Calcification No 76 (60%) 50 (40%) 0.18
Yes 25 (51%) 24 (49%)
Tumor 
necrosis
No 24 (32%) 52 (68%) <0.001
Yes 76 (78%) 22 (22%)
*: after a complete response (Rödel 2), post treatment factors could not be assessed. Bold values 
indicate statistical significance. Abbreviations: ypT: pathological T stage, ypN: pathological N stage, 
ypTNM: pathological tumor stage, CRM: circumferential margin.
p
re
-t
re
at
m
en
t
p
o
st
-t
re
at
m
en
t*
taBLe 1. CorreLatIonS BetWeen tuMor reGreSSIon and pre- and poSt-treatMent FaCtorS
TUMOR 
TyPE
C
lin
ic
o-
pa
th
ol
og
ic
H
is
to
lo
gi
c
FACTOR CATEGORy RÖDEL 0 RÖDEL 1 RÖDEL 2 P-VALUE
Therapy
Clinical T
stage
Differ ntiation
grade
ypT stage
ypN stage
ypTNM stage
CRM
Radiotherapy
Radiochemo
therapy
cT3
cT4
Good/
Moderate
Poor/
Undifferentiated
ypT1, T2
ypT3, T4
ypN0
ypN1
ypN2
Stage I
Stage II
Stage  III
Negative
Positive
53 (72%)
48 (38%)
38 (46%)
63 (53%)
56 (58%)
20 (36%)
5 (29%)
96 (59%)
65 (50%)
24 (51%)
12 (52%)
5 (36%)
51 (62%)
36 (55%)
71 (52%)
30 (70%)
15 (20%)
64 (50%)
32 (38%)
47 (40%)
31 (32%)
29 (52%)
12 (71%)
66 (41%)
49 (37%)
19 (40%)
11 (48%)
9 (64%)
31 (38%)
30 (45%)
66 (48%)
13 (30%)
6 (8%)
15 (12%)
13 (16%)
8 (7%)
10 (10%)
7 (12%)
17 (13%)
4 (9%)
0 (0%)
<0.001
0.38
0.12
0.03
0.02
0.16
0.03
Type
Differentiation
grade
Growth
pattern
Lymphoid
reaction
Eosinophilic
infiltrate
Lymphangio
invasion
Adenocarcinoma
Good/
Moderate
Mucinous
Poor/
Undifferentiated
Circumscript
Diffuse
None/Few
Moderate
Extensive
None
Moderate/
Extensive
No
75 (55%)
19 (53%)
62 (56%)
39 (59%)
17 (68%)
83 (56%)
56 (55%)
32 (57%)
12 (80%)
71 (55%)
29 (64%)
94 (58%)
62 (45%)
17 (47%)
49 (44%)
27 (41%)
8 (32%)
64 (44%)
 45 (45%)
24 (43%)
3 (20%)
57 (44%)
16 (36%)
69 (42%)
yes
Calcification
Tumor
necrosis
No
yes
No
yes
6 (54%)
76 (60%)
25 (51%)
24 (32%)
76 (78%)
5 (45%)
50 (40%)
24 (94%)
52 (68%)
22 (22%)
0.50
0.40
0.20
0.20
0.19
0.54
0.18
<0.001
*: after a complete response (Rödel 2), post-treatment factors could not be assessed. Bold values 
indicate statistical significance. Abbreviations: ypT: pathological T stage, ypN: pathological N 
stage, ypTNM: pathological tumor stage, CRM: circumferential margin.
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C
lin
ic
o-
pa
th
ol
og
ic
taBLe 2. unIvarIate anaLySIS oF poSt-treatMent pathoLoGICaL paraMeterS In reLatIon  
 to local recurrence and oVerall surViVal
FACTOR
TyPE
H
is
to
lo
gi
c
FACTOR CATEGORy n(%) % LR at 24 months P-VALUE
ypT
stage
CRM
ypT0-ypT2
Stage I
Stage II
Stage  III
38 (19%)
162 (81%)
3%
19%
9%
0.061 0.04
Patients with missing data were excluded from local recurrence and overall survival analysis. Bold 
values indicate statistical significance. Abbreviations: LR: local recurrence, ypT: pathological T stage, 
ypN: pathological N stage, ypTNM: pathological tumor stage. 
P-VALUE
% alive at 
24 months
89%
ypT3, ypT4 72%
ypN
stage
ypTN0 131 (65%) 0.001 81% 0.001
ypTN1 47 (23%) 25% 69%
ypTN2 23 (12%) 46% 40%
No residual
tumor
ypTNM 14 (7%) 0% 0.022 100% 0.004
19 (9%)
97 (49%)
70 (35%)
0%
13%
29%
81%
82%
59%
Negative 158 (79%) 8% <0.001 80% 0.004
Positive 43 (21%) 43% 58%
Type Adenocar-
cinoma
137 (79%) 13% 0.04 75% 0.02
Mucinous 37 (21%) 32% 60%
Differentia-
tion grade
Good/
Moderate
111 (63%) 12% 0.04 80% 0.05
Poor 66 (37%) 26% 61%
Growth
pattern
Circumscript 25 (14%) 17% 0.90 59% 0.35
Diffuse 147 (86%) 18% 76%
Lymphoid
reaction
None/
few
101 (58%) 22% 0.23 67% 0.19
Moderate 56 (32%) 15% 75%
Extensive 16 (9%) 8% 94%
Eosinophilic 
infiltrate
None 129 (74%) 19% 0.85 73% 0.33
Moderate/
extensive
45 (26%) 17% 77%
Lymphangio
invasion
None 163 (94%) 16% 0.51 75% 0.04
yes 11 (6%) 30% 40%
Calcification No 126 (71%) 19% 0.58 75% 0.56
yes 51 (29%) 13% 67%
Tumor
necrosis
No 76 (43%) 6% 0.02 68% 0.76
yes 99 (57%) 22% 75%
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Figure 2: Kaplan-Meier curves of circumferential margin (CRM) involvement in relation to A: local recurrence 
(LR) and B: overall survival (OS). Black lines depict patients with an involved margin and the grey lines 
indicate patients with a free CRM.
multivariate analysis of clinicopathological factors
Since histological factors could not be determined in patients with a complete response, 
multivariate analysis for LR and OS was performed for clinicopathological factors 
(category ypT stage, ypN and CRM) and the Rödel system only. A hazard ratio (HR) of 
1 was attributed to the most favorable category. In case of LR, the CRM was the only 
factor significantly associated with this event (HR=4.44, confidence interval (CI):1.83-
10.81, p=0.001). With respect to OS, Both N status and CRM were selected by the Cox 
regression model using conditional backward elimination: ypN1: HR=1.75, CI: 1.01-3.05, 
p=0.046, ypN2: HR=2.60, CI: 1.28-5.27, p=0.008 and CRM: HR=1.68, CI 0.99-2.85, 
p=0.054.
Correlations between post-treatment factors and regression
Histological post-treatment factors could only be correlated to Rödel 0 and 1 since 
no tumor cells were left after complete tumor regression (Rödel 2). However, after 
complete tumor regression at the site of the primary tumor, positive lymph nodes, were 
still found in 4 (19%) out of 21 complete responders (Table 1). In two cases no lymph 
nodes were found. More extensive histological tumor regression was present in ypT1 and 
ypT2 tumors, as could be expected.  As a consequence, an involved CRM was observed 
more than twice as often in patients with limited regression (Rödel 0) compared to 
patients with Rödel 1. (70% vs 30%, p=0.03). No significant correlations were found 
between regression and histological post-treatment factors. Tumor necrosis, which 
might be considered as an alternative parameter for regression, was inversely related to 
the degree of regression. In 78% of the tumors with minimal (less than 25% of the tumor 
mass) or no regressive changes, necrotic areas were observed. After more extensive 
regression these areas were identified in only 22 (22%) of tumor specimens.
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regression grading and prognosis
Surprisingly, none of the regression systems analyzed was found to be significantly 
associated with LR. In addition, no correlation with OS was found (Table 3). We repeated 
the analysis correcting for CRM status, since this factor was found the most potent 
predictor of prognosis. In the CRM negative cases (n = 158), again grading of tumor 
regression lacked prognostic implications for LR and OS.
Table 3. Univariate analysis of regression systems in relation to local recurrence and 
overall survival
Total population (n=201) CRM negative patients only (n=158)
system n (%) % LR at 24 p-
% 
alive 
at 24 
p- n (%)
% 
LR 
at 24 
p- % alive at 24 p-
Dworak
Grade 0 18 (9%) 30% 59% 0.13 13 (8%) 10% 74%
Grade 1 83 (41%) 18% 75% 59 (38%) 7% 85%
Grade 2 57 (28%) 19% 70% 48 (30%) 12% 66%
Grade 3 22 (11%) 0% 75% 17 (11%) 0% 78%
Grade 4 21 (11%) 5% 94% 21 (13%) 5% 94%
Scott
48 (42%) 19% 68% 59 (37%) 10% 0.11 79% 0.15
35 (18%) 17% 73% 27 (17%) 13% 74%
Good 61 (30%) 9% 76% 51 (33%) 0% 77%
21 (10%) 5% 94% 21 (13%) 5% 94%
TRG 5 17 (9%) 31% 0.19 57% 12 (8%) 11% 72%
TRG 4 82 (41%) 18% 72% 58 (36%) 7% 81%
TRG 3 58 (29%) 19% 77% 47 (30%) 13% 76%
TRG 2 23 (11%) 0% 66% 20 (13%) 0% 69%
TRG 1 21 (10%) 5% 94% 21 (13%) 5% 94%
Rödel
0 101 
(50%)
20% 74% 0.15 71 (45%) 8% 86% 0.15
1 79 (39%) 14% 69% 66 (42%) 9% 68%
2 20 (11%) 5% 94% 21 (13%) 5% 94%
Abbreviations: TRG: tumor regression grade, LR: local recurrence.
reproducibility of regression grading
In order to test reproducibility of our results and to determine the inter-observer 
variability, tumor regression was also assessed by a second pathologist in all cases 
(n=201). Analysis with the data obtained by the second pathologist confirmed our initial 
finding (data not shown). In order to express inter-observer variability, measurements 
of agreement were indicated in kappa values for each system (supplemental data). 
Kappa values for the regression system as a whole and for two successive categories 
taBle 3. uniVariate analysis of regression systems in relation to local 
recurrence and oVerall surViVal
% lr
at 24 
months
% lr
at 24 
months
% alive
at 24 
months
% alive
at 24 
months
p-
value
p-
value
p-
value
p-
valuen (%)system
dworak
GRADE 0 18 (9%)
83 (41%)
57 (28%)
22 (11%)
21 (11%)
48 (42%)
35 (18%)
61 (30%)
21 (10%)
17 (9%)
82 (41%)
58 (29%)
23 (11%)
21 (10%)
101 (50%)
79 (39%)
20 (11%)
Abbreviations: TRG tumor regression grade, LR: local recurrence
13 (8%)
59 (38%)
30%
31%
18%
19%
18%
19%
0%
0%
5%
5%
5%
20%
14%
5%
19%
17%
9%
70%
75%
74%
69%
94%
94%
94%
94%
57%
72%
77%
66%
68%
73%
76%
48 (30)
17 (11%)
21 (13%)
21 (13%)
12 (8%)
58 (36%)
47 (30%)
20 (13%)
21 (13%)
71 (45%)
66 (42%)
21 (13%)
59 (37%)
27 (17%)
51 (33%)
30%
75% 85%
66%
78%
94%
94%
79%
74%
72%
81%
76%
69%
69%
86%
94%
77%
10%
7%
7%
13%
12%
0%
0%
0%
5%
5%
5%
8%
9%
11%
13%
0.21
0.26
0.19
0.44
0.13
0.29
0.29
0.15
0.31
0.15
0.66
0.15
0.61
0.17
0.53
0.95
GRADE 1
GRADE 2
GRADE 3
GRADE 4
scott
r del
Bouzourene
Minimal
Moderate
Good
0
1
2
TRG
TRG4
TRG3
TRG2
TRG1
Maximal
n (%)
totaL popuLatIon (n=201) crm negatiVe Patients only (n=158)
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within a system were calculated. Categories defining minimal regressive changes are 
more difficult to discriminate from on another (kappa’s ranging from 0.29 to 0.47) than 
categories defining extensive to complete regression (kappa’s ranging from 0.77 to 
0.85). All four systems showed that that kappa values improve as the amount of residual 
tumor decreases.
discussion
Our study demonstrates the great importance of optimal surgery for patients with 
LARC who are treated with RCT. Although it has been suggested that neoadjuvant 
therapy could compensate for poor surgery, we demonstrate that radical excision (free 
circumferential margins) is essential for local control (Figure 2). The prognostic value of 
standard clinicopathological factors such as CRM, lymph node status and tumor stage 
is superior to grading therapy-induced tumor regression in patients with LARC (Table 
1). This finding was also confirmed in a multivariate model. CRM involvement is a very 
important risk factor for local recurrence that is vastly influenced by treatment factors 
(neoadjuvant therapy and surgery). Evaluation of the CRM could therefore be considered 
as an early alternative endpoint for future randomized trials comparing different 
treatment regiments for patients with LARC 17. The most advantageous treatment 
strategy for this specific subset of patients requires a multidisciplinary approach. This 
not only implies high quality surgery and neoadjuvant therapy but also optimal imaging 
in order to identify patients who will benefit of this strategy and accurate pathological 
assessment of CRM involvement 11,12 for evaluating successfulness of the strategy.
The degree of tumor regression was found to be correlated with the neoadjuvant 
treatment regimen used. Tumor regression was found to be more extensive after RCT 
compared to long-term RT which is in accordance with literature 18,19. We were not able 
to show any prognostic impact of regression scoring, irrespective of stratification for 
CRM involvement. However, tumor regression is important because the chance to 
obtain a negative CRM is increased after extensive tumor regression (Table 1). 
The percentage of patients with a positive margin (21%) was relatively low taking into 
account that the inclusion criterion was a threatened CRM. This finding is in agreement 
with reports by Mawdsley et al and Glynne-Jones and co workers who found that 
20% of the patients with LARC had a positive CRM after RCT 17,20. LARC was defined 
by these authors as borderline resectable or irresectable disease, patients underwent 
curative surgery after neoadjuvant chemoradiation. Univariate analyses performed in 
the present study confirmed the importance of the CRM for both OS (p=0.004) and LR 
(p<0.001). Multivariate analysis of clinicopathological factors confirmed the importance 
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of CRM involvement for the prediction of local recurrence, (HR=4.44, CI: 1.83-10.81, 
p=0.001). Several other studies report similar results regarding the importance of the 
CRM as a predictor for outcome after neoadjuvant treatment. 17,21-24
Numerous studies investigated the prognostic value of tumor response after 
neoadjuvant therapy in rectal cancer, without consistent results. Similar to our study, 
no correlation was found in three different studies 19,25,26 with a total number of 385 
patients. On the other hand,  tumor regression was associated with  LR (389 patients), 
8,27-29, OS (247 patients), 8,30 or DFS (270 patients).8,9,28,30
However, reproducibility of tumor regression assessment leaves room for improvement 
(supplemental data). Measurements on the variance between two successive categories 
within each system showed that kappa values improve as the amount of residual tumor 
decreases. Distinguishing absence (Figure 1A) from little regressive signs (Figure 1B) 
was reproduced poorly, probably because formation of fibrosis is also an intrinsic 
characteristic of tumor development. Discriminating intrinsic tumor fibrosis from 
therapy-induced fibrosis based on morphology is difficult. A complete tumor response, 
on the other hand, which is the only clearly definable degree of tumor regression 
largely depends on tissue processing and sampling which are often responsible for 
discrepancies in literature regarding the rate of complete responders 9,30. A possible 
way to standardize the criteria for a complete response could be as follows; sample 5 
sites of the tumor area, if no tumor is present in these blocks the whole area suggestive 
for disease should be embedded in paraffin blocks. If still no tumor is present, H&E 
slides will be obtained from each block at three levels. If no tumor was found after this 
procedure, a complete response was established 31. The lack of clear definitions with 
respect to the morphological aspects of therapy-induced fibrosis and a complete tumor 
response explains both inter-observer and inter-study variance. 
The term locally advanced is also not clearly defined. Definitions range from patients 
who received long-term neoadjuvant RT or RCT, to patients with positive lymph nodes, 
advanced cT3 or cT4 or patients with a threatened CRM. Three out of the nine studies 
investigating the prognostic value of grading tumor regression stated to have analyzed 
patients with LARC 8,25,29. The percentages of stage cT4 in these three reports range 
from 12% 25 to 32% 29 and are relatively low compared to the percentage of cT4 in the 
present population (59%). Moreover, none of the reports on LARC selected patients 
based on a threatened CRM (a predicted CRM on MRI of less than 2 mm). These unique 
pre-treatment characteristics distinguish the present population from other reports 
concerning patients with LARC. These differences in patient selection can also explain 
the inconsistency, regarding the prognostic implications of tumor regression, between 
the findings described in the present study and those described by others.
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Our data indicate that tumor response to neoadjuvant long-term RT or RCT results 
in tumor shrinkage (arrow, Figure 3) rather than fragmentation of the tumor (dotted 
arrow, Figure 3). The scenario of tumor fragmentation implicates that the degree of 
tumor regression is not informative for depth of infiltration; e.g. vital tumor cells may 
still be scattered throughout the whole fibrotic area and reach the pre-treatment level 
of tumor invasion. Tumor fragmentation after neoadjuvant treatment still results in 
CRM involvement. However, our data suggest that tumor shrinkage is the main event 
after neoadjuvant therapy, resulting in negative CRM, which was obtained in almost 
80% of patients with a clinically threatened margin. Moreover, our data revealed that 
patients with a negative CRM experienced significantly less local recurrence compared 
to patients with a positive CRM. This indicates that the fibrotic area that is depicted 
in grey in Figure 3B is sterile, pleading for the scenario of tumor shrinkage. However, 
if the CRM is involved, patient prognosis remains poor despite elaborate histological 
regression after neoadjuvant treatment (Figure 3C). 
In case of OS, lymph node status revealed to have strong prognostic implications. Since 
treatment of patients with LARC consists of intensified local treatment aimed on the 
primary tumor, loco-regional tumor spread resulting in positive lymph nodes (and as 
a consequence decreased OS) is essentially not affected by this treatment. This was 
illustrated by our finding that positive lymph nodes can still be found after complete 
regression of the primary tumor mass (Table 1) which can explain why these patients 
can still develop metastasis. 
In this study, which investigates a unique population of patients with LARC which had a 
threatened CRM and a high percentage of cT4, we have shown that assessment of the 
CRM is the most important pathological factor after RCT. Extensive tumor regression, 
resulting in tumor shrinkage, is essential for obtaining a free CRM, but incomplete 
resection implies a poor prognosis irrespective of the degree of these regressive 
changes. 
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Figure 3: Schematic representation of the relation between the degrees of tumor regression and 
circumferential margin (CRM) involvement. Areas with vital tumor cells are depicted in black and 
fibrotic areas are depicted in grey. A: Pre-treatment situation: the tumor is locally advanced (cT4) and 
the CRM is threatened The contours of this pre-treatment stage are also depicted in panel B, C and D. 
After neoadjuvant long course radiotherapy (RT) or radiochemotherapy (RCT) two different scenarios 
concerning tumor regression are sketched (B, D). B illustrates the “tumor shrinkage” scenario in which 
the infiltration depth is less  extensive than in the pre-treatment situation. D illustrates the scenario of 
“tumor fragmentation” which implies scattered tumor cells throughout the whole fibrotic area, reaching 
the initial infiltration depth. However, if the CRM is still positive after tumor shrinkage (panel C) patients’ 
outcome will still be poor irrespective of the degree of tumor regression.
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Background
Tumor budding is a histological feature that reflects loss of adhesion of tumor cells and 
is associated with locoregional metastasis of colorectal carcinoma. Although nuclear 
localization of β-catenin is associated with tumor budding, the molecular mechanism 
remains largely elusive. In this study, we hypothesize that the epithelial cell adhesion 
molecule (Ep-CAM) is involved in tumor budding. 
Patients and methods 
In order to address this question we performed immunohistochemistry on Ep-CAM using 
3 different antibodies (monoclonal antibodies Ber-ep4 and 311-1K1 and a polyclonal 
antibody) and a double staining on β-catenin and Ep-CAM. In addition, Ep-CAM mRNA 
was monitored with mRNA in situ hybridization. Subsequently, we determined the 
effect of Ep-CAM staining patterns on tumor spread in rectal cancer. 
results
In contrast to the tumor mass, budding cells of colorectal carcinoma displayed lack 
of membranous but highly increased cytoplasmic Ep-CAM staining and nuclear 
translocation of β-catenin. mRNA in situ hybridization suggested no differences in Ep-
CAM expression between the invasive front and the tumor mass. Importantly, reduced 
Ep-CAM staining at the invasive margin of rectal tumor specimens (n=133) correlated 
significantly with tumor budding, tumor grade and an increased risk of local recurrence 
(p=0.001, p=0.04 and p=0.03 respectively). 
conclusion
These data demonstrate abnormal processing of Ep-CAM at the invasive margin of 
colorectal carcinomas. Our observations indicate that loss of membranous Ep-CAM 
is associated with nuclear β-catenin localization and suggest that this contributes to 
reduced cell-cell adhesions, increased migratory potential and tumor budding.
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introduction
Budding of dedifferentiated tumor cells at the invasive margin is well described in 
colorectal cancer. Tumor budding or sprouting is a histologic feature of loss of adhesion 
and is associated with locoregional tumor spread 1,2. These budding tumor cells have 
been described to exhibit nuclear β-catenin 3. In the nucleus, β-catenin can activate 
the transcription of genes associated with cell proliferation and differentiation 4. When 
β-catenin is bound to the cytoplasmic domain of E-cadherin, it enables E-cadherin 
to function as a cell-cell adhesion molecule and mediates the interplay of adherence 
junction molecules with the actin cytoskeleton (4). Aberrations of E-cadherin expression 
can lead to abundant cytoplasmic β-catenin and subsequent nuclear localization. Based 
on these well described interactions between β-catenin and E-cadherin, it is plausible 
that modulation of E-cadherin-mediated adhesion is involved in tumor budding. 
However, Masaki and co-workers did not find a correlation between nuclear β-catenin 
and changes of E-cadherin characteristics in budding colorectal tumor cells 5. 
In addition to E-cadherin, the Epithelial Cell Adhesion Molecule (Ep-CAM, also known 
as Ber-EP4, CO17-1A, GA733 and EGP2) can also mediate cell-cell adhesion of epithelial 
cells. The adhesions between epithelial cells are facilitated by the extracellular domain 
of the protein 6. The smaller intracellular domain is known to interact with the actin-
skeleton via α–actinin 7. Ep-CAM does not share significant homology with any of 
the four major families of adhesion molecules (cadherins, selectins, integrins and 
the immunoglobulins). Increased Ep-CAM expression is associated with enhanced 
proliferation and a lower differentiation grade of epithelial cells under non-pathological 
conditions. In the proliferative phase, Ep-CAM expression is associated with epithelial 
tissue remodeling. After cell proliferation, Ep-CAM expression declines and cellular 
differentiation initiates. An interesting example illustrating the correlations between 
Ep-CAM expression and cell proliferation in normal tissue is the hair follicle where Ep-
CAM is only expressed by cells in the highly proliferative zone 8. Furthermore, differential 
Ep-CAM expression is observed during embryonic development of different tissues 
such as pancreas and lung 9,10. In these perspectives Ep-CAM can thus be regarded as a 
morphoregulatory protein.
Among neoplastic tissues, Ep-CAM is abundantly expressed in tumors of epithelial 
origin, e.g. lung, breast, prostate, renal cell and colorectal carcinoma 11,12. Ep-CAM is 
present in high amounts in normal colorectal tissue but its expression increases even 
further in polyps 13 and carcinomas 14. In tumor cells, increased Ep-CAM expression 
promotes cell-cell adhesion.  Ectopic expression the murine Ep-CAM ortologue (mEGP) 
by murine colorectal carcinoma cells increased cell-cell adhesion, attenuated tumor cell 
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invasion in Matrigel, and decreased tumor incidence and metastasis when inoculated 
into the spleen of mice 15. Thus these data suggest that Ep-CAM expression antagonizes 
tumor growth and metastasis. Because tumor budding is well described in colorectal 
cancer and is associated with poor prognosis (1, 2), we hypothesized that altered 
Ep-CAM characteristics in rectal cancer may correlate with tumor budding and poor 
disease outcome. To this end, we have performed a detailed analysis of intra-tumoral 
Ep-CAM staining patterns using three different antibodies, and correlated these 
patterns with local and distant recurrence rates in patients with rectal cancer. By using 
2 monoclonal antibodies with different epitopes on the Ep-CAM ectodomain we could 
closely monitor changes in epitope availability of this domain. The combination of these 
two monoclonal antibodies with a polyclonal antibody, which recognizes the whole Ep-
CAM protein (Figure 1), enabled us to study sub-cellular distributions of Ep-CAM and 
possible modifications of the protein such as cleavage or aberrant localization.
Figure 1: schematic overview 
of the Ep-CAM protein with the 
positions of the Ber-EP4 and 311-
1K1 epitopes and binding sites of 
the polyclonal antibody. Ber-EP4 
and 311-1K1 are monoclonal 
antibodies which have specific 
epitopes (bold arrows). The 
polyclonal antibody recognizes 
numerous parts of the EP-CAM 
protein as depicted by the dotted 
line.
materials and methods
immunohistochemistry
Immunohistochemical staining of Ep-CAM was performed on paraffin-embedded 
tissue sections using monoclonal antibodies Ber-EP4 (1:100, Dako, Glostrup, Denmark) 
and 311-1k1 (1:50, Pickcell laboratories, Leiden, the Netherlands, 1:50). The localization 
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of their epitopes is depicted in Figure 1. In case of β-catenin, immunohistochemical 
staining was performed with the Clone 14 monoclonal antibody (1:6000, Transduction 
Laboratories, Lexington, USA). Staining was performed using the avedin-biotin 
peroxidase complex in case of visualization with 3, 3’-diaminobenzide hydrochloride 
solution (DAB) and the avidin-biotin alkaline phosphatase complex for staining 
with fast blue. Paraffin sections were de-waxed and re-hydrated. All reactions were 
performed at room temperature, unless stated otherwise. Endogenous peroxidase 
activity was blocked by incubation in phosphate-buffered saline (PBS) containing 3% 
H2O2 for 30 min. After rinsing with PBS, antigen retrieval for Ber-EP4 staining consisted 
of incubation with 1% pronase at 37 °C for 10 min. Retrieval for 311-1K1 and β-catenin 
staining involved microwave boiling in a 10 mM sodium citrate buffer (pH 6.0) for 10 
min. After boiling, the slides were allowed to cool down for at least 30 min. After rinsing 
with PBS, slides were pre-treated with 20% normal horse serum for 10 min. to reduce 
non-specific staining. All sera and antibodies were dissolved in PBS with 1% BSA. 
Subsequently, slides were incubated in a humidity chamber with the primary antibody 
at 4 °C for 16-20 h. This long incubation time resulted in saturation of the reaction and 
therefore optimal staining. Staining of the DAB substrate was intensified with a 0.5% 
copper sulfate solution, in case of double straining this step was omitted. Slides were 
counterstained with Hematoxylin solution or Nuclear Fast Red for 1 min, dehydrated 
and enclosed with Permount (Fisher Chemicals, New Jersey, USA).
A complete loss of Ber-EP4 staining was never observed and no distinction was made 
between the various degrees of decrease which were very subtle. Therefore, staining 
patterns of the Ber-EP4 antibody were categorized as follows: (i) no decrease of staining, 
(ii) decrease of staining at the front, or (iii) decreased staining throughout the tumor.
Immunofluorescence
Immunofluorescence double stainings were performed with Ber-EP4 and a chicken 
polyclonal anti-Ep-CAM antibody (kindly provided by Dr. S. Litvinov) and with Ber-EP4 
and a monoclonal anti cytokeratin antibody, Cam 5.2 (1:40, Becton Dickinson, Franklin 
Lakes, USA). Briefly after dewaxing and re-hydration, slides were rinsed with PBS and 
incubated in this solution at 4 °C for at least 16 h to reduce auto-fluorescence. In case 
of Ber-EP4 and CAM 5.2 double staining antigen retrieval involved incubation with 1% 
pronase at 37 °C for 10 min. Antigen retrieval for the Ber-EP4 and Ep-CAM polyclonal 
antibody double staining consisted of microwave boiling in a 10 mM sodium citrate buffer 
(pH 6.0) for 10 min. After cooling down and rinsing with PBS, Slides were incubated with 
20% normal goat serum for 10 min. Slides were incubated with the primary antibody 
Ber-EP4 at 4 °C overnight. After rinsing, slides were incubated with goat anti-mouse 
IgG-conjugated Alexa 488/594 (1:200, Invitrogen Molecular Probes, Eugene, USA) 
for 30 min. After rinsing, slides were incubated with 20% goat serum or 100% normal 
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goat serum to reduce non-specific binding of the polyclonal antibody. Subsequently, 
slides were incubated with the second primary antibody of choice at 4 °C overnight. 
The polyclonal antibody was detected with goat anti chicken IgG-conjugated Alexa 594 
(1:200, Invitrogen Molecular Probes) for 30 min. CAM 5.2 binding was visualized with 
goat anti-mouse IgG2a-conjugated Alexa 488 (1:200, Invitrogen Molecular Probes) for 
30 min. After washing in PBS, slides were stained with 4’-6-diamidino-2-phenylindole 
(DAPI) for 30 sec. Sections were enclosed in fluorteck (Euro-Diagnostica, Arnhem, the 
Netherlands). For analysis a fluorescent microscopy (Leica, Solms, Germany) was used. 
Images were captures, using a 5X, 10X, 20X or 40X objective and were prepared with 
Adobe Photoshop version 7.0.
ep-CaM mrna in situ hybridization
A 420 bp human cDNA fragment was generated by reverse transcriptase-polymerase 
chain reaction (RT-PCR) according to standard procedures. Briefly, total RNA 
isolated from the CaCo2 colon carcinoma cell line was isolated with Trizol (Gibco 
BRL) according to the manufacturer’s protocol and 0.5 µg was reverse-transcribed 
at 42ºC for 1 hour using SuperScript II (Promega) and oligo dT16-18 primer. Ep-CAM 
cDNA was amplified using specific primers (5’-CTGGCCGTAAACTGCTTTGT and 5’-
CTTCCTCTAGTGTTGCGCAA) and were based on the reported sequence of human Ep-
CAM (gi: 10439469). Amplification consisted of pre-incubation at 95ºC for 5 minutes 
before adding Taq polymerase and then 30 cycles at 95ºC for 1 minute, 55ºC for 30 
seconds and 72ºC for 30 seconds. A PCR product of the predicted size was cloned into 
the pGEM-T easy vector (Promega, Madison, USA) and sequence was verified. The 
plasmid containing the partial cDNA of Ep-CAM was linearized by digestion with PstI 
or SphI and antisense and sense riboprobes were synthesized using T7 and SP6 RNA 
polymerase, respectively, and dioxygenin-labelled rUTP (Roche, Basel, Switzerland) 
according to standard procedures. mRNA in situ hybridization of paraffin-embedded 
tissue sections was performed as previously described 16.
Patient selection
In order to study the effect of Ep-CAM distribution in colorectal tumors on local and 
distant recurrence, we used data obtained from the radiotherapy (RT) + Total Mesorectal 
Excision (TME) trial. The TME trial was initiated in The Netherlands and included 1530 
patients from January 1996 until December 1999 17,18. This prospectively randomized 
trial evaluated TME surgery with or without preoperative radiotherapy (5x5 Gy). To be 
eligible, patients had to have histologically confirmed rectal adenocarcinoma, without 
evidence of distant metastasis. Patients with previous or coexisting cancer and those 
who had previously undergone large-bowel surgery, chemotherapy or radiotherapy 
were excluded. The TME trial was approved by the medical ethics committees of all 
participating hospitals and after informed consent had been obtained, selected patients 
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were randomized and assigned to either radiotherapy (5 Gy on each of five days) followed 
by TME or to TME alone. Radiotherapeutical, surgical and pathological procedures were 
standardized and subjected to strict quality control 19. Outcome measures included 
local and distant recurrences confirmed by radiographic imaging and/or histological 
diagnosis. Since local recurrence rates were very low after TME surgery, an artificial 
selection of 160 patients was made to study the role of biological markers in both local 
and distant recurrence 20. 40 stage II and 40 stage III patients without local recurrence 
or distant metastasis, 40 with distant metastasis and without local recurrence and 40 
patients with local recurrence and without distant metastasis were selected. Former 
results obtained by studying this population 20 indicated sufficient statistical power in 
this population. The selection implies that local- and distant recurrence percentages 
cannot be extrapolated towards the total population studied. Patients were selected 
from both randomization arms to exclude possible therapy related effects. From these 
160 patients tumor samples were available for Ep-CAM immunohistochemistry of 133 
patients. The median follow-up was 41.7 months. 
Pathology procedures
Tumor staging was performed by the use of the tumor-node-metastasis (TNM) classification 
21. Growth pattern assessment was performed according to Jass. A circumferential margin 
of 1 mm or less was considered positive. Histological differentiation grade was classified 
as undifferentiated, poorly differentiated, moderately and well. The grading decision 
was based on the least differentiated area 22. Tumor budding at the invasive margin was 
assessed as described by Ueno et al 23,24. In case of 117 tumors (88%) a representative HE 
staining of the tumor area assessed with Ber-EP4 could be obtained. After choosing a 
field where budding was most intensive, the number of budding foci was counted using 
a 25X microscope objective.  A budding focus was defined as a single isolated tumor cell 
or a cluster of tumor cells composed of fewer than 5 cells. Subsequently, these data were 
categorized as follows: I: 0-4 budding foci, II: 5-9 budding foci, III: 10-19 budding foci and 
IV: more than 20 budding foci.
statistical analysis
Ep-CAM staining patterns of patients included in the Dutch TME trial were correlated 
with local, distant and overall recurrence using Kaplan-Meier curves and log-rank 
testing. Associations between Ep-CAM patterns and histopathological parameters 
were analyzed by Chi-Square testing. P values of <0.05 (two tailed) were considered as 
statistically significant.
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results
Loss of the Ber-ep4 epitope in budding tumor cells
Normal colon mucosa was intensely stained with Ber-EP4 and 311-1K1 monoclonal 
antibodies (Figure 2 A, B). In colorectal tumors, decreased staining was predominately 
observed in budding tumor cells at the invasive margin. Additionally, we found 
focally decreased staining with these antibodies within the tumor mass (Figure 2 C, 
D, E, and F). In order to identify potential Ber-EP4-negative tumor cells, we used an 
immunofluorescence (IF) double staining with Ber-EP4 and the tumor marker CAM 
5.2 (cytokeratin 7 and 8). With this method, a pattern of decreased Ber-EP4 staining 
on isolated infiltrating tumor cells was observed (Figure 3 A, B, C). To demonstrate a 
true correlation between localization of β-catenin and the presence or absence of the 
Ber-EP4 epitope, we performed double stainings. Double staining of Ber-EP4 and β-
catenin showed that tumor cells with decreased Ber-EP4 immunoreactivity frequently 
displayed nuclear translocation of β-catenin (Figure 4A, B).
These data suggested either an inhibition of Ep-CAM mRNA expression or abnormal 
processing of Ep-CAM at the invasive front. Ep-CAM mRNA in situ hybridization and 
Ber-EP4 immunohistochemistry on consecutive sections demonstrated that mRNA 
expression in cells displaying decreased Ber-EP4 staining was not reduced (Figure. 
5). Therefore, these results suggested that the focal loss of Ber-EP4 and 311-1K1 
immunoreactivity was probably caused by abnormal processing of Ep-CAM.
Figure 2: Representative Ep-CAM staining 
patterns in normal mucosa of the colon 
and colorectal adenocarcinoma with 
monoclonal antibodies Ber-EP4 and 
311-1K1. A, Normal mucosa stained 
with Ber-EP4 (original magnification: 
50X). B, Normal mucosa stained with 
311-1K1 (original magnification: 100X). 
C, Decreased staining with Ber-EP4 in 
sprouting tumor cells, arrow (original 
magnification: 200X). D, Decreased 
staining of tumor mass with the 
311-1K1 antibody, arrow (original 
magnification: 50X). E and F, serial 
sections with clusters of tumor cells 
stained with Ber-EP4 (E) and 311-1K1 
(F) (original magnification: 50X). Loss 
of immunoreactivity of isolated tumor 
cells and small clusters was observed 
with both 311-1K1 and with Ber-EP4 
antibodies (arrowheads).
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Figure 3: Immunofluoresence 
double staining of the 
invasive margin. A, Ber-EP4 
immunoreactivity. B, staining 
with tumor marker cytokeratin 
8. C, merge, Ber-EP4 staining 
is depicted in red, cytokeratin 
in green. Arrows indicate 
that infiltrating tumor cells 
show a loss of Ber-EP4 
immunoreactivity (original 
magnifications: 100X).
→ color figures
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Figure 4: Double staining of 
Ep-CAM (Ber-EP4 epitope) 
and β-catenin of tumor 
masses with sprouting 
tumor cells. The Ber-EP4 
epitope was visualized with 
DAB (brown) and β-catenin 
was displayed with fast 
blue staining (blue); nuclei 
were counterstained with 
Nuclear Fast Red. A, Tumor 
nodule with distinct budding 
of tumor cells which show 
a nuclear staining pattern 
of β-catenin and decreased 
staining of the Ber-EP4 
epitope, arrows (original 
magnification 100X). This 
staining pattern of β-catenin 
was not observed centrally in 
the tumor nodule. B, Budding 
tumor cells spreading into 
the mesorectal fat. Isolated 
tumor cells exhibit loss of the 
Ber-EP4 epitope and nuclear 
β-catenin, arrow (original 
magnifications: 100X).
→ color figures
Cytoplasmic patterns of ep-CaM immunoreactivity in budding tumor cells
We subsequently addressed whether loss of membranous immunoreactivity could also 
be detected with a polyclonal anti-Ep-CAM antibody. Double staining with Ber-EP4 and 
the polyclonal antibody showed that a decreased Ber-EP4 staining was accompanied by 
cytoplasmic staining of Ep-CAM as visualized by the polyclonal antibody (Figure 6 D, F). 
This was predominantly observed in budding tumor cells or clusters. In normal mucosa, 
both antibodies showed a membranous staining pattern of Ep-CAM with equal staining 
intensity (Figure 6 A-C). These data demonstrated that loss of membranous Ep-CAM 
immunoreactivity coincided with increased cytoplasmic staining.
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Figure 5: Ep-CAM mRNA in situ 
hybridization (ISH) and Ber-
EP4 immunohistochemistry 
on serial sections. A, Ep-
CAM mRNA ISH. B, Ber-EP4 
staining of clusters of tumors 
cells at the tumor front of 
the same tumor area. Tumor 
cells with decreased Ber-EP4 
staining do not present to 
have lower amounts of Ep-
CAM mRNA (arrows, original 
magnifications: 100X).
→ color figures
clinical relevance of heterogeneous staining patterns
In order to analyze the prognostic value of decreased Ber-EP4 immunoreactivity in 
budding tumor cells, the relation between Ber-EP4 staining patterns and local, distant 
and overall recurrence was assessed by using data from the TME trial in which patients 
were randomized for TME surgery only or radiotherapy followed by TME surgery. 
No correlations were found between the surgery only and the irradiated group with 
respect to the immunohistochemical staining patterns. Furthermore, no correlations 
were found between Ep-CAM staining patterns and lymph node involvement, tumor 
depth, circumferential margin involvement and tumor stage (Table 1).
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Figure 6: Immunofluorescence 
double staining of Ep-CAM with both 
monoclonal Ber- EP4 and polyclonal 
antibody. A, Normal mucosa of 
the colon shows a membranous 
staining pattern with Ber-EP4. B, The 
polyclonal antibody also presents 
a membranous staining pattern in 
normal colon mucosa. C. Merge 
Ber-EP4 is visualized in green and 
the polyclonal antibodies in red, 
nuclei are counterstained wit DAPI 
(blue). D, An isolated tumor cluster 
(arrow head) next to a tumor gland 
(arrow), immunohistochemistry 
was performed with the Ber-EP4 
antibody. E, immunohistochemical 
expression of Ep-CAM evaluated 
with the polyclonal antibody. F, 
Merge Ber-EP4 is visualized in 
green and the polyclonal antibody 
in red, nuclei are counterstained 
wit DAPI (blue). Loss of Ber-EP4 
staining intensity is associated with 
a cytoplasmic staining pattern with 
the polyclonal anti Ep-CAM antibody 
(original magnifications: 400X).
→ color figures
 Differentiation grade and presence or absence of membranous Ep-CAM at the invasive 
margin was found to be significantly correlated (Table 1). Tumors with selective loss 
of membranous Ep-CAM at the invasive margin were scored as poorly differentiated 
or undifferentiated in 35% of the cases in contrast to 20% of tumors with no loss of 
membranous Ep-CAM (p=0.04). Differentiation grading alone failed to show significant 
correlations to local-, distant- or overall recurrence (data not shown), indicating that loss 
of membranous Ep-CAM expression in budding cells of rectal carcinoma is of higher 
prognostic value than tumor differentiation grade. In addition, a significant correlation 
was found between loss of membranous Ep-CAM and the extent of tumor budding 
(Table 1, p= 0.001). Loss of membranous Ep-CAM was associated with a higher extent 
of tumor budding. This correlation between tumor budding and loss of membranous Ep-
CAM is emphasized by the finding that tumor budding was also significantly correlated 
with tumor grade. A higher degree of budding was correlated with a lower degree of 
differentiation (p=0.048, χ2 testing).
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randomization
lymph node 
involvement
tumor depht
circumferential 
margin
tnm stage
differentiation 
grade
tumor budding
mean values smallest crm (cm)
RT and Surgery
Surgery alone
positive lymph nodes
no positive lymph nodes
T2
T3
T4
negative
positive
Stage I/II
Stage III/IV
well/moderate
poor/undifferentiated
I
II
III
14 (36%)
25 (64%)
27 (69%)
12 (31%)
9 (23%)
30 (77%)
0 (0%)
27 (69%)
12 (31%)
11 (28%)
28 (72%)
24 (62%)
15 (38%)
13 (38%)
14 (41%)
7 (21%)
0.45
30 (43%)
40 (57%)
39 (56%)
31 (44%)
19 (27%)
50 (72%)
1 (2%)
54 (77%)
16 (23%)
31 (44%)
39 (56%)
56 (80%)
14 (20%)
43 (69%)
18 (29%)
1 (2%)
0.9
0.31
0.12
0.66
0.25
0.073
0.04
0.001
0.055*
factor category
decrease at 
tumor front
no decrease at 
tumor front p-vaLue
Abbreviations, RT: radiotherapy, *:P-value calculated with Mann Whitney test. 
Bold values indicate statistical significance.
taBLe 1. ep-CaM patternS In reLatIon to CLInICopathoLoGICaL FaCtorS
ep-CaM patterns
Tumors (n=133) were stained and scored as (i) no decrease of Ep-CAM staining (70/133, 
53%), (ii) decrease of staining at the tumor front (39/133, 29%), or (iii) decrease of 
staining throughout the tumor (24/133, 18%). Tumors with a decreased Ber-EP4 staining 
throughout the whole tumor were found to be a distinct group. This subpopulation 
of tumors behaved differently with respect to distant recurrence from tumors with 
decreased Ber-EP4 staining restricted to the tumor front. A loss of membranous Ep-
CAM throughout the tumor was found to be correlated with an elevated risk on local 
recurrence alone compared to patients with no decrease of membranous Ep-CAM (p= 
0.05). Moreover, in our opinion, this sub-population is not suitable for studying the 
process of tumor budding at the invasive margin. Because this sub-population has 
prognostic implications which are distinct from tumors with decreased Ber-EP4 staining 
exclusively observed at the front it could interfere with the prognostic implications of 
the latter group. Because of this reason the effect of the Ep-CAM characteristics at 
the tumor front was conducted in 109 (39+70) cases. Decreased staining intensity of 
Ber-EP4 at the invasive front was always accompanied by a focally infiltrating growth 
pattern. Loss of membranous staining at the infiltrative margin correlated with a 
significantly higher risk of local recurrence (p= 0.03, Figure 7) compared to tumors with 
homogenous Ep-CAM patterns. A decrease of Ep-CAM staining at the front indicated 
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an elevated risk on distant recurrence, but this finding was not statistically significant 
(p= 0.06). For overall recurrence, loss of membranous Ep-CAM strongly correlated with 
a significant higher risk of this event (p=0.01).
Figure 7: Kaplan-Meier curves presenting the 
correlation between different Ep-CAM staining 
patterns and local recurrence (A), distant 
recurrence (B) and overall recurrence (C), (N=109). 
Black line: selective decrease of Ber-EP4 staining 
at the invasive margin, grey line: no decrease of Ber-
EP4 immunoreactivity at the tumor front.
discussion
In this study, we demonstrate a focal loss of membranous Ep-CAM immunoreactivity 
at the invasive margin predominantly in sprouting tumor cells, which was frequently 
accompanied by nuclear β-catenin translocation. These findings strongly suggest that 
the morphoregulator Ep-CAM is involved in budding of rectal carcinoma.
Analysis of Ep-CAM mRNA expression in rectal carcinoma did not reveal strong 
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differences in levels of transcription indicating that Ep-CAM at the invasive margin 
evidences abnormal post-translational processing. It has to be emphasized that budding 
cells are not deprived from Ep-CAM. Post-translational modifications did not affect 
Ep-CAM expression, i.e. the polyclonal antibody showed that it was still present, but 
altered its cellular localization. Therefore, infiltrating cells possibly retain the features 
that contribute to high levels of Ep-CAM, e.g. enhanced proliferation and loss of 
differentiation 25. Additionally, lack of extracellular Ep-CAM can enhance the migratory 
capacity by attenuating cell-cell adhesion. 
The aberrant localization of Ep-CAM could contribute to tumor budding. During 
embryonic development of the pancreas, the highest levels of Ep-CAM expression are 
found in islet-like cell clusters budding from the ductal tree, suggesting that increased 
expression contributes to budding under non-pathological conditions 9. In contrast, 
we found post-translational modification of Ep-CAM in budding tumor cells of rectal 
cancers in which Ep-CAM was already abundantly expressed. Assessment of the extent 
of tumor budding showed that loss of membranous Ep-CAM was significantly correlated 
to a higher extent of tumor budding. Furthermore, tumors with loss of membranous 
Ep-CAM at the invasive margin are more often graded as poorly or undifferentiated. 
Also, the clinical implications of tumor budding, i.e. increased locoregional spread are 
reflected by the loss of membranous Ep-CAM staining since it correlated with increased 
local recurrence following surgical removal of the tumor. Tumor cells at the invasive 
front that exhibit loss of extracellular Ep-CAM have increased migratory potential and 
can spread through the bowel wall more easily. This is also reflected by the percentage 
of involved margins; 31% and 23% for tumors with and without loss of extracellular 
Ep-CAM at the tumor front respectively (Table 1). Increased local tumor spread due to 
loss of extracellular Ep-CAM could account for non-curative resections and therefore 
increased local recurrence. 
Loss of membranous Ep-CAM (Table 1) and tumor budding do mot correlate with 
TNM-criteria. Although we do not have a proven explanation, it might be that tumor 
budding is a biological phenomenon that can occur at various moments during tumor 
development and is described to occur at various T stages including T1 and T2 26,27. 
Thus, tumor budding reflects interaction on the level of the tumor microenvironment 
and is independent of the T stage itself. A significant correlation between loss of 
membranous Ep-CAM and lymph node (Table 1) and distant metastasis was also not 
observed (Figure 7). Invasion due to loss of adhesion, although related to metastasis is 
a distinct feature during tumor progression. In order to metastasize tumor cells require 
more characteristics than increased invasive potential such as extracellular matrix 
remodelling, induction of angiogenesis, and modulation of cell-cell and cell-matrix 
adhesive properties. 
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Infiltrating, sprouting tumor cells are discriminative from the tumor mass with respect 
to modifications of the Ep-CAM protein and thus suggests a role for this protein in the 
formation of tumor budding. Therefore, cytoplasmic Ep-CAM localization could alter 
its morphoregulatory capacity as compared to its membranous localization, and that 
sustains tumor budding.
Loss of membranous Ep-CAM can modulate changes of the cytoskeleton and hence 
change cell morphology. The extracellular domain of Ep-CAM with its two EGF-
like repeats in a cystine rich domain followed by a cystin poor domain is similar to the 
organization of the extracellular domains of the lin21/Notch family. These proteins 
are involved in inter-cellular signaling and cell cell-interactions that are important for 
differentiation and segregation 28. It has been demonstrated that the cytoplasmic domain 
of Ep-CAM interacts with the actin-cytoskeleton 7. Recently, it was demonstrated that high 
cytoplasmic expression of actinin-4, a modulator of the cytoskeleton, is predominantly 
observed in budding cells of colorectal carcinoma 29. Furthermore, high levels of actinin-4 
are associated with increased cell motility 30. Although it remains elusive whether there is 
a causal relation between cytoplasmic Ep-CAM and actinin-4 expression, it is tempting to 
speculate that both proteins are closely involved in tumor budding.
It remains elusive how Ep-CAM retains its cytoplasmic localization in budding tumor 
cells. The observed decrease in immunoreactivity of two monoclonal antibodies 
binding to the extracellular epitopes and a cytoplasmic staining pattern with the 
polyclonal antibody suggests internalization of Ep-CAM remnants after proteolytic 
modifications. Internalization of Ep-CAM has been reported previously by Litvinov 
and co-workers 31. Our finding that loss of membranous Ep-CAM frequently concurs 
with nuclear β-catenin expression (Figure 4) makes a scenario of proteolytic Ep-CAM 
modifications plausible. The Lef/Tcf transcription factors, which are activated after 
β-catenin translocation, have been described to modulate the expression of different 
matrix metalloproteinases (MMP’s) such as MMP-1 and MMP-7 32-34. Since proteolysis of 
cell-cell adhesion molecules is a common feature in cancer 35, cleavage of Ep-CAM could 
be a downstream effect of nuclear translocation of β-catenin. This view is supported by 
a recent study by Hörkkö and co/workers who postulate that nuclear accumulation of 
β-catenin is a requirement for tumor budding but other factors, which are more related 
to sprouting, also play role 36.
Alternatively, loss of membranous Ep-CAM in budding cells could be explained by 
splice variants of Ep-CAM. However, Balzar et al conducted an extensive analysis of Ep-
CAM mRNAs in a large number of carcinoma cell lines and did not reveal any variations 
in Ep-CAM mRNA splicing 25. Furthermore, alternative glycosylation of the Ep-CAM 
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ectodomain can shield of Ber-EP4 and 311-1K1 epitopes. This in combination with 
impaired translocation to the membrane could also explain our findings. We have not 
addressed this possibility in our study.
Because high amounts of Ep-CAM are present on the membranes of many tumor 
types, it is an attractive target for immunotherapy. Since the 90’s, a number of trials 
investigated the therapeutic value of postoperative treatment with the 17-1A Ep-CAM 
antibody (Edrecolomab) 37-39. This antibody also binds to EGF domain I 40 and its epitope 
is in close proximity to Ber-EP4 (Figure 1). The results of these studies are conflicting, 
attributing positive, no or adverse effects of Edrecolomab therapy on survival and 
disease free survival of patients with colorectal cancer. The findings presented in this 
study may explain these conflicting results. A subpopulation of tumor cells which were 
located at the invasive margin is undetectable for the Edrecolomab antibody. These 
cells lacked large amounts of extracellular Ep-CAM on their surfaces, which not only 
conceals them from the antibody, but also increased their migration capacity due to 
attenuated Ep-CAM-mediated cell-cell adhesion. 
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Background
Approximately 10% of all colorectal carcinomas are mucinous carcinomas, characterized 
by extracellular mucin. Occasionally, mucin accumulates intracellular in these tumors, 
causing signet ring cell differentiation. We hypothesize that signet ring cells arise from 
a separate genetic pathway. In this study the molecular background of signet ring cell 
differentiation is investigated by analysing genetic changes, changes in the expression of 
adhesion molecules, and mucin content. Furthermore, its clinical relevance is addressed. 
Patients and methods
Cell lines of colorectal tumors with non-mucinous (AC), mucinous (MC) and signet 
ring cell phenotype (MCSRC) were used for Multiplex Ligation-dependent Probe 
Amplification to detect deletions and amplifications in specific oncogenes and tumor 
suppressor genes. Furthermore, the expressions of E-cadherin, β-catenin, ITF (intestinal 
trefoil factor) and MUC2 in signet ring cells were studied by immunohistochemisty, 
immunofluorescence, and mRNA in situ hybridization. Results were validated using 
a large cohort of colorectal carcinomas from which clinicopathological data were 
available.
results
Specific amplifications and deletions in cell lines of AC, MC and MCSRC were detected. 
Bcl-2 was amplified in MCSRC and MC cell lines, but not in AC cell lines. Bcl-2 FISH analysis 
confirmed this in patient material. 
Signet ring cells have a decreased expression of adhesion molecules (E-cadherin, β-
catenin) and are strongly positive for ITF and MUC2, two peptides which are normally 
only produced by goblet cells. RNA in situ hybridization confirmed the production of ITF.
Carcinomas with signet ring cell differentiation present at a higher T stage (16% versus 
3-5%, p<0.001) and are more frequently node positive (77% vs. 39-44%; p<0.001) 
compared to adenocarcinomas and adenocarcinomas with mucinous differentiation. 
Prognosis is significantly worse.
conclusion
The presence of signet ring cells in carcinomas with mucinous differentiation correlates 
with increased T-stage and poor prognosis. These cells, characterized by ITF and MUC2 
production, showed a disruption of the E-cadherin/β-catenin complex, as well as an 
amplification of Bcl-2. 
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introduction
The most common type of colorectal malignancies is adenocarcinoma n.o.s. (AC). 
Approximately 10% of all colorectal carcinomas are mucinous carcinomas, characterized 
by large amounts of extracellular mucin 1,2. Sometimes mucin accumulates intracellular 
as well, resulting in signet ring cell morphology. We call these tumors mucinous 
carcinoma with signet ring cells (MCSRC). This tumor type has to be distinguished from 
signet ring cell carcinoma, in which there is no extracellular mucin present. More than 
96% of the signet ring cell carcinomas arise in the stomach. Signet ring cell carcinoma 
of the colorectal area is an uncommon, yet distinctive, type of malignancy present in 
0.7-2.6% of all primary colorectal carcinomas 3-6.
Signet ring cells are usually presented as single cells or in loose clusters, which implicates 
a disruption in the cell-cell adhesion. This could explain their aggressive behavior with 
regard to invasion and metastasis. E-cadherin and β-catenin are important molecules 
that mediate the cell-cell adhesion, which might be altered in signet ring cells and 
therefore further investigated in this study. 
Another characteristic of signet ring cells is their abundant cytoplasmic mucin, 
which might results either from increased mucin production or mucin uptake from 
the environment. The latter might be a possibility when signet ring cells develop in 
adenocarcinomas with mucinous differentiation (MC), in analogy with the formation 
of muciphages in mucin producing tumors 7. Both Intestinal Trefoil Factor (ITF or TFF3) 
and various MUCs are the main components of mucin. Normally, ITF and some types of 
mucin (e.g. MUC2) are only produced by goblet cells 8. In this study, we compared mucin 
content of goblet cells and signet ring cells. 
Development of malignancies is partly dependent on genomic deletions and 
amplifications. Each type of malignancy supposedly has its own pathway of genetic 
alterations leading to different phenotypes. Differences in the genetic background of 
tumors are often reflected by differences in clinical behavior and response to therapy. 
Identification of such genetic marker with prognostic or therapeutic implications in a 
molecular diagnostic setting can be of great additional value.
Zhang et al.9 describe a sekparate genetic pathway for MC, explaining their biological 
behavior. However, the genetic pathway involved in the development of signet ring cells 
has not been studied before. We hypothesize that signet ring cells arise from a separate 
genetic pathway. In this study the development of signet ring cell differentiation in MC is 
further investigated by examining the clinical relevance, the role of genetic alterations, 
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adhesion molecules and characteristics of mucin. In vitro results were confirmed using 
patient material from a well characterized clinical trial.
materials and methods
tumor samples
Patients
Patients were selected from the Total Mesorectal Excision (TME) study, a large 
multicenter trial in the Netherlands, in which 1530 patients with rectal cancer were 
included from January 1996 until December 1999 10. Pathological data from this trial 
are well documented and standardized. In this randomized trial patients were assigned 
to TME surgery with preoperative radiotherapy or TME surgery alone; however, 
therapy was not of importance in this study. Final histology review identified 296 cases 
with mucinous differentiation (MC, mucinous component is more than 1%), one case 
as primary colorectal signet ring cell carcinoma, and 31 cases as MC with signet ring 
cells (percentages of signet ring cells vary between 10-40%, no invasive signet ring cell 
component).
cell lines and cell culture
Cell lines were used for DNA isolation and subsequently MLPA. Colon carcinoma cell 
lines with a non-mucinous phenotype (AC) were used: HT-2911, Caco-212, SW-48013, 
Colo-32014, T8415. The LoVo cell line consists of signet ring cells (SRC)16. Colon carcinoma 
cell lines with a mucinous phenotype (MC) were Ls174T (ATCC CL-188)17 and 5585-S 
(kindly provided by Dr. P.T.M. Moerkerk, University of Maastricht, the Netherlands). In 
the latter, signet ring cells were observed as well18. These cells were grown in Dulbecco’s 
modified Eagle’s minimum essential medium (DMEM) containing 10% heat-inactivated 
fetal calf serum and 0.1% gentamicin. 
Multiplex ligation probe ampification
DNA isolation
DNA isolation of all cell lines and blood samples was performed using the DNeasy 
Tissue Kit (Qiagen, Hilden, Germany), according to the manual of the manufacturer. 
The concentration and purity of DNA was measured by the GeneQuant UV 
spectrophotometer (Pharmacia LKB Biochram Ltd, Cambridge, England).
Multiplex Ligation-dependent probe amplification
MLPA was performed using the P005 salsa human chromosomal aberrations test kit 
(MRC-Holland, Amsterdam, the Netherlands), which contains target sequences of 
41 genes that are often deleted or amplified in various tumors. Supplemented buffer 
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solutions were used from the kit. Procedures were described before19. Data were 
analysed with Genotyper software (Applied Biosystems). To calculate the probe ratio, 
peak values identified by the Genescan software were imported in Excel files for further 
process. The probe ratio was then calculated by dividing the peak value of each probe 
amplification product by the total peak value of all 41 probes. This ‘relative peak area’ 
was then divided by the ‘mean relative peak area’ of the probe within all normal tissue 
samples (blood samples of healthy men and women). Thresholds to detect gains and 
losses were set at 1.2 and 0.8 respectively20. 
immunohistochemistry and in situ hybridization
Immunohistochemistry
Immunohistochemistry was performed using the avidin-biotin peroxidase complex 
method. A rabbit anti-human ITF polyclonal antibody (kindly provided by A. Giraud, 
University of Melbourne, Australia, 1:3000), a mouse anti-human E-cadherin monoclonal 
(clone 36, BD Transduction Laboratories, USA, 1:500), a mouse anti-human β-catenin (BD 
Transduction Laboratories, USA, 1: 200), and a mouse anti-human MUC2 monoclonal 
antibody (Santa Cruz, California, USA, 1:300) were used. Pretreatment was performed 
with sodium citrate buffer (10mM). Staining intensities were graded as negative (no 
staining), weak (light brown), moderate (brown) and intense (dark brown). All cases were 
scored by two independent observers.
Immuno-fluorescence double-staining
Immuno-fluorescence double-staining was performed with an extracellular (HECD-1, 
monoclonal, 1:100, Takara Bio Inc, Japan) and transmembranal (clone 36, monoclonal, 
BD Transduction Laboratories, USA) epitope of E-cadherine, and with ITF and β-catenin. 
Procedures were performed as described above, with the secondary antibodies goat 
anti-mouse IgG conjugated with alexa 594 (1:200; Molecular Probes, Inc; Eugene, USA) 
and donkey anti-rabbit IgG conjugated with alexa 594 (1:200; Molecular Probes, Inc; 
Eugene, USA) respectively. After the application of the second primary antibody, the 
second secondary antibody (goat anti-mouse IgG 2a conjugated with alexa 488 (1: 200; 
Molecular Probes, Inc; Eugene, USA) was applied. A fluorescence microscope equipped 
with 490/20 and 575/30-filters (Leica; Solms; Germany) was used.
ITF mRNA In situ Hybridization
A 221 bp sequence for human Intestinal Trefoil Factor was subcloned into Bluescript II 
SK (kindly donated by R. Poulsom, Histopathology Unit, Cancer Research UK, London, 
UK). Plasmid DNA was linearized with Pst1 (sense) and Xho1 (α-sense) and transcribed 
with T7 and T3 RNA polymerase respectively21. In situ hybridizations procedure was 
performed as described previously. 22.
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Bcl-2 FISH
An IgH/Bcl-2 FISH probe mix (Vysis Inc.) was used to visualize Bcl-2 gene amplification. 
One μl Vysis probe was dissolved in 7 μl LSI hybridization buffer and 2 μl distilled 
water. Sections were denatured 10 minutes at 80°C, hybridized at 37°C overnight. 
Subsequently, nuclei were stained with DAPI (0.2 mg/ml, 0.5 minutes) and analyzed 
with a fluorescence microscope as described above. All cases were scored by two 
independent observers.
statistical analysis of clinical data
Statistical analyses were performed using the TME database and cases were analyzed 
with SPSS statistical software. An ANOVA test was used to compare means and Kruskal-
Wallis tests were used to compare quantitative and ordered variables. Chi-square tests 
were used to compare proportions; analysis of distant recurrence and survival was 
carried out by the Kaplan-Meier method, and the evaluation of differences between 
the groups was performed with the log-rank test. P-values < 0.05 were considered 
significant. 
results
In order to establish the importance of signet ring cell differentiation in carcinomas 
with mucinous differentiation we started analyzing genetic aberrations in this type of 
cells, using cell lines as a model. Our findings were validated on patient material, with 
special attention for adhesion molecules, based on both our current results as well as on 
literature results. After establishing the nature of these cells, we confirmed their clinical 
importance by using data from a clinical trial.
dna copy number changes
DNA copy number changes were examined using MLPA analyzing 41 different loci genes 
to compare the different tumor types. Peak values of cell lines with characteristics of 
AC (HT-29, Caco-2, SW480, Colo320, T48), MC (Ls174T) and MCSRC (Lovo, 5585S) were 
identified by Genescan and probe ratios of the different cell lines were compared (Figure 
1). Almost all genes showed an aberration in at least one cell line. Deletions (probe ratio 
of < 0.8) were more frequently observed than amplifications (probe ratio of > 1.2). 
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Figure 1: Illustration of 
amplifications and deletions 
of 41 genes (divided into four 
graphs). Normal range is 
between 0.8 and 1.2 (dotted 
line). Some cell lines showed 
an amplification of more than 
2 in certain genes (*). Genes 
described in results (MYC, 
CDH1, Bcl2) are marked.
→ color figures
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Bcl-2 amplification was observed in MCSRC and MC (LoVo, Ls174T, 5585S) in contrast to 
the deletion observed in AC cell lines. This difference was confirmed in patient material 
using Bcl-2 FISH analysis. Only 8% (2/25) of the AC showed an amplification of the Bcl-2 
gene, against 44% (7/16) of the MC and 38% (6/16) of MCSRC (p=0.017). Furthermore, 
high copy amplifications (probe ratio of >2) of MyC in almost all AC cell lines were 
detected, whereas no amplifications were present in the MC and MCSRC. 
e-cadherin expression in signet ring cells
It has been reported that E-cadherin and β-catenin expression is reduced or absent 
in colorectal signet ring cells 23. Our MLPA analysis on cell lines did not reveal 
consistent genomic aberrations of the CDH1 gene that encodes E-cadherin. Therefore, 
immunohistochemical staining for E-cadherin and β-catenin was performed on patient 
material. Both transmembranous and extracellular E-cadherin were markedly decreased 
in signet ring cells. In cases with an intact transmembrane part of E-cadherin, the 
extracellular epitope was not available (Figure 2). Staining of membranous β-catenin 
was variable in signet ring cells, but most cases showed a decrease in membranous 
staining of β-catenin. These findings suggest a disruption of the E-cadherin/β-catenin 
complex.
Figure 2: Illustration of E-cadherin by 
immunofluorescence staining. The nuclei are 
represented by the blue colour. Subtype clone 
36 (transmembrane) is represented by the 
green colour, subtype HECD-1 (extracellular) is 
represented by the red colour. The yellow colour of 
the normal mucosa (A) indicates that both epitopes 
are still present. (B) A signet ring cell at high 
magnification (100x), the transmembranal epitope 
is still available, while the extracellular epitope was 
partly not detected. 
→ color figures
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nuclear β-catenin and high expression of Intestinal trefoil Factor
Disruption of E-cadherin function might be caused by ITF, a component of mucin, by 
specific tyrosine phosphorylation of β-catenin 24. Therefore, the possible correlation 
between β-catenin and ITF in signet ring cells was subsequently investigated (Figure 
3). In the normal mucosa (Figure 3A) β-catenin is confined to the membrane and the 
goblet cells are filled with ITF. ITF is sometimes secreted into the lumen (arrowheads). 
In signet ring cells membranous staining of β-catenin correlated with weak cytoplasmic 
ITF staining (Figure 3B), while nuclear staining for β-catenin was observed in cases with 
intense staining of ITF. These data demonstrate a relation between high levels of ITF 
and nuclear translocation of β-catenin. 
Figure 3: Immunofluorescence illustration of a normal mucosa (A) with goblet cells (arrows) secreting 
ITF (red, arrowheads) into the lumen; (B) signet ring cell showing a strong membranous and cytoplasmic 
staining of β-catenin (green) and weak cytoplasmic staining of ITF; and (C) a signet ring cell showing 
a weak membranous staining of β-catenin and strong cytoplasmic staining of ITF, while β-catenin has 
moved to the nucleus (D).
→ color figures
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distribution of Intestinal trefoil Factor and Mucin-2 
The origin of ITF in signet ring cells is not clear; in analogy with muciphages mucin 
with ITF might be absorbed from the environment. On the other hand, ITF might be 
produced by signet ring cells, in analogy with goblet cells. Indeed, goblet-like cells 
surrounding the mucinous lakes in MC also show an intense staining of ITF (data not 
shown). The staining pattern in signet ring cells is highly variable (Figure 4A-B). mRNA 
in situ hybridization of ITF showed a positive staining in signet ring cells (Figure 4C), 
suggesting that signet ring cells can produce their own ITF, like goblet cells.
In order to further evaluate the analogy between signet ring cells and goblet cells 
MUC2 expression was analyzed. Goblet cells in the normal mucosa showed an intense 
staining of the secreted MUC2 (Figure 4E), just as the goblet-like cells around the mucin 
lakes in MC. A weak staining of MUC2 in the cytoplasm and intense staining in the cell 
membrane was observed in clustered signet ring cells. Solitary signet ring cells showed 
a weak or moderate distribution of MUC2 (Figure 4F). Thus, although signet ring cells 
and goblet cells have a distinct morphology, they show similar features with respect to 
MUC2 and ITF expression.
Figure 4: ITF distribution 
in clustered signet ring 
cells (A) and solitary signet 
ring cells (B). Signet ring 
cells were positive for ITF 
mRNA (C, dark purple) and 
negative using the sense 
probe (D, negative control), 
indicating that signet ring 
cells can produce their own 
ITF. Expression of MUC2 
in normal mucosa (E) and 
solitary signet ring cells (F).
→ color figures
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clinicopathological factors
In order to address the clinical relevance of MCSRC, we have correlated the presence of 
signet ring cells with prognosis. The total number of patients included in the statistical 
analysis was 1462 (incomplete data of 68 patients); most tumors were AC (RT+TME: n= 
545, TME: n= 589). The tumors with mucinous differentiation (mucinous component is 
more than 1%) were divided into tumors without signet ring cells (MC; RT+TME: 164, 
TME: 132) and with signet ring cells (MCSRC; RT+TME: 20, TME: 11). There was one 
signet ring cell carcinoma without mucinous differentiation.
Clinicopathological factors were not different between the randomization arms (data 
not shown). Therefore, both groups were analyzed together (Table 1). MCSRC presents 
at a later T stage (T
3
: 67.7% and T4: 16.1%) compared to both AC (T4 2.9%) and MC (T4 
4.7%, p < 0.001, Table 1). The number of node positive patients was significantly higher 
in MCSRC than in AC and MC (77.4% vs. 39.3% and 44.1% respectively; p< 0.001). 
The mucinous component can be located deep, superficial or total (spread through the 
whole surface area). Whereas in the majority of the MCSRC the mucinous spread was 
total (80.6%), in the MC the distribution was in 67.2 % limited to the deep areas (p < 
0.001). MCSRC have a larger mucinous component than MC (p<0.001, Table 2). 
taBle 1. Pathological characteristics for the Various tumor tyPes
localization  (distance 
from the anal verge)
<5.0 cm
≤2.0 cm
28.7% 35.8% 48.4%
9.0% 3.8% 6.5%
5.9 % 3.0 % 0%
60.7% 55.9% 22.6%
T1
N0
5 - 9.9 cm
2-5 cm
41.9% 37.2% 25.8% 0.057
68.5 % 71.4% 54.8% 0.026
33.0 % 32.1 % 16.1 %
<0.001
22.2% 23.4% 16.1%
T2
N1
≥ 10 cm
>5 cm
29.3% 27.0% 25.8%
22.5% 24.8% 38.7%
57.3% 59.8% 67.7%
11.7% 12.9% 41.9%
2.9% 4.7% 16.1%
5.4% 7.8% 19.4%
T3
N2
T4
N3
invastion depth
lymph node status
tumor size
factor category ac
n = 1134
ac
n = 296
mcsrc
n = 31
p-vaLue
Differences were tested with the Kruskal-Wallis test. Bold values indicate 
statistical significance. Abbreviations: AC: adenocarcinoma, MC: mucinous 
carcinoma, MCSRC: mucinous carcinoma with signet ring cells
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Patients with MCSRC have a poor prognosis (Figure 5). Distant recurrence rate was 67% 
after 5 year, compared with 28% (AC) and 34% (MC, p = 0.0017). Survival was decreased, 
45% versus 64% and 56% respectively (p = 0.016). When we compared only T3/4 tumors, 
the difference was still there (42%, 40% versus 26%), although not longer significant (p 
= 0.30). Survival of patients without lymph node metastases is not affected by tumor 
type (52%, 59%, 60% respectively, p = 0.26). However, in the lymph node positive group 
survival was significantly worse in patients with signet ring cells (33%, 23% versus 18%, 
p =0.002). Prognosis was determined in the non-irradiated group of the trial. Patients 
with short-term radiotherapy show the same results. Thus, the presence of signet ring 
cells in mucinous carcinomas correlates with increased invasion depth and presence 
of lymph node metastases. The presence of signet ring cells is a N-stage independent 
prognostic marker for increased recurrence rate and decreased survival. 
Figure 5: (A) Distant recurrence in months since surgery and (B) survival in months since surgery
taBle 2. mucinous comPonent and distriBution for the Various tumor tyPes
mucinous
component
0%
0-20%
20-40%
40-60%
60-80%
80-100%
0%
129 (43.6%)
35 (11.8%)
34 (11.5%)
31 (10.5%)
67 (22.6%)
0%
1 (3.2%)
4 (12.9%)
2 (6.45%)
4 (12.9%)
20 (64.5%)
<0.001*
1134
(100%)
No mucinous component
Superficial
Deep
Total
1134
(100%)
0 (0%)
8 (2.7%)
199 (67.2%)
89 (3.2%)
0 (0%)
1 (3.2%)
5 (16.1%)
25 (80.6%)
<0.001#
distribution
factor category ac mc mc p-vaLue
*: χ2-test, #: Kruskal-Wallis test. Bold values indicate statistical significance. 
Abbrevations: AC: adenocarcinoma, MC: mucinous carcinoma, 
MCSRC: mucinous carcinoma with signet ring cells.
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discussion
Signet ring cell differentiation in colorectal carcinomas is a rare phenomenon. In the 
present study the incidence of primary signet ring cell carcinoma was 0.06%, while 
the incidence of MCSRC was 2%, which confirms other observations 25-27. Formation 
of signet ring cells is associated with a poor prognosis. However, the mechanisms 
underlying the formation of signet ring cells are poorly understood. We applied various 
strategies to detect the possible mechanisms and to understand the poor prognosis of 
these patients.
Clinical analysis revealed that MCSRC were most frequently diagnosed when the 
disease was advanced, which is consistent with other reports 28-32. As a consequence, 
distant recurrence was more frequently observed and survival was decreased 33-35. 
Differences in biological behavior of tumors might be a reflection of their development 
along different genetic pathways. To detect differences in genetic aberrations between 
MCSRC, MC and AC we applied a screening assay on cell lines, to be tested on patient 
material. We found an amplification of Bcl2 in MCSRC, whereas a deletion is more 
common in AC. Verification in patient tissue confirmed this observation. Since Bcl-2 is a 
suppressor of apoptosis36, amplification of this gene might account for more aggressive 
growth. Based on literature, MyC amplification was expected in MC 37, but our cell line 
analyses revealed only amplification in AC, but not in MC and MCSRC.
In analogy with hereditary signet ring cell gastric carcinoma, E-cadherin is expected 
to be absent in signet ring cells. Indeed, a deletion was observed in the MCSRC cell 
line, which was subsequently verified in patient material and is in accordance with other 
studies 38-40. Immunofluorescence showed that the extracellular part of the E-cadherin 
molecule in signet ring cells was not detected. The transmembranal part of the 
molecule was less affected. These alterations in E-cadherin expression could implicate 
a disruption of the adhesion complex. In addition, the membranous localization of β-
catenin was slightly reduced, whereas nuclear expression was present in signet ring 
cells. By reduced cell-cell adhesion, signet ring cells have the opportunity to lose contact 
with the surrounding structure and spread diffusely through the whole body. It can be 
suggested that the aggressive biological behavior of MCSRC is partly contributed by a 
decreased expression of E-cadherin and β-catenin.
Tyrosine phosphorylation of β-catenin results in the disruption of the E-cadherin 
function and altered migratory activity of tumor cells might be caused by ITF41,42. ITF is 
a trefoil peptide which is specifically produced by goblet cells 43, but might show uptake 
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by surrounding cells. The role of ITF in prognosis of colorectal carcinomas is a point 
of discussion 44-47. In present series goblet-like cells in MC situated around the mucin 
lakes showed strong staining patterns for both ITF and MUC2. Signet ring cells showed 
variable, though positive ITF staining patterns. Similar patterns were observed with 
MUC2 staining. Weiss et al.48 reported that MUC2 (as well as ITF) is goblet cell specific, 
and expression of MUC2 mRNA was preserved in MC (goblet cell phenotype), while 
expression in AC (enterocytic phenotype) was decreased. Signet ring cells have a goblet 
cell phenotype, suggesting that it is possible that they can produce their own ITF and 
MUC2. Indeed, ITF mRNA expression was present in signet ring cells. 
In conclusion, in the current study we demonstrate that the presence of signet ring cells 
in MC correlates with increased T-stage and poor prognosis. These cells, characterized 
by ITF and MUC2 production, showed a disruption of the E-cadherin/β-catenin complex, 
as well as an amplification of Bcl-2. 
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Purpose
To determine the impact of cyclooxygenase-2 (Cox-2) expression on clinical behavior in 
irradiated and non-irradiated rectal carcinomas.
Patients and methods
Tumor samples were collected from 1231 patients of the Dutch TME trial in which 
rectal cancer patients were treated with standardized surgery, and randomized for 
preoperative short-term (5 times 5Gy) radiotherapy or no preoperative radiotherapy. 
Tissue micro arrays were constructed from primary tumor material and Cox-2 expression 
was assessed by immunohistochemistry. Tumor cell apoptosis was determined by M30 
immunostaining. 
results
A high level of Cox-2 expression after radiotherapy was associated with low levels of 
tumor cell apoptosis (p=0.001). Cox-2 expression had no significant impact on patient 
survival or tumor recurrence in non-irradiated tumors. However, in patients receiving 
preoperative radiotherapy, high level of Cox-2 expression was associated with higher 
incidence of distant recurrences (p=0.003, HR: 1.7, CI: 1.2-2.5), and shorter disease free 
survival (p=0.002, HR: 1.5 CI: 1.2-2.0) and overall survival (p=0.009, HR: 1.8, C.I.: 1.1-
2.5), independent of patient age, tumor stage, tumor location or the presence of tumor 
cells in the circumferential resection margin.
conclusion
A high level of Cox-2 expression following preoperative radiotherapy in resection 
specimens is associated with apoptosis resistance, high distant recurrence rates and a 
poor prognosis in rectal cancer.
 Value of Cox-2 assessment
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introduction
In recent years the role of a key enzyme in prostaglandin synthesis, cyclooxygenase-2 (Cox-
2) has been appreciated in cancer development and progression. Cox-2 is responsible for 
the conversion of arachidonic acid to prostaglandins and other eicosanoids. In addition 
to its well-known role in inflammatory reactions, Cox-2 plays a role in tumor progression, 
angiogenesis, metastasis and abrogation of the anti-tumor immune response 1-4. Cox-2 
prevents apoptosis by generation of anti-apoptotic PGE2 
5 and PGI2 
6 and by removal of 
the pro-apoptotic substrate arachidonic acid 7. PGE2 induces transformations that result 
in increased Bcl-2 expression, and prolong the cell cycle G1 phase with increased cyclin 
D1 expression 8.
Numerous epidemiological studies have indicated that the use of NSAIDs and Cox-
2 inhibitors is associated with a significant decreased incidence and mortality rate in 
colorectal cancer 9-12. In addition, selective Cox-2 inhibitors have been shown to decrease 
Cox-2 expression and Cox-2 activity in gastrointestinal malignancies 13.The clinical impact 
of Cox-2 expression has been evaluated in a large number of studies in colorectal cancer 
but results have not been consistent 9,14,15. Considering the distinct differences in tumor 
biology 16, treatment, recurrence rates and metastatic behavior, it is regrettable that 
most studies make no distinction between rectal and colon cancer.
The purpose of the current study was to obtain a conclusive answer of the clinical rele-
vance and prognostic value of immunohistochemically-determined Cox-2 expression 
in rectal cancer and to investigate the effects of radiation therapy on Cox-2 expression 
and subsequent biological and clinical behavior. The investigated patients were included 
in the Dutch TME trial, a prospective multicenter trial, and were randomized between 
standardized preoperative radiotherapy treatment followed by TME surgery or TME 
surgery alone 17.
methods
study population
Patients were obtained from the Dutch TME trial, a large multicenter trial in which 
1861 patients were included from January 1996 until December 1999. Patients with 
a resectable carcinoma of the rectum were included in this international multicenter 
clinical trial and were subsequently randomized for radiotherapy (5x5 Gray) followed 
by TME surgery or for TME surgery alone without preoperative radiotherapy 17. 
Radiotherapeutical, surgical and pathological procedures were standardized and 
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quality-controlled 17-19. Patients who complied with the eligibility criteria of the TME 
trial 17 with sufficient paraffin-embedded tumor material were selected for this study. 
Archival tumor material was collected from the 1530 Dutch patients that were included 
in the trial. Tumor material was available from 1231 patients. For the evaluation of 
Cox-2 expression, patients were only included if at least 2 of the 3 included punches on 
the tissue microarray (TMA) could be evaluated, leaving 1038 eligible stage I-III rectal 
cancer patients for analyses of clinical impact of Cox-2 expression. 
tissue microarray preparation
Tissue micro arrays from formalin-fixed, paraffin-embedded tumors included in the 
Dutch TME trial were constructed with a custom-built precision tissue arrayer (Beecher 
Instruments, Silver Spring, MD) using a 2-mm-diameter punch as described previously 20. 
immunohistochemistry
For the quantification of Cox-2 expression, 4-µm sections of the TMAs were stained 
with Cox-2-specific mouse anti-human monoclonal antibodies (clone CX229, Cayman 
Chemical Co., Ann Arbor, Michigan, USA). The immunohistochemical procedures were 
described in detail elsewhere 21. Antigen retrieval was performed by boiling the sections 
in 10mM citrate buffer (pH 6.0) for 10 min. Sections were incubated overnight at room 
temperature with antibodies against human Cox-2 (1:100). Specificity of the antibodies 
was confirmed in this study by staining randomly selected rectal cancer specimens 
with and without pre-absorption of the primary antibody with human Cox-2 antibody-
blocking peptides (10μl/mL, Cayman Chemical) for 1 hour at room temperature before 
the staining procedure. All tumor specimens were stained simultaneously to avoid inter-
assay variation. Cox-2 immunostaining was assessed by two independent observers 
(P.H. and M.J.E.M.G.) in a blinded manner.
For high-throughput analysis of the TMAs, the scoring criteria proposed by Buskes et 
al. 21 were used: A score of 0 indicates no staining; score 1, weak diffuse cytoplasmic 
staining (may contain stronger intensity in <10% of the cancer cells); score 2, moderate 
to strong granular cytoplasmic staining in 10%-90% of the tumor cells; and score 3, 
more than 90% of the tumor cells stained with strong intensity. The stained 3 TMA 
punches taken from each tumor were scored independently. The median score of the 
punches was used for analysis. In case of disagreement a consensus score was obtained. 
In the present study Cox-2 scores 0, 1 and 2 were defined as Cox-2 low, a score of 3 was 
defined as Cox-2 high.
Apoptosis levels had previously been characterized in this series of patients by 
immunohistochemical analysis of M30 expression 20. Data on Cox-2 expression and 
apoptosis was available in 1024 patients.
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statistical analyses
All analyses were performed with SPSS statistical software (version 12.0 for Windows, 
SPSS Inc, Chicago, IL). Paired samples t-test, Mann-Whitney U, Kruskall-Wallis, and 
Spearmans’ Rho tests were used to compare continuous variables. The χ2-test was 
used to compare categorical variables. Patient survival was estimated according to the 
Kaplan-Meier method and compared using the log-rank test. The entry date for the 
survival analyses was the time of surgery of the primary tumor. Events for time to local 
recurrence, distant recurrence, disease-free and overall survival were defined as follows; 
time from of surgery to: time of local disease relapse, distant disease relapse, time of 
disease relapse or death and time of death respectively. Cox’ regression analyses were 
used to calculate Hazard Ratios (HR) with 95% confidence intervals (CI). Variables with 
a p-value of ≤0.10 in the univariate analyses were subjected to a multivariate analysis. 
Inter-observer variability was calculated by κ statistic, as described by Landis and Koch: 
κ-values of 0.2 to 0.4 indicate “fair”, of 0.4 to 0.6 “moderate”, and of > 0.6 “excellent” 
results 22.
results
Cox-2 protein expression in rectal cancer tMas
The immunohistochemical Cox-2 staining pattern exhibited a brown diffuse granular 
cytoplasmic staining (Figure 1). No staining of Cox-2 was observed in 5 tumors (0.5%) 
(Figure 1A). A weak diffuse, moderate or strong staining was observed in respectively 
114 (11.0%), 602 (58.0%) and 317 (30.5%) of the tumors (Figure 1B-D) 
The inter-observer κ-value score for evaluation of Cox-2 expression was 0.62, indicating 
minimal inter-observer variation. Ten randomly selected rectal cancer specimens were 
stained with Cox-2 antibodies with or without blocking peptide. All tumor cell signals 
were blocked by this control procedure in all specimens.
Cox-2 expression and clinicopathological parameters
Clinical data and conventional prognosis factors (TNM stage, age, histology, localization) 
of the patients in the current study have been published previously 17,20. Cox-2 expression 
did not significantly differ between irradiated and non-irradiated tumors (p=0.27, Table 
1) and were distributed evenly in non-irradiated and irradiated patients with regard 
to various clinical and pathological parameters as age, gender, tumor size, depth of 
invasion, lymph node involvement, TNM stage, type of surgery, circumferential margin 
and distance from anal verge. All p-values were not significant 
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Figure 1: Representative stainings of Cox-2 expression in tissue microarray cores from the 1231 rectal 
cancer specimens evaluated in this study. Figure 1A: Cox-2 negative tumor (score 0). Figure 1B: weak 
diffuse cytoplasmic staining (score 1). Figure 1C: moderate to strong granular cytoplasmic staining 
(score 2). Figure 1D: strong intensity of the staining (score 3). → color figures
(data not shown). A poor grade of differentiation was borderline significantly associated 
with high Cox-2 expression levels in non-irradiated tumors (p=0.06). High levels of Cox-
2 expression were more often observed in adenocarcinomas (as compared to tumors of 
the mucinous type) in irradiated and non-irradiated tumors (p=0.05/p=0.04).
0
1
2
3
total
3 (0.6%)
51 (9.7%)
300 (56.8%)
174 (33.9%)
528
2 (0.4%)
63 (12.4)
302 (59.2%)
143 (28.0%)
510
5 (0.5%)
114 (11%)
602 (58%)
317 (30.5%)
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Cox - 2 expreSSIon tme rt + tme total
Abbrevations: TME: total mesorectal excision, RT: radiotherapy
taBLe 1. dIStrIButIon oF Cox-2 expreSSIon In IrradIated and non-IrradIated 
rectal cancer sPecimens
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Cox-2 expression in relation to radiotherapy and apoptosis
Cox-2 expression was not associated with apoptosis in resection specimens of non-
irradiated rectal cancer tumors (p=0.13), but was significantly associated with decreased 
levels of apoptosis 20 in irradiated tumors (p=0.001, Mann Whitney test). As can be seen 
in Figure 2, the analysis remained significant when Cox-2 scores were dichotomized as 
score 0-2 (Cox-2 low) versus score 3 (Cox-2 high) (p=0.001, Mann Whitney test).
Figure 2: Dichotomized Cox-2 expression is associated with 
decreased levels of apoptosis in irradiated tumor specimens 
with high levels of Cox-2 expression. Black columns represent 
patients receiving preoperative radiotherapy (RT+) followed 
by TME surgery. Gray columns represent patients receiving 
TME surgery alone (RT-).
The median time period from completion of radiotherapy to surgery was 4 days (Inter 
Quartile Range: 3-6 days). No significant differences were observed between the levels 
of Cox-2 expression with regard to the median time between radiotherapy and surgery 
(p=0.06, Kruskall-Wallis test). 
Cox-2 expression in relation to radiotherapy and tumor prognosis
Subsequently, we analyzed the impact of Cox-2 expression on tumor recurrence and 
patient survival. Figure 3A-C shows the impact of Cox-2 expression in non-irradiated 
tumors on local recurrence rates, overall survival and disease free survival. 
Cox-2 expression did not have an impact on local recurrence (Figure 3A, p=0.44), 
distant recurrences (Figure 4, p=0.77), overall survival (OS) (Figure 3B, p=0.61) 
or disease free survival (DFS) (Figure 3C, p=0.57) in non-irradiated rectal cancer 
specimens. As can be seen in Figure 4, after radiotherapy, tumors with high levels of 
Cox-2 expression showed a significantly higher rate of distant recurrences (p=0.005), 
but this was not observed in non-irradiated tumors. Figure 5A-C shows tumors with 
high levels of Cox-2 expression after radiotherapy to be associated with poor DFS 
(p=0.004) and OS (p=0.006), but not with local recurrence rates (p=0.92).
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Figure 3: Kaplan-Meier survival estimates by dichotomized Cox-2 tumor epithelial staining in non-irradiated 
(RT-) rectal tumors for local recurrence (A), overall survival (B) and disease free survival (C). Grey lines 
denote low levels of Cox-2 and black lines high levels of Cox-2 expression.
Figure 4: Kaplan-Meier survival 
estimates by dichotomized Cox-2 
tumor epithelial staining in irradiated 
and non-irradiated rectal tumors. 
Distant recurrence rates estimates 
by Cox-2 tumor epithelial staining 
in irradiated and non-irradiated 
patients. Cox-2 expression does 
not have an impact on distant 
recurrences in non-irradiated tumors 
(gray lines, p=0.77), but significantly 
impacts distant recurrences in 
irradiated tumors (black lines, 
p=0.005).
Figure 5: Kaplan-Meier survival estimates by dichotomized Cox-2 tumor epithelial staining in irradiated 
(RT+) rectal tumors for local recurrence (A), overall survival (B) and disease free survival (C). Grey lines 
denote low levels of Cox-2 and black lines high levels of Cox-2 expression. High Cox-2 expression is a 
poor prognostic factor for disease free (p=0.004) and overall survival in irradiated rectal cancer patients 
(p=0.006).
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univariate and multivariate analyses in irradiated patients
Univariate Cox regression analyses were performed to identify prognostic factors for 
OS in irradiated patients. Advanced patient age (HR: 1.03, C.I.: 1.01-1.05, p<0.0001), 
advanced pathological stage (HR: 1.75, C.I.: 1.47-2.03, p<0.0001), tumor-positive 
circumferential resection margins (HR: 2.46, C.I.: 1.82-3.33, p<0.0001), distal location 
of the tumor (HR: 1.46, C.I.: 1.01-2.06, p=0.05) and high Cox-2 expression (HR: 1.48, 
C.I.: 1.11-1.96, p=0.006) proved to be significant in the univariate analyses and were 
subjected to Cox multivariate analysis (Table 2). Patient age above the median, 
advanced pathological stage, tumor-positive circumferential resection margins and 
high Cox-2 expression (HR: 1.46, C.I.: 1.10-1.94, p=0.009) retained their strength as 
independent prognostic factors for OS (Table 2). In addition, Cox-2 proved to be an 
independent prognostic factor for high distant recurrence rates (p=0.003, HR: 1.7, CI: 
1.2-2.5) and DFS (p=0.002, HR: 1.8, C.I.: 1.2-2.5).
discussion
The major observation in the current study is that increased Cox-2 expression in 
irradiated rectal cancer specimens is associated with reduced levels of apoptosis and 
poor prognosis. This indicates that Cox-2 expression can be used to identify a cohort of 
patients with a poor prognosis after radiotherapy. 
age
tnm stage
crm
distance of 
tumor from 
the anal verge
Cox-2 
expression
Below median
Above median
I
II
III
Negative
Positive
10.1 - 15 cm
5.1 - 10 cm
≤ 5 cm
Low
High
1
1.03
1
1.83
2.88
1
1.94
1
1.48
1.44
1
1.46
1.01 - 1.05
1.22 - 2.74
1.96 - 4.22
1.41 - 2.67
1.03 - 2.13
1.01 - 2.03
1.10 - 1.94
<0.0001
<0.0001
<0.0001
0.07
0.009
factor category hazard ratio 95% CI p-vaLue
A variable was included in the multivariate analysis if the p-value in the univariate 
analysis was less than 0.10. Patients with missing data were excluded from the 
analysis. Bold values indicate statistical significance. Abbrevations, CI: confidence 
interval, CRM: circumferential margin.
taBle 2. results of multiVariate cox regression analysis for oVerall 
SurvIvaL aMonG 510 IrradIated reCtaL CanCer patIentS
Chapter 6 
124
In several forms of cancer, radiation exposure is associated with an increase in 
eicosanoid production. Within hours after radiation, increased levels of prostaglandin’s 
and thromboxanes are detectable in most tissues and increased levels may persist for 
several days or weeks 23,24. In the current study high Cox-2 expressions after radiotherapy 
were associated with apoptosis resistance and can therefore decrease the levels of 
radiotherapy-induced apoptosis. 
Anti-apoptotic proteins of the Bcl-2 family are able to suppress radiation-induced cell 
death 25. Cox-2 is known to induce Bcl-2 expression 4 and is associated with apoptosis 
resistance 8. De Bruin et al. demonstrated by immunohistochemical evaluation of M30 
that intrinsic apoptosis is a prognostic factor for local recurrence in rectal cancer 20. 
However, radiotherapy-induced apoptosis was not of prognostic value 26. Since the 
current study found a prognostic impact of Cox-2 in irradiated patients only, whereas 
apoptotic rates were only prognostic in non-irradiated cases, our findings can not 
provide a mechanistic explanation of our observations in relation with tumor cell 
apoptosis.
A possible explanation for the clinical behavior of tumors with high levels of Cox-2 
expression after radiotherapy lies in the fact that Cox-2 is an immediate early response 
gene 27. The interval between the short-term radiotherapy and surgery could be 
sufficient for a change in Cox-2 activity and subsequent prostaglandin production to 
influence the clinical behavior of the tumor 23,28. Elevated Cox-2 expression has shown 
to lead to alterations in the invasive and metastatic potential of cancer cells 2. Cox-2 
expression and prostaglandin production induce cell-surface glysosyltransferases and 
type-I sialyl Lewis antigens, leading to enhanced tumor cell adhesion to endothelial cells 
29,30 and animal studies reported that Cox-2 inhibition prevented the formation of distant 
metastases 30. Moreover, the immunosuppressive effect of increased prostaglandin 
production 31 may allow circulating tumor cells to escape the host anti tumor response 
and metastasize. However, it is not very likely that these events will take place during 
the short interval between completion of radiation and surgery.
It has been established in several animal models and clinical studies that Cox-2 inhibitors 
synergize with radiotherapy and can be administered safely 28,32-34. Cox-2 inhibitors 
could prevent the adverse effects of elevated Cox-2 levels and subsequent increased 
prostaglandin production that can occur during radiotherapy. It is tempting to speculate 
that the addition of Cox-2 inhibitors to preoperative radiotherapy may help to reduce 
distant recurrences and improve patient survival. 
In the current study, using patients from a trial that evaluated TME surgery with or 
without preoperative radiotherapy, Cox-2 expression did not have any impact on 
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local recurrence rates or prognosis in non-irradiated tumors. We have not studied 
pre-treatment biopsies but our results regarding non-irradiated tumors indicate that 
evaluation of Cox-2 expression in non-irradiated rectal cancer specimens or pre-
radiation biopsies is not a useful discriminator for response to therapy or prognosis. The 
prognostic value of Cox-2 expression has extensively been investigated in retrospective 
studies with colorectal cancer specimens 14,15 (and reviewed in9), but the independent 
prognostic value of Cox-2 expression remains unclear. The disagreement on the 
prognostic value of Cox-2 in colorectal cancer in previous studies might be due to the 
apparent lack of prognostic value of Cox-2 expression in non-irradiated rectal cancer as 
seen in the current study, hereby confounding the results in studies that compile rectal 
and colon patients. The low numbers of Cox-2 negative tumors in the current study 
(<1%) as compared to the 10-30% negative tumors reported in studies evaluating Cox-2 
expression in colorectal cancer specimens 35 suggest a biological difference in tumors 
originating from the proximal or distal large bowel. Whether this is due to a larger 
number of mismatch repair defective tumors (which show reduced Cox-2 expression 
36,37) in right-sided tumors 38,39 or other factors is beyond the scope of the current study. 
However, the apparent differences in tumor biology do confound the evaluation of the 
clinical relevance of Cox-2 expression in the large bowel and underscore the need for 
Cox-2 assessment in well-defined, standardized and uniformly treated patient groups 
as was performed in the present study.
In conclusion, in the current study we showed that high levels of Cox-2 after radiotherapy 
are associated with diminished apoptosis and high distant recurrence rates. Our data 
indicate that evaluation of Cox-2 expression after radiotherapy can be used to identify 
patients with a poor prognosis. These results suggest that the addition of Cox-2 
inhibitors to pre-radiotherapy may help to reduce distant recurrences and improve 
patient survival.
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Background
Thymidylate synthase (TS) is a potentially valuable marker for therapy response since 
it is the molecular target of 5-fluorouracil (5-FU). TS can be analyzed at the DNA (gene 
polymorphisms and amplification) and protein level (immunohistochemistry). This 
study investigated the predictive role of TS at the DNA and protein levels in patients 
with N+ colon cancer (n=38). 
Patients and methods
Tumor and normal tissues were genotyped using PCR for variable number of tandem 
repeats (VNTR), a single nucleotide polymorphism (SNP) in the 3R allele and a 6-bp 
deletion (1494del6) in the TS gene. Tumor tissues were additionally analyzed for loss 
of heterozygosity (VNTR polymorphism). A newly developed real time PCR assay was 
used to detect the presence of TS gene amplifications in tumor tissues. 
results
VNTR analysis in normal tissue was significantly associated with distant tumor 
recurrence (8% for 2R/2R versus 52% for patients carrying a 3R allele, p=0.038) and 
cancer specific survival (p=0.021). IHC was not found to be significantly associated 
with patients’ outcome. No correlations between TS gene polymorphisms and IHC 
were found. However, TS gene amplification was correlated with a strong IHC staining 
intensity. 
conclusion
This study indicates that DNA based analysis is more predictive for patient outcome 
than TS IHC. 
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introduction
A substantial number of patients with colon cancer who received adjuvant 5-fluorouracil 
(5-FU) -based therapy will not benefit. Therefore, predictive markers are needed in 
order to discriminate between responsive and non-responsive patients. Thymidylate 
synthase (TS) is a central enzyme in DNA synthesis and is a potentially valuable marker 
since it is the molecular target of 5-FU. TS protein expression is affected by three 
different functional polymorphisms in the untranslated regions (UTR’s) of the gene. 
Sensitivity to 5-FU based therapy might be largely influenced by the intra-cellular levels 
of the TS protein. 
TS protein levels can be studied directly by western blotting, enzyme activity assays 1,2, 
ELISA 3,4 and immunohistochemistry (IHC) 5,6. The mainstream method is IHC because 
it is a relatively cheap, widely implemented technique that enables studying protein 
expression in situ. At the DNA level, TS protein expression is affected by different 
underlying functional polymorphisms as shown by several functional studies 7-12. These 
polymorphisms are: a variable number of tandem repeats (VNTR) containing two (2R) 
or three (3R) repeats of 28-bp 7, a single nucleotide polymorphism (SNP) of a G to C 
substitution in the 3R allele 9 in the 5’UTR and a 6-bp deletion at nucleotide 1494 in the 
3’UTR (1494del6) 12. Recently, a SNP of a G to C substitution in the first repeat of the 
2R allele has also been found (hereafter referred to as the 2RC allele) 13,14. TS mRNA 
with three repeats has greater translation efficiency than mRNA with two repeats 7,11. 
Individuals with a 3R/3R genotype will, in theory, have higher TS protein levels than 
individuals homozygous for the 2R allele. Furthermore, the SNP has been described 
to decreased translation efficiency of the 3R allele to the level of the 2R allele 8-10.  The 
1494del6 polymorphism was found to be associated with decreased mRNA stability 
and lower TS protein levels 12.
Although TS expression can be studied using either IHC or genotyping, it is still unclear 
which methodology is clinically most valuable, as recently indicated in the ASCO 
2006 update for recommendations for the use of tumor markers in gastrointestinal 
cancer 15. In addition, the experimental procedures for both methods remain unclear. 
In the case of IHC it is undecided which antibody should be used  and on what tissue 
type (tumor, normal or metastatic) it should be performed 16,17. These differences in 
technical approach, the semi-quantitative nature of IHC analysis, observer dependence 
and incomplete standardization for IHC assessment could account for the significant 
heterogeneity between studies investigating the predictive role of TS with IHC. In the 
adjuvant and advanced settings, a predictive role of TS IHC was found by some studies 2,18 
but enfeebled by others  19-23, which was also confirmed by the meta-analysis conducted 
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by Popat et al 24.  With respect to TS genotyping, it is still unclear which polymorphism(s) 
should be analyzed and whether the germline or somatic genotype should be investigated. 
That is, TS genotype in tumor tissue can deviate due to chromosomal aberrations such as 
loss of heterozygosity (LOH) and gene amplification 25-27. 
This study aimed to perform a detailed analysis of the predictive values of TS at both 
the protein level (IHC) and DNA level (genotyping) in patients with colon cancer. In 
order to achieve this, TS was thoroughly evaluated with these two methodologies in 
both tumor and normal tissue in a homogenous patient population of patients with N+ 
colon adenocarcinoma who received postoperative 5-FU based chemotherapy.
Patients and methods
Patient population
Thirty-eight patients treated in the Catharina hospital in Eindhoven, the Netherlands 
were investigated in this study. Patients diagnosed with an adenocarcinoma in the 
colon between 1995 and 2002 and staged as any T, N+, M0 (stage III) were selected 
for this retrospective study. Patient and tumor characteristics are depicted in Table 
1. This specific patient population was studied because all patients received adjuvant 
chemotherapy and the absence of metastasis at time of diagnosis enabled us to 
study the distant recurrence free interval as a clinical parameter. All patients received 
postoperative 5-FU based chemotherapy according to the National treatment 
guidelines. Chemotherapy consisted of leucovorin (20 mg/m2) iv bolus followed by 5-FU 
(370-425 mg/m2) iv bolus. Both drugs were administered on days 1 to 5 of each cycle (28 
days), patients received 6 cycles. For five patients mestastatic tissue from liver (n=2, 
obtained 13 and 27 months after primary surgery), ovarium (n=1, collected 48 months 
after primary surgery) and peritoneum (n=2, collected 17 and 7 months after primary 
surgery) was also available. 
Patient data were obtained from the Comprehensive Cancer Centre South (Eindhoven, 
Cancer Registry). Trained registrars recorded the following tumor characteristics: 
tumor grade (well/ moderately differentiated versus poorly or undifferentiated tumors), 
postoperative tumor depth (T1/T2, T3, T4) and lymph node involvement (N1, N2). 
Clinical factors such as adjuvant chemotherapy, year of diagnosis and, if applicable, 
dates of death were also recorded. Additional data on recurrence dates were retrieved 
from patient records.
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ts genetic analysis
 DNA isolation
Genomic DNA was obtained from archival formalin-fixed paraffin-embedded normal 
and tumor tissues. In the case of tumor specimens, enrichment was performed by 
macro dissection of tumor areas with more than 50% tumor cells 28. DNA was extracted 
by overnight incubation with proteïnase K (Merck, Darmstadt, Germany) at 56°C 
followed by boiling for 5 min 28. Subsequently, DNA was purified using the high pure 
PCR template preparation kit (HPPTP kit, Roche Diagnostics, Mannheim, Germany).
VNTR analysis
The VNTR region was amplified by a PCR. The primers and PCR conditions 
used were previously described by Kawakami et al 29 and were optimized for our 
laboratory settings. Briefly, primers: 6-FAM 5’-GCGGAAGGGGTCCTGCCA-3’ and 5’ 
TCCGAGCCGGCCACAGGCAT-3’, 1 unit of AmpliTaq Gold Polymerase, PCR Gold buffer 
age (median), [range]*
sex
localization
invasion depth
lymph node status
tumor differentiation grade
Co-morbidity
Male
Female
Cecum
Appendix
Colon ascendens
Hepatic flexure
Colon transverse
Splenic flexure
Colon descendens
Sigmoid colon
T2
T3
T4
N1
N2
Well differentiated
Moderately
Poorly or undifferentiated
Unknown
No co-morbidity
One additional disease
Two or more additional diseases
Unknown
(64.5), [39-74]
28 (74%)
10 (26%)
8 (21%)
0 (0%)
3 (8%)
4 (10.5%)
2 (5,3%)
3 (7.9%)
2 (5.3%)
16 (42.1%)
4 (10.5%)
30 (79%)
4 (10.5%)
28 (74%)
10 (26%)
2 (5.3%)
24 (62.3%)
11 (28.9%)
1 (2.6%)
21 (55%)
9 (24%)
7 (18%)
1 (3%)
factor category frequency
*in case of scale variables the median and range values are depicted.
taBle 1. Patient and tumor characteristics
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(Applied Biosystems, Foster City, California, USA), 1.5 mM MgCl2 and 5% DMSO (Merck, 
Darmstadt, Germany). Primers were labeled to facilitate, if necessary, more detailed 
fragment analysis using the ABI Prism 310 Genetic Analyzer. PCR conditions were as 
follows: pre-heating: 5 min. at 95 °C; 40 cycles: 45 seconds at 95°C, 45 seconds at 58°C, 
45 seconds at 72°C and 5 min. at 72°C. The presence of the 3R (135 bp) or 2R (107 bp) 
repeats was evidenced after electrophoresis on a 2% agarose gel and ethidium bromide 
staining. In the case of heterozygous patients, both PCR products were observed.
SNP analysis
Digestion of the VNTR PCR products with HaeIII during 1 hour at 37°C (New England 
Biolabs, Ipswich, United Kingdom) was used to detect the SNP of a G to a C substitution 
in the 3R allele 8. In the case of a SNP, an additional 94 bp fragment was observed after 
gel electrophoresis on a 3% agarose gel and ethidium bromide staining. In order to 
study the SNP in the first repeat of the 2R allele which has been recently described 13,14, 
fragments after digestion were additionally analyzed with the ABI Prism 310 Genetic 
Analyzer 
1494del6 analysis
The TS 6-bp deletion polymorphism at nucleotide 1494 was assessed using PCR 
and primers 6-FAM 5’-CAAATCTGAGGGAGCTGAGT -3’ and 5’-CAGATAAGTG 
GCAGTACAGA-3’ 30, 1 unit of AmpliTaq Gold Polymerase, PCR Gold buffer (Applied 
Biosystems) and 2.5 mM MgCl2 for amplification. PCR conditions were similar to the 
ones described for the VNTR analysis. PCR products were analyzed with the ABI Prism 
310 Genetic Analyzer in order to distinguish between the +6-bp and -6-bp alleles.
allelic imbalance
 Loss of heterozygosity
Loss of heterozygosity (LOH) was analyzed in patients heterozygous for the VNTR 
polymorphism (2R/3RG, 2R/3RC) (n=16). LOH was determined by assessment of the 
peak surfaces ratios acquired by ABI Prism 310 Genetic Analyzer. After analysis in 
normal tissue the peak surface of the 2R allele was divided by the surface of the 3R allele 
(ratio in normal tissue). This number was divided by the ratio between the 2R and 3R 
allele found in tumor tissue. An obtained LOH ratio of 0.76-1.00 or 1.00-1.30 indicated 
retention of both alleles. A LOH ratio of ≤  0.59 (loss 3R) or ≥ 1.70 (loss 2R) indicated 
LOH. Intermediate ratios (0.60-0.75 and 1.3-1.69) were considered as inconclusive.
TS gene amplification
TS gene amplification was determined by a newly developed multiplex quantitative real 
time PCR using a LightCycler 2.0 apparatus (Roche Molecular Biochemicals, Mannheim, 
Germany) and Taqman probes. TS gene copy number was normalized to the reference β-
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globin gene. For both genes, specific Taqman probes (Applied Biosystems) were newly 
designed to anneal to region to be amplified as a duplex PCR assay by using the LightCycler 
Probe Design software 2.0 to fit proper primer/probe criteria for optimal multiplex analysis. 
Two differently labeled Taqman probes enabled simultaneous quantification of the TS 
and reference gene; respectively FAM-5’ AGGCCATTACTTTGCCATAATTGTACGACC-
3’ and VIC-5’-AGTCTGCCGTTACTGCCCTGTGG-3’. In case of the TS gene, PCR primers 
with the following sequences were used: 5’-GCTTTGGGAAAGGTCTGG-3’ and 5’-
CGGACATGAGGAGCAATTAC-3’. These primers amplified a portion of the TS gene 
resulting in a fragment of 99-bp 27. PCR primers used for the reference gene (β-globin), 
5’-ACACAACTGTGTTCAC TAGC-3’ and 5’-CAACTTCATCCACGTTCACC-3’ resulting in 
a fragment of 110-bp were previously described 31. The PCR reaction for both genes 
was performed using a LC FastStart DNA Mastermix Plus Hybridization Probes kit 
(Roche). PCR conditions were 10 min. 95°C; 45 cycles of 10 seconds at 95°C, 10 seconds 
at 55°C, 10 seconds at 72°C. The normalized amplification rate (relative quantification) 
was calculated with the Light Cycler Relative Quantification Software (Roche). A TS / β-
globin ratio of > 1.5 was considered positive for TS gene amplification. This amplification 
ratio was calculated by dividing the ∆Cp of the target gene by the ∆Cp of the reference 
gene.
immunohistochemistry
Immunohistochemical staining of TS was performed on 4 µm sections obtained from 
paraffin-embedded normal and tumor tissues using the TS-106 antibody (1:1000, 
DakoCytomation, Glostrup, Denmark, kindly provided by DakoCytomation, the 
Netherlands). This clone is commonly used to investigate TS with IHC, as reviewed 
by Popat et al 24. Staining was performed using the PowerVision plus method 
(ImmunoVision, Brisbane, California, USA) and visualization occurred with 3,3’-
diaminobenzide hydrochloride solution (DAB). Briefly, paraffin sections were de-waxed 
and re-hydrated. Endogenous peroxidase activity was blocked by incubation for 30 min. 
in aquadest containing 3% H2O2 (Fisher Chemicals, Fair Lawn, New Jersey, USA) and 
0.1% sodium azide (Fisher Chemicals). Antigen retrieval consisted of boiling in an EDTA 
buffer (pH 9.0). Subsequently, slides were allowed to cool down for at least 30 min. Before 
applying the antiserum, slides were pre-treated with 0.5% casein (Sigma-Aldrich, St. 
Louis, Missouri, USA) and 0.1% sodium azide in phosphate-buffered saline (PBS) for at 
least 10 min. To reduce non-specific staining, antibodies were dissolved in PBS with 2% 
goat serum (Gibco, Invitrogen Corporation Carlsbad, California USA) and 0.1% sodium 
azide. Next, slides were incubated in a humidity chamber with the primary antibody for 
20 hours (overnight) at 4 °C. Staining was developed with PowerDAB (ImmunoVision) 
during 5 min. Slides were counterstained with hematoxylin solution, dehydrated and 
enclosed with Permount (Fisher Chemicals). All reactions were performed at room 
temperature, unless stated otherwise. All slides were stained simultaneously in order 
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to reduce inter-sample variability. Test slides of normal and cancer tissue revealed that 
(immature) lymphocytes were intensely stained and that normal epithelial cells were 
primarily stained in the basal area of the colonic crypts. These observations were in 
agreement with the performance characteristics of the antibody as mentioned in the 
DakoCytomation datasheet. 
TS staining intensity and localization were evaluated in matched tumor and normal 
tissues by two observers, one being a pathologist (ITG), who were not acquainted with 
patients’ clinical outcome. Slides were evaluated with respect to several IHC parameters 
by both observers at the same time in order to achieve a consensus score immediately. 
Staining intensity was categorized as follows: (0) no staining, (1) weak staining, 
(2) moderate staining and (3) intense staining (Figure 1). Immature lymphocytes 
displayed a consistently high TS staining intensity (3) and were therefore used as an 
internal reference point. In addition to the overall staining intensity (the intensity that 
was observed in more than 50% of tumor cells), the strongest staining intensity and 
percentage of cells stained with this intensity were also assessed. Furthermore, the 
staining localization was scored as nuclear (N) or nuclear and cytoplasmatic (N+C). 
Finally, the ratio between the overall intensity observed in the tumor and normal 
epithelia was assessed. A ratio of 0 indicated equal staining intensities. When the 
normal tissue showed a stronger intensity than the tumor tissue, the ratio was –. In the 
case of reverse observations the ratio was scored as +.
assignment to ts categories
Patients were categorized into low or high TS producers based on their genotypes 
(Table 2) and immunohistochemically assessed protein levels. Dichotomization into low 
and high TS producers was performed for both tumor and normal tissue. Heterozygous 
individuals were categorized as high producers following a dominant model. The 
3RC allele was considered to encode for amounts of TS proteins equal to a 2R allele. 
Therefore, the 3RC/3RC and 2R/3RC genotypes were categorized as low TS producers. 
In case of IHC, TS levels were dichotomized based on the chromogen intensity as 
follows: low TS producers: an overall staining intensity of 0-1, high TS producers: an 
overall staining intensity 2- 3 as described by several other studies 19,22,32,33.
statistical analysis
Relations between various parameters were analyzed using the Chi-square and One-way 
ANOVA method. The correlation of the TS amplification assay which was performed in 
duplicate was determined using the Pearson correlation. Survival analyses of time to 
cancer related death or the occurrence of distant metastasis were performed using the 
Kaplan-Meier method, with the time of surgery as entry date. Patients who experienced 
were excluded from survival analysis (n=4) since these patients probably already had
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Figure 1: Different 
staining intensities 
observed after 
TS IHC with 
monoclonal 
antibody TS-106 
(DakoCytomation) 
in tumor tissue (B, 
D, F and H) and 
normal tissue (A, C, 
E and G), original 
magnifications: 
200X. Arrows 
depict intensely 
stained immature 
lymphocytes. 
Staining intensities 
of 0, 1, 2 and 3 
are respectively 
indicated by panel 
A and B, C and D, E 
and F and G and H. 
→ color figures
 
metastasis at time of diagnosis that were undetected. These patients had 2R/2R (n=2) 
and 2R/3R (n=2) genotypes and will be categorized as low (2) and high (2) TS producers, 
respectively, after dichotomization.
Differences in observed survival between groups were tested for statistical significance 
using log-rank tests. A p-value of < 0.05 was considered statistically significant.
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results
distribution of ts polymorphisms
VNTR analysis and subsequent digestion resulted in clear visible bands after gel 
electrophoresis (Figure 2A, B). The presence of a 6 bp deletion in the 3’UTR region 
could be easily analyzed after detailed fragment analysis with the ABI Prism Genetic 
Analyzer (Figure 2C).
Figure 2: Representative images of TS PCR products after gel 
electrophoresis. A: Variable number of tandem repeat (VNTR) 
analysis, B: Subsequent digestion of the amplified VNTR 
region. The appearance of a fragment of 94 bp indicates a 
base pair substitution of a C to a G. In panel C: PCR products 
after analysis with the ABI Prism 310 Genetic Analyzer are 
depicted. M=marker.
The distribution and categorization of the three different polymorphisms is depicted in 
Table 2. The majority (42%) of the patients was found to be heterozygous for the VNTR 
polymorphism. Although 4 up to 9 repeats in the VNTR region have been described 34,35, 
no alleles with more than three tandem repeats were observed. Seventeen of the 33 3R 
alleles (52%) revealed to have a G to C substitution. Combining the VNTR polymorphism 
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with the SNP analysis resulted in the following genotype distribution: 32% 2R/2R, 3% 2RC/
2R, 21% 2R/3RC, 21% 2R/3RG, 10% 3RC/3RC, 10% 3RG/3RG and 3% 3RG/3RC (Table 2). 
The majority (58%) of the patients had no 6-bp deletion in the 3’UTR region. VNTR with 
subsequent SNP analysis were performed in both tumor and normal tissue. Genotypes 
were similar in both groups except for heterozygous individuals exhibiting LOH.
allelic imbalance
Loss of heterozygosity
LOH was found in tumor specimens in eight of sixteen (50 %) patients heterozygous for 
the VNTR polymorphism. Of the remaining eight patients, retention and intermediate 
ratios were observed in four patients each (Table 2). Additional LOH analysis affected 
the tumor genotype in 21% of the total patient population. Loss of the 3R allele was 
most frequently observed (75%). Heterozygous tumors with loss of the 3R allele were 
categorized as low TS producers and tumors with loss of the 2R allele remained high TS 
producers.
vntr*
vntr+Snp*
Vntr+snP+loh#
1494del6*
2R/2R
2R/3R
3R/3R
2R/2R
2RC/2R
2R/3RG
2R/3RC
3RG/3RG
3RC/3RG
3RC/3RC
2R/loss
3RC/loss
3RG/loss
2R/3RC R
2R/3RG R
2R/3RC IR
2R/ 3RG IR
+6bp/+6bp (wt)
+bp/-6bp
-6bp/-6bp
13 (34%)
16 (42%)
9 (24%)
12 (32%)
1 (3%)
8 (21%)
8 (21%)
4 (10%)
1 (3%)
4 (10%)
6 (37%)
0
2 (13%)
3 (19%)
1 (6%)
1 (6%)
3 (19%)
22 (58%)
15 (39%)
1 (3%)
Low
High
High
Low
Low
High
Low
High
High
Low
Low
Low
High
Low
High
Low
High
High
High
Low
PolymorPhism genotyPe frequency
Predicted leVel of 
Protein exPression
*dominant model, #only analyzed in tumor tissue of patients heterozygous 
for the VNTR polymorphism (n=16). Abbreviations: R: retention, 
IR: intermediate ratio, wt: wild type
taBle 2. distriBution of the ts PolymoPhisms
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TS gene amplification
In this study a new real time PCR was developed to determine TS gene amplification. 
This was done by comparing the amount of PCR products of the β-globin reference 
gene with the TS gene. For this it is crucial that the efficiency, as measured by the curve 
slopes, of both PCR reactions is comparable. Our data showed that in control DNA (15 
ng/µg human genomic DNA, LightCycler control kit DNA, Roche Applied Science) the 
efficiency of the TS and β-globin amplification gene was equal; also after analyzing 
a tenfold dilution-series. The curve shape and slope as observed after analysis of 
the control DNA were confirmed in formalin-fixed paraffin-embedded tissue. Serial 
dilutions of DNA isolated from tumor samples showed similar amplification curves 
for the TS and β-globin gene (Figure 3A). TS gene amplification could be determined 
by this newly developed assay in 37 of the 38 patients (Table 3). Amplification was 
performed in duplicate. The correlation between these two measurements was highly 
significant (p<0.001, correlation coefficient = 0.927, Pearson correlation) indicating
 Figure 3: Amplification curves observed after the 
newly developed real time PCR assay, performed 
on DNA obtained from formalin-fixed paraffin-
embedded tissue. A dilution series (panel A) and 
an example of TS gene amplification (panel B) are 
depicted. Panel A: amplification curves of the TS 
gene (solid line) and β-globin gene (dotted line), *: 
undiluted, **: 10X diluted, ***: 100X diluted.  The 
∆ indicated the difference of Cp (crossing point) 
values between the TS and reference gene for each 
dilution. The Cp value is defined as the cycle at which 
the fluorescent signal exceeds the threshold value 
as determined by the automatic fit point module. 
Panel B: S: sample (tumor DNA), R: reference 
(normal DNA), ∆: difference in Cp values between 
the TS and β-globin gene. The amplification ratio 
was calculated by dividing the ∆Cp of the target 
gene by the ∆Cp of the reference gene.
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ts nr
tS 01
tS 02
tS 03
tS 04
tS 05 
tS 06
tS 07
tS 08
tS 09
tS 10
ts 11
ts 12
ts 13
ts 14
ts 15
ts 16
ts 17
ts 18
tS 19
tS 20
ts 21
ts 22
ts 23
ts 24
ts 25
ts 26
ts 27 
ts 28
tS 29
tS 30
ts 31
ts 32
ts 33
ts 34
ts 35
ts 36
ts 37
ts 38
3C-3C
2/2
3G/3G
2/_
3G/_
2/_
2/2
3C/3C
2/2
2/2
3C/3C
3G/3G
2/3G
2/3C
2/_
2/2
2/_
2/2
3G/3G
2/_
2/2
2/2
2/2
2/3C
2/2
2/2
3G/3C
2/_
3G/3G
2/3G
2/3C
2/2
2/3G
2/3C
2/3G
3C/3C
3G/_
2/2
3C/3C
2/2
3G/3G
2/3C
2/3G
2/3C
2/2C
3C/3C
2/2
2/2
3C/3C
3G/3G
2/3G
2/3C
2/3G
2/2
2/3G
2/2
3G/3G
2/3C
2/2
2/2
2/2
2/3C
2/2
2/2
3G/3C
2/3C
3G/3G
2/3G
2/3C
2/2
2/3G
2/3C
2/3G
3C/3C
2/3G
2/2
2
2
2
.
0
2
2
2
2
1
.
0
2
2
2
1
1
3
2
3
2
2
2
1
2
2
2
1
1
3
2
2
2
1
2
1
2
2
2
3
2
2
2
1
3
1
1
0
1
0
1
1
2
1
2
2
2
1
2
2
1
1
1
1
1
1
1
2
2
2
1
0
1
0
2
1
3
1
2
2
2
1.71
0.76
0.87
0.56
0.88
0.6
2.3
1.0
1.0
0.8
1.3
1.2
1.0
0.8
0.7
0.8
0.9
0.9
1.0
0.5
1.8
1.2
1.2
1.4
1.2
1.1
0.8
0.7
0.5
0.9
0.8
0.8
0.8
0.9
1.0
0.9
0.9
1.0
1.0
1.1
1.1
0.7
+6bp/+6bp
+6bp/+6bp
-6bp/+6bp
+6bp/+6bp
-6bp/+6bp
+6bp/+6bp
+6bp/+6bp
-6bp/+6bp
+6bp/+6bp
+6bp/+6bp
+6bp/+6bp
+6bp/+6bp
-6bp/+6bp
-6bp/+6bp
-6bp/+6bp
-6bp/+6bp
-6bp/+6bp
-6bp/+6bp
+6bp/+6bp
-6bp/+6bp
+6bp/+6bp
+6bp/+6bp
-6bp/+6bp 
+6bp/+6bp
-6bp/+6bp
+6bp/+6bp
-6bp/+6bp
-6bp/+6bp
-6bp/+6bp
+6bp/+6bp
+6bp/+6bp
+6bp/+6bp
+6bp/+6bp
+6bp/+6bp
-6bp/+6bp
+6bp/+6bp
+6bp/+6bp
+6bp/+6bp
Abbreviations: G: genotype, T: tumor, N: normal, PT: primary tumor, M: metastasis, amp ratio: 
amplification ratio of the TS gene * the mean amplification ratio was found to be correlated to the 
IHC intensity as observed in the majority of the tumor cells (p=0.001). This correlation is also 
depicted in Figure 5.
gt gn ihc
n
ihc
t*
ihc
m
1494del6 mean amp 
ratio pt*
mean amp 
ratio m
taBle 3. comParison BetWeen ts gentotyPes and immunohistochemistry
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that the amplification assay was highly reproducible. A mean amplification ratio of >1.5 
was found in 2 out of 37 tumors (5%) (Figure 3B). In addition, one out of five (20%) 
metastasis had a mean ratio of >1.5. The primary tumor (TS03) of the metastasis with 
TS gene amplification did not demonstrate amplification (mean ratio 1.0). 
immunohistochemical assessment of ts 
Respectively 11%, 47%, 37% and 5% of the tumors displayed an overall staining 
intensity of 0, 1, 2 and 3 (Table 4).  Overall TS staining intensity in the normal mucosa 
could be evaluated in 36 out of 38 patients; normal tissue could not be found in one 
patient, in the case of another patient IHC of normal tissue could not be assessed due 
to an artefact. Staining was predominately localized in the nucleus (tumor tissue: 71%, 
normal tissue 89%).
prognostic significance
The different IHC parameters (overall and strongest staining intensities, staining 
localisation and the ratio of staining between normal and tumor cells) failed to 
demonstrate a significant association with distant recurrence (DR) and cancer specific 
survival (CSS). TS dichotomization based on the VNTR analysis in normal tissue (as 
summarized in Table 2) was found to be of prognostic significance for DR (p=0.038) and 
CSS (5-year survival proportions for TS low: 88 % and TS high: 37%, p=0.021) (Figure 
4A, B). As illustrated in Figure 4C, additional SNP analysis of DNA extracted from 
normal tissue did not add prognostic information. This was also observed for DR. 
Although it was decided on forehand to exclude 4 patients who experienced a metastasis 
during the administration of chemotherapy (i.e. within six months after surgery) because 
these patients would probably have stage IV disease at time of diagnosis instead of 
stage III disease, we also performed survival analysis on the total population based on 
clinical practice at time of diagnosis (CSS: TS low: 74%, TS high: 34%, p=0.076; DR: TS 
low: 33%, TS high: 60%, p=0.148). In contrary to the IHC parameters, a strong trend 
0
1
2
3
localisation
2 (6%)
8 (22%)
23 (64%)
3 (8%)
n: 32 (89%)
n + c: 4 (11%)
4 (11%)
18 (47%)
14 (37%)
2 (5%)
n: 27% (71%)
n+c: 11 (29%)
ihc score normal tissue tumor
Abbreviations: IHC = immunohistochemistry, 
n=nucleus, c=cytoplasm
taBle 4. distriBution of the different staining intensities and staining 
LoCaLISatIon oBServed In the MajorIty oF tuMor/norMaL epItheLIaL CeLLS
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towards a significant difference between TS low and high producers, especially with 
respect to CCS, could still be observed after analysis of the total population, confirming 
that TS genotyping is a better prognostic marker than IHC. Most likely the outcome in 
stage IV disease is rather a product of both the intrinsic tumor biology and sensitivity to 
5FU and it would be interesting to further study this in a larger study population. 
Figure 4: Kaplan-Meier survival curves of A: distant recurrence (DR) and B cancer specific survival (CSS).
TS low: solid line, TS high: dotted line. Patients developing metastasis within 6 months were excluded 
from analysis. C: Kaplan-Meier survival curve demonstrating the effect of SNP analysis in normal tissue. 
Patients with 3RC/3RC or 2R/3RC genotype (striped line) behave differently from patients with the 2R/2R 
genotype (solid line). 
correlation between ts genotype and ihc
No correlation was found between the predicted protein levels (high, low) based on 
TS polymorphisms and overall or strongest TS staining observed after IHC. This 
correlation was lacking for both tumor and normal tissues. Combining the strongest 
staining intensity with the percentage of maximal stained cells also did not result 
in a significant correlation with TS genotype. The other IHC parameters (staining 
localization, percentage of cells with strongest staining and staining ratio between 
normal and tumor tissue) also failed to show a correlation with TS genotype. However, 
the overall staining intensity was significantly correlated (p=0.001, One-Way ANOVA) 
with the mean amplification ratio (Figure 5). This p value was still significant after 
correcting for multiple comparisons (p<0.0083 in case of 4 groups). This relationship 
was mostly pronounced in tumors with gene amplification because these tumors were 
intensely stained in specific subpopulations of tumor cells as depicted in Figure 1H. The 
observed staining pattern of this tumor is very heterogeneous; some tumor cells are 
completely negative and others display an intensely stained nucleus.
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Figure 5: Scatter plot depicting the correlation between TS gene amplification in the primary tumor and 
TS staining intensity as observed in the majority of the tumor cells. T=tumor.
discussion
This study shows that the intrinsic variable number of tandem repeats (VNTR) was 
the only polymorphism of the TS gene demonstrating a significant association with 
distant recurrence (DR) and cancer specific survival (CCS) (Figure 4A, B). Assessment 
of the other two polymorphisms; the single nucleotide polymorphism (SNP) and the 
3’UTR deletion (1494del6) did not add prognostic information. The different TS IHC 
parameters were also not predictive for patients’ outcome.
 
The clinical implications of VNTR analysis with respect to the favorable outcome of 
patients with a 2R/2R genotype in the adjuvant setting was similar to that of several 
other studies 11,36,37. In addition, the lack of prognostic information of VNTR combined 
with SNP analysis is in accordance with the findings of Dotor et al 30. This was clearly 
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illustrated in Figure 4C; patients who had low predicted protein levels due to a SNP in 
the 3R allele had a worse prognosis than patients with a 2R/2R genotype. However, 
others found that the 3R/3R genotype was associated with a better outcome which 
is in contrast with our findings 30. This observation was confirmed by Jakobsen et al 
investigating patients with disseminated disease 38. However, nothing can be said about 
the differences in 5-FU sensitivity alone because the outcome is affected by both the 
intrinsic tumor biology and sensitivity to 5-FU.
In contrast to TS genotyping, this study demonstrated that IHC is not predictive for 
therapy response. A predictive role of TS IHC, in the adjuvant and advanced settings, 
was found in some studies 2,18 but enfeebled by others 19-23.
This supports that TS IHC is prone to inter-laboratory variation and is not adequate 
for quantification of protein levels. Differences in tissue fixation, observer dependant 
assessment of staining patterns, severe heterogeneity in staining intensities between 
cells and most importantly, antibody binding may all cause an inaccurate reflection of 
the protein content of the specimen. 
In the present study, 52% of the 3R alleles revealed to have a G to C substitution. The 
frequency of this SNP varies between ethnic groups and has been described to be 56% 
for Caucasians 39 which is in agreement with our findings. Even though SNP analysis did 
not add prognostic information, it would have been desirable to study LOH in patients 
with three repeats heterozygous for the SNP because it can affect the predicted protein 
levels. i.e., 3RC/3RG individuals with loss of the 3RG allele would have low predicted 
protein levels. However, with current techniques, LOH analysis in 3RC/3RG individuals 
was found to be too challenging from a technical point of view. In the future, other 
techniques like primer extension might facilitate this analysis and is presently under 
investigation. In addition, we identified the recently identified SNP in the fist tandem 
repeat of the 2R allele 13,14 in one patient who was homozygous for the VNTR but 
heterozygous for the SNP in the 2R allele (2R/2RC). The frequency of the 2RC allele has 
been described to be 4.2 % 14 to 1.5% 13. In our population, the frequency of the 2RC 
allele was found to be 1.3% which is consistent with previous findings.
Although several in vivo and in vitro studies indicated that TS genotype and TS 
protein levels are correlated 7-12, the present study indicated that this correlation could 
not be confirmed with IHC. Patients with a 3R/3R genotype did not show higher TS 
staining intensities than patients with a 2R/2R genotype. This finding might explain 
the discrepancies in literature concerning the predictive value of TS as indicated by the 
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal 
cancer. 15. Dotor and co-workers also observed that the three polymorphisms were not 
associated with IHC staining intensities (evaluated in 129 tumors) 30. Besides the technical 
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considerations of IHC, several other mechanisms could account for the finding in the 
present study that IHC did not confirm the TS protein levels predicted by genotyping. 
Firstly, a variety of post-translational mechanisms such as protein glycosylation, folding 
and protein-protein interactions can influence epitope-availability of monoclonal 
antibodies directed against TS. Secondly, the antibody used largely affects the staining 
pattern. Indeed, even using antibodies of the same clone (TS-106) but from different 
companies (Abcam versus DakoCytomation) resulted in poor reproducibility (data not 
shown). 
This is the first study reporting an association between TS gene amplification and IHC 
(Figure 5). This observation makes it tempting to speculate that the variations in TS 
protein levels caused by the TS polymorphisms are very subtle and can therefore not be 
clearly visualized with IHC. TS gene amplification, on the other hand, can increase the 
concentration of TS proteins to such an extent that IHC staining patterns will be more 
pronounced in those specific tumor cells. Figure 1H depicts a staining pattern which 
can be best characterized as “dotted” with some tumor cells displaying an intense 
nuclear staining and others lacking staining. It was also observed that these intensely 
stained cells often displayed mitotic spindle figures indicating cell proliferation. Since 
amplification analysis was performed on DNA extracted from a selected tumor area 
containing >50% tumor cells and tumors are known to be very heterogeneous, the 
intensely stained cells would probably have an amplification ratio of for example 5 
or 6 to compensate for those with no amplification. This hypothesis could be further 
investigated by using fluorescent in situ hybridization (FISH) since this technique can 
visualize differences in copy numbers between individual tumor cells.
TS gene amplification is not frequently observed in primary tumors in contrast to 
tissue exposed to 5-FU based therapy 27. This is consistent with our results since we 
found that 5% (2/37) of the primary tumors demonstrated amplification versus 20% 
(1/5) of the metastatic tissues. This percentage is in accordance with Wang et al. who 
reports TS gene amplification in 23% of liver metastasis that have been exposed to 5-
FU 27. The single metastasis with TS gene amplification also demonstrated a strong (3) 
IHC staining intensity, which is in agreement with our finding that gene amplification 
is correlated with IHC staining intensity. However, due to small patient numbers firm 
conclusions cannot be drawn. Treatment with 5-FU might provoke selection of tumor 
cells with TS gene amplification 40,41. Loss of heterozygosity (LOH), which can also result 
in allelic imbalance, was frequently reported at the site of the TS gene. LOH frequencies 
of 63% up to 73% were found in patients with a 2R/3R genotype 25,42. These findings 
were confirmed by the present study which reported LOH in eight of sixteen (50 %) 
patients heterozygous for the VNTR polymorphism. Although, we have performed 
macro dissection for purposes of tumor enrichment, the percentage of LOH reported 
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could be underestimated if substantial numbers of normal cells are still present.
Although the number of patients in the present population is relatively small (38 patients), 
significant differences regarding CSS and DR based on VNTR analysis in germline DNA 
were obtained. Studying these germ line DNA alternations has several advantages. 
Analysis can be performed on readily available tissue such as peripheral blood and 
does not require harvesting of tumor tissue. Moreover, genomic polymorphisms are 
stable providing certain robustness in favor of DNA based assays. To validate the data 
obtained by this study, TS genotyping will be further investigated in a large group of 
well defined patients with colorectal cancer to study the predictive value for response 
to 5-FU.
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Background
Not all patients with locally advanced rectal cancer (LARC) respond equally to neo-
adjuvant radiochemotherapy (RCT). Patients with highly apoptotic less advanced rectal 
cancers do not benefit from short-term radiotherapy. This study investigates whether 
this is also the case in the setting of RCT for LARC.
Patients and methods
Tissue micro arrays (TMA) were constructed of biopsy and resection specimens of 
201 LARC patients. Apoptosis (M30) and several apoptosis regulating proteins (p53, 
Bcl-2, Bax, cyclooxygenase-2 and maspin) were studied with immunohistochemistry. 
Subsequently, predictive values for local recurrence (LR), overall survival (OS) and 
histological tumour regression were analyzed. 
results
Apoptotic levels, quantified as the number of apoptotic cells/mm2 tumour epithelium, 
were higher in post-therapy tissues compared to biopsies (p<0.001). Biopsies from 
cT4 tumours demonstrated significantly higher levels of apoptosis than cT3 tumours 
(p=0.020). Therapy-induced apoptosis was higher when the interval between the last 
day of irradiation and surgery increased (p<0.001, cc=0.355). Pre- and post-therapy 
apoptosis, p53, Bcl-2, Bax and Cox-2 were not associated with LR, OS or tumour 
regression. Intense pre-therapy cytoplasmic staining of maspin indicated a higher risk 
on LR (p=0.009) only.
conclusion
Combined RCT is also successful in highly apoptotic tumours and is therefore indepen-
dent of intrinsic apoptosis.
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introduction
Patients with locally advanced rectal cancer (LARC) are at high risk of local failure. 
Therefore, surgery alone is often not curative and neoadjuvant radio(chemo)therapy 
(RCT) is required in order to improve local control and achieve a radical resection. 
Tumour response to RCT varies considerably and various stages of histological tumour 
regression can be observed in the surgical resection specimens. Markers that can 
predict therapy outcome would permit adaptation of the therapeutic strategy and 
improve treatment of LARC; e.g. poor responders could be offered a different therapy 
regimen or could be operated much sooner with more extensive surgery. 
In order to prevent local recurrences and improve local control, patients with mobile 
rectal cancer (T1-T3) currently receive short-term neoadjuvant radiotherapy as 
standardized treatment for rectal cancer in the Netherlands. However, not all patients 
benefit equally; some might experience side effects 1. Therefore, we would like to 
predict tumour response. De Bruin et al showed that levels of apoptosis (assessed 
with M30) can attribute to the selection of patients with a high risk on local failure 
2, since radiotherapy  was effective in patients with low levels of intrinsic apoptosis, 
but patients who had high levels of intrinsic apoptosis in their primary tumour and 
did not receive radiotherapy had the same risk on developing a local recurrence as 
patients that did receive radiotherapy 2. It is however unclear what the prognostic 
implications of intrinsic and therapy-induced apoptosis are in patients with LARC in 
the neoadjuvant setting.
Radiotherapy and chemotherapy can both induce apoptosis in malignancies of the 
gastrointestinal tract. However, the complexity of the apoptotic pathway enables 
tumour cells to escape from apoptosis inducing therapy resistance and affecting 
patient’s outcome. At the cellular level, the regulation of apoptosis depends on a very 
complex balance between pro- and anti-apoptotic proteins. Amongst them are p53, 
Bcl-2, Bax, cyclooxygenase-2 (Cox-2) and mamma serine protease inhibitor (maspin). 
The extensively described oncogene p53 is commonly inactivated in colorectal cancer 
and is a cell cycle regulator and a potent inducer of apoptosis as a response to DNA 
damage 3-5. Bcl-2 and Bax act as antagonists and are members of the same family of 
proteins. While Bcl-2 is an important inhibitor of apoptosis, over expression of Bax 
induces programmed cell death 6,7. During irradiation, Cox-2 has been described to act 
as a survival factor by inhibiting apoptosis 8. Maspin is a multifaceted protein that has 
been described to promote apoptosis 9.
In the present study we evaluated the prognostic value of intrinsic and induced 
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apoptosis (M30) and 5 different apoptosis regulating proteins: p53, Bcl-2, Bax Cox-
2 and maspin, in patients with LARC who were treated with RCT. Local recurrence 
and overall survival were the main outcome parameters. In addition, the association 
between these markers and histological tumour regression was investigated. 
Patients and methods
Patient selection
The patient population consisted of a consecutive series of 201 LARC patients with 
biopsy proven adenocarcinoma as described previously 10. All patients received 
multimodality treatment at the Catharina hospital between 1994 and 2005 
11.Treatment decision was based on the best regiment according to the national 
guidelines of that moment in time. 
histological assessment of therapy-induced tumour regression
Histological therapy-induced tumour regression was assessed according the 
regression grading system described by Rödel et al.12 The degree of tumor was 
estimated and subdivided into the following categories: 0: no regression or < 25% 
of tumour mass, 1: 25% to >50% tumour regression, 2: complete regression. The 
degree of tumour regression was determined semi quantitatively by an experienced 
pathologist (JHJMvK) who was unfamiliar with patients’ clinical outcome. The 
investigations of the clinical value of therapy-induced tumor regression assessment in 
this patients population has been extensively described in a previous study 10.
tissue microarray construction
Tissue micro arrays (TMA) were constructed from formalin-fixed, paraffin-embedded 
biopsy tissues (three 0.6 mm punches) and resection specimens (three 2 mm punches) 
using an Alphelys TMA booster (Westburg, Leusden, the Netherlands). Three punches 
have been previously described to be sufficient to overcome tumour heterogeneity 
13. Moreover, most studies validating the use of TMA for studying markers with IHC 
advise to use tree to four punches of 0.6 mm 14-16. We used an equivalent of 10 tumor 
punches of 0.6 mm which is well above the advised number of 0.6 mm punches. In 
case normal tissue was available, one punch was also taken from this area in order to 
construct a TMA containing normal tissues only. Preferably, normal tissue adjacent 
to the tumour this tissue was used (55%). If this was not present, normal tissue was 
obtained from another paraffin block (45%).
immunohistochemistry
Immunohistochemical stainings were performed on 4 µm TMA sections using the 
Apoptosis in LARC
15
PowerVision plus method (ImmunoVision, Brisbane, California, USA). Visualization 
involved incubation with PowerDAB (ImmunoVision) for 5 min. Methods for antigen 
retrieval and the dilutions of the antibodies used can be found in Tabel 1. Slides were 
incubated in a humidity chamber with the primary antibody for 20 hours (overnight) 
at 4 °C. Negative controls involved incubation with PBS with 2% goat serum and 0.1% 
sodium azide only. Slides were counterstained with hematoxylin. Staining patterns of 
p53, Bcl-2, Bax Cox-2 and maspin were all evaluated semi-quantitatively (Table 1) by 
two independent observers who were unfamiliar with patients’ outcome. In case of 
disagreement, a consensus score was obtained which was used for further analysis.
M30
CytoDEATH
(Roch, Roche Applied
science, Indiapolis, USA)
P53
(BioGenex, 
San Ramon, USA)
Bcl-2
Oncoprotein
(Dako, Glostrup,
Denmark)
Bax 
(Santa Cruz 
Biotechnology,
Santa Cruz, USA)
Cox-2
(Cayman Chemicals, 
Ann Arbor, USA)
maspin
(Becton Dickinson
Pharmingen, Franklin
Lakes, USA)
1:500
1:10,000
1:500
1:1000
1:100
1:20,000
Incubation with 
a 10mM sodium 
citrate buffer
(pH6.0) for 30 
minat 98°C
M30
specific for 
human 
cytokeratine 
18
BP 53-12
124
B-9
CX229
G167-70
Number of apoptotc 
cells per mm2 tumour 
epithelial was quantified
Intensity of nuclear 
staining (0-3) and the 
proportion of negative 
cells: 10-30%, 30-60%, 
or 60-90%*
Intensity of cytoplasmic 
staining (0-3)*
Intensity of cytoplasmic 
staining (0-3)*
Combination of intensity 
and proportion of cyto-
plasmic staining*17,18
Intensity of cytoplasmic 
and nuclear staining 
(0-3)*
antiBody
( company)
clone dilution antigen
retrieVal
ihc assessment
* Staining patterns were assessed by two independent observers.
 Abbreviations: IHC: immunohistochemistry
taBle 1. immunohistochemical sPecifications of the antiBodies used
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Quantification of apoptosis
In case of M30 immunohistochemistry, the number of apoptotic tumour cells per 
mm2 tumour epithelium was assessed for each punch. In order to establish the area 
of tumour epithelium for each punch, TMA were stained with the pancytokeratin 
MAK-6 (1:10, protease antigen retrieval, Zymed Laboratories, Invitrogen, Carlsbad, 
USA). Microscopic images measuring 0.74 mm2 were digitized using an RGB CCD 
camera (AxioCam MRc, Zeiss, Germany), resulting in a specimen level pixel size 
of 1.3x1.3um2. Quantitative measurements of the tumour area or area of normal 
epithelium were performed using a digital image analysis system (KS400, Carl Zeiss, 
Germany). Punches of 0.6mm diameter were analyzed using a 10X objective and 2 
mm punches using an objective of 2.5X. Digitized images were corrected for unequal 
illumination using a stored image of an empty microscopic field. The immuno-positive 
area (in mm2) was calculated automatically. Subsequently, the number of apoptotic 
cells was manually counted to calculate the apoptotic level defined as the number 
of apoptotic cells per mm2 tumour epithelium. Values that exceeded the standard 
deviation two times were considered outliers and were therefore excluded from 
further analysis.
statistics
Data were analyzed with the SPSS package (Statistical Product and Service Solutions 
11.0 for Windows, SPSS inc., Chicago, Illinois, USA). Inter-observer variability 
was calculated by κ statistic as described by Cohen 19,20. κ-values of 0.2 to 0.4 
indicate “fair”, 0.4 to 0.6 “moderate”, and values of > 0.6 “excellent” agreements 21. 
Correlations between apoptosis and the interval between the last day of irradiation 
and surgery were analyzed according to the Spearman rank correlation test. 
Univariate survival analyses of time to death or local recurrence were performed using 
the Kaplan-Meier method and log-rank testing with the time of surgery as the entry 
date. Patient outcome parameters were local recurrence (LR), and overall survival 
(OS). P-values of ≤ 0.05 were considered as statistically significant.
Multiple variable analyses involved Cox’s proportional hazards regression (enter 
method), logistic regression (enter method) and building of decision trees using the 
DTREG software for predictive modeling and forecasting (www.dtreg.com). Single 
tree models for classification using the Gini splitting algorithm in which the variables 
were equally weighted were constructed. Pruning and validation of the tree model 
was performed with the V-Fold cross validation in order to determine the statistically 
optimal tree size. 
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results
Patient and tumour characteristics
Patient, treatment and tumour characteristics are summarized in Table 2. The 
majority (59%) of the patient population initially presented with a tumour invading 
into other adjacent organs or structures (cT4). Complete histological tumour 
regression was observed in 21 (11%) patients. Poor (Rödel 0) and moderate (Rödel 1) 
tumour regression grades were observed in 50% and 39% patients, respectively.
Medianage, (range)
sex
ct-stage
neoadjuvant therapy
medianinterval: last day
rt-surgery
crm
ypt-stage
ypn-stage
histologic regression
pre-treatment apoptosis
(mean of cells)
post-treatment apoptosis 
(mean of cells)
male
female
cT3
cT4
RT
RCT
interrupted
RCT
continuos
positive
negative
ypT0
ypTis
ypT1
ypT2
ypT3
ypT4
n.a.
N0
N1
N2
0
1
2
63, (35-8)
122 (61%)
79 (39%)
83 (41%)
118 (59%)
74 (37%)
102 (51%)
25 (12%
7.8* weeks
43 (21%)
158 (79%)
20 (10%)
1 (0.5%)
2 (1%)
15 (7%)
132 (66%)
30 (15%)
1 (0.5%)
131 (65%)
47 (24%)
23 (11%)
101 (50%)
79 (39%)
21 (11%)
0*
10.39%
factor
Abbreviations: RT: radiotherapy, RCT: radiochemotherapy, CRM: 
circumferential margin, n.a.: not assessed, *: not a number but 
the mean or median is given. 
taBLe 2. patIent, treatMent and tuMor CharaCterIStICS
n(%)*category
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Apoptosis; prognostic significance and correlations with clinicopathological factors
Representative staining patterns observed after M30 IHC are depicted in Figure 
1A. The apoptotic levels in neither the post-therapy resection specimens nor the 
pre-treatment biopsies were associated with (LR) or (OS). The amount of apoptotic 
cells was significantly higher in post-treatment resection specimens compared to 
pre-treatment biopsies (median 10.4 vs. 0, p=<0.001, Wilcoxon test). M30 IHC was 
also performed on TMA containing normal tissues. This revealed that the amount of 
apoptosis in normal epithelium was significantly lower in patients who received the 
capecitabine containing continuous schedule (7.2 apoptotic cells per mm2 epithelium) 
compared to patients who received the interrupted RCT (15.3 apoptotic cells per 
mm2 epithelium) schedule (p=0.018). Apoptotic levels did not differ between normal 
tissues obtained adjacent to the tumour of from another paraffin block (p=0.163). The 
amount of apoptotic tumour cells did not significantly differ between the different 
therapy regiments (Table 3). 
ct-stage
neoadjuvant
therapy
interval: 
last day
rt-surgery
ypt-stage
ypn-stage
crm
histologic
regression
cT3
cT4
RT:
RTC:
interrupted 
RTC:
continuous
ypT0,
ypTis,
ypT1, ypT2
ypT3, ypT4
N0
N1
N2
positive
negative
0
1
2
0/5.89
3.65/11.71
0/9.51
2.47/9.43
6.03/2.47
p=0.34c, cc=0.084
0/8.40
0/9.52
0/9.45
3.32/10.62
0/5.56
0/9.34
0/9.28
0/8.94
5.42/10.80
1.24/5.94
11.37/21.12
9.78/17.95
11.45/19.23
9.68/20.11
10.71/18.08
p=0.001c, cc=0.328
9.28/21.39
10.39/18.84
9.48/19.91
17.14/18.79
11.45/16.33
11.45/18.47
9.48/19.50
12.40/22.11
3.9410.68
n.a.
0.57a
0.97b
0.75a
0.87b
0.811
0.003a
0.020a
0.12b
0.93a
0.23b
0.96
0.041b
factor category pre-treatMent 
aPoPtosis
(MedIan/Mean)
pre-treatMent 
aPoPtosis
(MedIan/Mean)
p-vaLue p-vaLue
taBle 3. correlation BetWeen aPoPtosis and clinicoPathological factors
a: Mann-Whitney U test, b: Kruskal Wallis test, c: Pearson correlation. Bold values 
indicate statistical significance. Abbreviations: RT: radiotherapy, RCT: radiochemo-
therapy, CRM: circumferential margin, cc: correlation coefficient, n.a.: not assessed.
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Associations between apoptosis and the different clinicopathological factors can 
be found in Table 3. Tumours with a clinical T4 stage (cT4) were found to have higher 
levels of intrinsic apoptosis than cT3 tumours (p= 0.020). In addition, M30 IHC 
revealed that a longer interval between last day of RT and surgery resulted in an 
increased number of apoptotic cells (p=0.001, Pearson correlation coefficient = 0.328), 
indicating a large effect of this parameter on the post-treatment apoptosis. Apoptotic 
levels were found to be significantly higher in resection specimens with limited tumour 
regression (Rödel 0) than in specimens with 25% to >50% tumour regression (Rödel 
0, p=0.003). Intrinsic apoptosis was not predictive for histological tumour regression 
since comparable levels of apoptosis were observed in patients with a poor and 
complete response (Table 3).
p53, Bcl-2, Bax, Cox-2 and maspin; prognostic significance
Representative staining patterns after staining for p53, Bcl-2, Bax, Cox-2 and maspin 
are depicted in panel B, C, D, E and F respectively of Figure 1. As indicated in Table 
1, IHC staining patterns for p53, Bcl-2, Bax, Cox-2 and maspin were assessed by two 
independent observers. In case of the resection specimens, the calculated mean 
kappa values of the three tumour containing punches were found to be 0.61, 0.79, 
0.79, 0.71 and 0.78 respectively for p53, Bcl-2, Bax, Cox-2 and maspin. For pre-
treatment biopsies these values were respectively 0.71, 0.85, 0.85, 0.58 and 0.86. 
These kappa values mainly indicate excellent degrees of agreement. Negative IHC 
controls showed no staining. 
Staining patterns and intensities of p53, bcl-2, Bax, Cox-2 and maspin that were 
assessed in the biopsies and resection specimens did not correlate with histological 
tumour regression. Pre-and post-therapy levels of p53, Bcl-2, Bax and Cox-2 did not 
influence LR or OS rates. Stratification for the different treatment regiments resulted 
in similar findings
A strong cytoplasmic staining of maspin in the biopsy tissues was associated with a 
higher risk on developing a local recurrence (Figure 2). However, this association was 
not observed after separate analysis of each treatment regiment.
Multiplevariable analysis for prediction of patients prognosis and therapy response
Investigation on the associations between apoptosis regulating proteins and apoptotic 
levels showed that increased nuclear staining of maspin in tumour biopsies were 
associated with increased levels of apoptosis in biopsy specimens (p=0.019). Increased 
Cox-2 staining intensities in the resection specimens were significantly associated with 
increased levels of apoptosis (p=0.028). However, this is not in consistency with the 
anti apoptotic effect of Cox-2 that has been described in literature 8,18.
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Figure 1: examples of immunohisto-chemical staining patterns observed after staining with M30 
CytoDEATH (A), p53 (B), Bcl-2 (C), Bax (D), Cox-2 (E) and maspin (F). The arrows in panel A depict 
examples of apoptotic tumour cells that demonstrate intense staining with the M30 antibody. Original 
magnifications B-F: 200X, A: 400X.
→ color figures
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Figure 2: Kaplan-Meier curves depicting the 
correlation between cytoplasmic staining 
patterns of maspin in the pre-therapy biopsies 
and local recurrence.
Cox’s proportional hazards regression indicated that different combinations of 
apoptosis and the different apoptosis regulating proteins were not predictive for LR or 
OS. In order to study whether combinations of apoptosis and the different apoptosis 
regulating proteins are predictive for tumour regression, logistic regression was 
performed and decision tree models were built. In the case of both logistic regression 
analysis and the CART analysis histological tumour regression was dichotomized in 
two different ways; Rödel 0 and 1 versus Rödel 2 and Rödel 0 versus Rödel 1 and 2. This 
analysis revealed that none of the variables or variable combinations was predictive 
for tumour regression. 
discussion
Pre-therapy (intrinsic) or post-therapy (induced) levels of apoptosis, p53, Bcl-2, Bax 
and Cox-2 in tumour cells were not found to be associated with local recurrence (LR) or 
overall survival (OS) in patients with LARC. Maspin was found to be correlated to LR 
only (Figure 2).These data implicate that success of neoadjuvant RCT is independent 
of these factors. In addition, we found that apoptosis of tumour cells was not 
predictive for the degree of tumour response in these patients. 
De Bruin et al also studied the prognostic value of apoptosis in TMA with M30 IHC 
which is similar to our study design 2. In concordance with that study we also found 
that the post-therapy apoptotic levels did not influence patients’ prognosis. However, 
the study reported by Bruin et al was a randomized trial in which the surgery only 
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arm acted as a control, while we did have access to pre-treatment biopsies. Tannapfel 
et al investigated intrinsic and therapy-induced levels of apoptosis in LARC patients 
who received RCT and did also not find a correlation between apoptosis and LR, OS 
or tumour regression after RCT which is consistent with our findings 22. However, 
other studies found that intrinsic levels of apoptosis were related to the degree of 
tumour regression and patients’ outcome 23,24 after long-term neoadjuvant RCT. 
These differences in literature indicate that the prognostic implications of apoptosis 
in patients with rectal cancer are not established and need further research in order 
to determine the clinical usefulness (reviewed in 25) Since radiotherapy is the main 
therapy used in the present population, it would also be interesting to study the 
clinical of apoptosis in the setting of systemic treatment with chemotherapy.
Our finding that apoptotic levels were significantly increased in the surgical resection 
specimens is in consistency with other reports 22,26. Based on the apoptosis inducing 
potential of radiotherapy and chemotherapy this was not an unexpected finding. 
Analysis of apoptotic levels in normal epithelial cells yielded the surprising result that 
the number of apoptotic cells significantly decreased in case of the continuous RCT 
schedule in comparison to the interrupted RCT schedule. This might be explained 
by the use of capecitabine in the continuous schedule which is, in contrast to 5-FU, 
converted into the active metabolite in cells with a higher metabolism delivering 
the 5-FU predominately to the tumour cells 27,28. Another, interesting finding was 
that when the interval between the last day of irradiation and surgery was longer, 
the post-therapy apoptotic levels increased. It is tempting to speculate that this 
observation could partially explain the positive effect of a prolonged interval between 
radio(chemo)therapy and surgery as indicated by a French trial 29. Several studies 
have shown that long course radiotherapy with concurrent 5 fluorouracil (5-FU) based 
chemotherapy contributed to tumour downstaging and increased local control 30,31. 
However, the optimal doses of radiotherapy and chemotherapy of this multimodality 
therapy and the type of 5-FU administration and combination with other cytotoxic 
agents can still be improved.
Our study design has several limitations. Firstly, investigations on post-therapy 
resection specimens have the general limitation that no tumour can be assessed after 
a complete response, especially after neoadjuvant RCT. An added problem of TMA 
evaluation is that after a high degree of tumour regression tumour sampling can 
be problematic. This can obscure the evaluation of the IHC staining patterns in the 
post-therapy specimens. Secondly, the complex interactions between the different 
apoptosis regulating proteins interfere with the analysis of each individual marker 
However, we tried to overcome this problem by adding a multiplevariable statistical 
approach. Numerous reports studying the predictive and prognostic role of apoptosis 
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controlling proteins can be found. However, the clinical implications of these markers 
remain elusive due to conflicting data. Our data shows that the regulating proteins 
did not have prognostic implications and, more importantly, the downstream effect 
of these markers (i.e. apoptosis of tumour cells) was also clinically irrelevant. This 
indicates that the discussion about the individual contributions of the regulation 
proteins is less relevant.
Finally, evaluation of apoptosis with the M30 CytoDEATH antibody detects only 
apoptotic events in tumour cells or normal epithelial cells 32 ;caspase independent 
apoptosis, mitotic catastrophe and apoptosis of stroma cells, caspase independent 
apoptosis are not detected. Other reports for example used the terminal 
deoxynucleotidyl transferase-mediated deoxyuridine triphosphatase-biotin nick-
end-labelling (TUNEL) method 12,33,34 or measured caspase activity 35,36. Evaluation of 
caspase-3 activity, measuring caspase dependant apoptosis in tumour- and stroma 
cells, in patients with rectal cancer indicated that low caspase activity in biopsies 
decreased the risk on LR 35. These findings could indicate that apoptosis in stroma cells 
could be of substantial importance as previously described by others 37. However, fresh 
frozen tissues are required for this assays which were unfortunately not available in 
the present patient population. 
In the present study we investigated the effect of apoptosis and 5 apoptosis regulating 
proteins on prognosis and tumour regression in patients with LARC. We studied the 
effect of apoptosis in patient with LARC by quantifying M30 positive tumor cells 
and semi-quantitatively analysing p53, Bcl-2, Bax, Cox-2 and maspin. Subsequently 
we analysed these data in both pre-and post-therapy tumour and normal tissues in 
a multiple variable fashion in a well characterized population of 201 patients with 
LARC. The data show that apoptosis of tumour cells does not predict local control or 
tumour regression in LARC patients. This indicates that, in contrary to short-term RT, 
the success of long-term RCT does not depend on this parameter since RCT is also 
effective in tumours with high intrinsic levels of apoptosis. This could suggest that the 
multimodality RCT regiment can adequately manage heterogeneity with respect to 
intrinsic levels of apoptosis.
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Background
The incidence of colorectal cancer is rising in Western countries. In the Netherlands, 
10000 patients are diagnosed with colorectal cancer each year. Patients’ prognosis re-
lies on a number of tumor and treatment-related factors. Tumor stage, type and grade 
are among the first group. The circumferential margin (CRM), defined as the smallest 
distance between the plane of resection and tumor invasion trough the bowel wall, is a 
treatment-related prognostic factor. The majority of colorectal cancer patients under-
go surgery combined with with neoadjuvant (pre operative) or adjuvant (post opera-
tive) therapy. Depending on the tumor sites (colon or rectum), stage, estimation of the 
CRM and other high risk factors, this (neo)adjuvant therapy consists of radiotherapy, 
chemotherapy or a combination of radio and chemotherapy.
Therapy-related tumor response also influences prognosis and can therefore be con-
sidered as a treatment related prognostic factor. The genetic profile of the tumor and 
the expression of proteins like cyclooxygenase-2 (Cox-2) and thymidylate synthase (TS) 
can influence the extent of response. This thesis describes several different pathologi-
cal and biological aspects of colorectal cancer treatment. In order to achieve this, three 
different patient populations have been studied:
1  Patients enrolled in the Total Mesorectal Excision (TME) trial. These patients were 
  diagnosed with a mobile (T1-T3) rectum carcinoma and were randomized for 
  either standardized TME surgery alone or short term radiotherapy (5X5 Gy) 
  followed by a TME.
2  Patients with a locally advanced rectum carcinoma (LARC). These patients were 
  diagnosed with an advanced, fixed rectal carcinoma (late T3-T4) and received long 
  term radio(chemo)therapy.
3  Patients with stage III colon carcinoma who received adjuvant 5-Fluorouracil 
  (5-FU) based chemotherapy.
summary
chapter 1 describes the effects of the changed treatment approach of rectal cancer 
on the prediction of patients’ prognosis. The introduction of Total Mesorectal Excision 
(TME) surgery and enhanced neoadjuvant therapies have improved patients’ progno-
sis drastically, as has been shown by several prospective randomized trials. However, 
tumor staging did not change and is still based on tumor-related prognostic factors. 
Modern staging should at least be partially based on treatment-related factors. In the 
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current era of neoadjuvant therapy, the value of the circumferential margin (CRM) is 
more important for the staging of rectal tumors than classic tumor-related prognostic 
factors such as T stage (tumor invasion depth).
The analyses of the TME trial indicating that the CRM should be included in modern 
staging of rectal cancer are described in chapter 2. The classic Tumor Node Metastasis 
(TNM) staging system is based solely on tumor-related prognostic factors. Univariate 
and multivariable analysis of overall survival demonstrate that NCRM staging, based 
on the CRM lymph node (N) stage, leads to a better prediction of patients’ survival than 
the conventional TNM system. These findings were validated in an independent data 
set of patients who participated in another prospective randomized trial. This chapter 
concludes that combining of treatment with tumor-related prognostic factors provides 
more information on patients’ prognosis than staging solely based on tumor-related 
factors.
chapter 3 deals with the prognostic implications of the CRM in a population of pa-
tients with locally advanced rectal cancer (LARC). All LARC patients presented with a 
threatened CRM (less than 2mm on magnetic resonance imaging (MRI)) and received 
radio(chemo)therapy (RCT) in order to improve local control. This chapter investigates 
which factors are the best indicators for survival or local recurrence after the intense 
RCT regiment. Histopathological factors and four different systems for assessing tu-
mor regression are evaluated. The data show that the CRM is the most important prog-
nostic factor after RCT. The prognostic implications of tumor regression are dependent 
on the CRM but after a higher degree of tumor regression, a free CRM can be obtained 
more easily. Tumor regression improves local control provided that a free CRM can be 
obtained.
After describing the different pathological aspects of rectal cancer treatment in chap-
ter 1-3, several biological aspects will discussed in chapters 4-7. chapter 4 describes the 
epithelial cell adhesion molecule (Ep-CAM) at the invasive front of colorectal cancers. 
Immunohistochemical experiments using three different antibodies directed against 
different epitopes of Ep-CAM link the loss of extracellular Ep-CAM with an increased 
migratory potential and tumor budding. Investigations of patients of the TME trial 
show that loss of extracellular Ep-CAM is significantly related to increased local recur-
rence rates and tumor budding at the invasive front. Additional results suggest that 
cleavage of Ep-CAM under influence of β-catenin causes internalisation of the protein 
remnants.
chapter 5 studies the clinical relevance and underlying biological mechanisms of signet 
ring cell differentiation in mucinous rectal carcinomas. The presence of signet ring cells 
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in mucinous tumors is relatively rare, and its molecular background poorly understood. 
Several cell lines with different phenotypes are studied with Multiplex Ligation-de-
pendent Probe Amplification (MPLA); this revealed that the Bcl-2 gene is amplified in 
cell lines with a mucinous phenotype and not in cell lines with a non-mucinous pheno-
type. Immunohistochemistry shows that signet ring cells are strongly positive for ITF 
and MUC2 and have declined levels of E-cadherin and β-catenin. Investigations on the 
clinical relevance showed that signet ring cell differentiation is associated with a poor 
prognosis.
The prognostic and value of cyclooxygenase-2 (Cox-2) in rectal carcinomas is described 
in chapter 6. Cox-2 is involved in the production of prostaglandins and plays an im-
portant role in tumor development. Immunohistochemical assessment of Cox-2 is per-
formed on tumor tissues obtained from patients of the TME trial. Irradiated patients 
demonstrate higher levels of Cox-2 in their tumors than patients who did not receive 
radiotherapy. Tumors with increased Cox-2 levels have significantly lower levels of ap-
optosis than patients with less Cox-2 expression. Furthermore, increased Cox-2 levels 
are associated with a poor overall and distant metastasis free survival. However, this 
only applies for patients who received short term radiotherapy. This chapter ends with 
the proposal that the administration of Cox-2 inhibitors during radiotherapy could im-
prove patients’ prognosis.
chapter 7 studies the predictive value of thymidylate synthase (TS) in stage III colon 
cancer at the DNA and protein level. TS is the target enzyme of 5-Fluorouracil (5-FU) 
which is the major component of the adjuvant chemotherapy administered to this pa-
tient population. Three functional polymorphisms and amplification of the TS gene 
are investigated with PCR. Immunohistochemistry was used to study TS at the pro-
tein level. The results demonstrate that the variable number of tandem repeats (VNTR) 
polymorphism in normal tissue is predictive for distant recurrence free survival and 
cancer specific survival. Patients homozygous for the double repeat (2R/2R) are found 
to have a favourable prognosis. Evaluations at the protein level are not associated with 
patients’ outcome. This chapter concludes that analysis of TS at the DNA level has a 
higher predictive value than analysis at the protein level.
chapter 8 describes the prognostic value of apoptosis and five apoptosis regulating pro-
teins (p53, Bcl-2, Bax, Cox-2 and maspin) in LARC patients who received RCT. immu-
nohistochemistry was performed on pre-therapy and post-therapy tissues. Apoptosis is 
investigated with the M30 antibody. Apoptosis or the related proteins (p53, Bcl-2, Bax 
and Cox-2) are not related with survival or local recurrence in this population. A strong 
cytoplasmatic staining pattern of maspin in pre-treatment biopsies significantly corre-
lates with an increased risk on local recurrence but is not associated with survival. These 
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data lead to the conclusion that success of RCT in patients with LARC is independent of 
the intrinsic levels of apoptosis or the apoptosis regulating proteins studied.
conclusions and future research
In this thesis several different studies related to treatment of colorectal cancer are de-
scribed. Investigations of the pathological aspects were performed on patients with 
rectal cancer. These studies indicate that the CRM is an important prognostic factor in 
patients with mobile rectal cancer and with a more advanced rectal tumor (LARC). The 
CRM should therefore be part of modern staging of rectal cancer. The value of tumor 
staging based on the CRM needs to be validated in future randomized trials before this 
can be incorporated into clinical practice.
The biological aspects that are described in this thesis indicate that adhesion molecules 
such as Ep-CAM, E-Cadherin and β-catenin play a role in respectively tumor budding 
and signet ring cell development in mucinous rectal cancers. Investigations on Ep-CAM 
(chapter 4) indicate that cleavage of this protein occurs. Additional studies with for ex-
ample cell lines could further elucidate this and could shed some light on the temporal 
aspects of this process. Studies on Cox-2 (chapter 6) suggest that the administration of 
Cox-2 inhibitors during short term radiotherapy could have an advantageous effect on 
survival and distant recurrence free survival of patients with rectal carcinoma. In order 
to further investigate this, a prospective randomized study should be conducted. How-
ever, the administration of selective Cox-2 inhibitors is nowadays controversial since 
the publication of the cardiovascular side effects of Rofecoxib. 
A currently important research field aims to identify prognostic biomarkers or biomar-
kers predictive for therapy response. Numerous studies have tried to identify these 
markers in tumor tissue but the number of tissue-based markers that is currently used 
for colorectal cancer in clinical practice is disappointingly low. Investigations on TS, mi-
crosatellite instability (MSI), p53, K-ras and deleted in colon cancer (DCC) revealed that 
there is insufficient evidence to recommend routine use of these markers as predictive 
or prognostic tools in colorectal cancer. The studies described in this thesis have inves-
tigated the predictive potential of TS (chapter 7) and apoptosis (chapter 8) for patients 
with colon cancer and LARC respectively. The predictive value of apoptosis seems to 
be modest; tumor response to RCT is independent of this parameter. The VNTR poly-
morphism of the TS gene appears to be a promising marker but since this conclusion is 
based on analyses in a small number of patients, it would be highly desirable to include 
this analysis in future clinical trial.
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achtergrond
De incidentie van dikkedarm-(colon) en endeldarm- (rectum) kanker in de Westerse 
landen is stijgende. In Nederland worden ieder jaar ongeveer 10.000 patiënten gedi-
agnosticeerd met colorectale kanker. De prognose na deze diagnose hangt af van een 
aantal tumor- en behandelingsgerelateerde factoren. Onder de eerst genoemde groep 
vallen het tumor stadium, type en de differentiatie graad. De circumferentiele marge 
(CRM), de kleinste afstand tussen het chirurgische snijvlak en de tumor ingroei in de 
darmwand, is een voorbeeld van een behandelingsgerelateerde factor. De behandeling 
van colorectale tumoren bestaat voor de meerderheid van de patiënten uit chirurgie in 
combinatie met adjuvante (na de operatie) en neoadjuvante (voor de operatie) thera-
pie. Deze (neo)adjuvante therapie kan bestaan uit radiotherapie, chemotherapie of een 
combinatie van radio- en chemotherapie afhankelijk van de tumor lokalisatie (colon of 
rectum), het tumor stadium, de inschatting van de CRM en andere risico factoren. 
De reactie van de tumor op deze behandeling heeft vervolgens ook weer invloed op de 
prognose en kan derhalve beschouwd worden als een behandelingsgerelateerde fac-
tor. In welke mate een tumor reageert op de toegediende therapie kan onder andere af 
hangen van het genetische profiel van de tumor en van de expressie van eiwitten zoals 
bijvoorbeeld cyclooxygenase-2 (Cox-2) en thymidylaat synthase (TS). Dit proefschrift 
beschrijft verschillende pathologische en biologische aspecten die een rol spelen bij de 
behandeling van colorectale tumoren. Daartoe zijn verschillende patiënten groepen be-
studeerd:
1  Patiënten die geïncludeerd zijn in de RT+TME trial. Deze patiënten hebben een 
  mobiel (T1-vroeg T3) rectum carcinoom en zijn gerandomiseerd voor wel of geen 
  kortdurende neoadjuvante radiotherapie (RT) gevolgd door gestandardisserde 
  “Totale Mesorectale Excisie” (TME) chirurgie. 
2  Patiënten met een lokaal voortgeschreden rectumcarcinoom (LARC). De tumoren 
  van deze patiënten populatie waren op het moment van diagnose in een 
  vergevorderd stadium (late T3 en T4). Al deze patiënten hebben derhalve 
  neoadjuvante langdurige radio(chemo)therapie ontvangen. 
3  Patiënten met een stadium III colon carcinoom die allen adjuvante 5-Fluorouracil 
  (5-FU) gebaseerde chemotherapie hebben gehad.
samenVatting
hoofdstuk 1 bediscussieert de invloed van de ontwikkelingen in de behandeling van 
het rectum carcinoom op de voorspelling van de prognose. Veranderingen in de behan-
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deling van het rectum zoals de introductie van de “Totale Mesorectale Excisie” (TME) 
chirurgische techniek en de introductie en verbetering van neoadjuvante behandelingen 
hebben de prognose van patiënten met een rectum carcinoom sterk verbeterd, zoals 
de laatste jaren is aangetoond in vele prospectieve gerandomiseerde trials. Echter de 
stadiëring van tumoren is niet wezenlijk veranderd en berust nog steeds op enkel tumor 
gerelateerde factoren. Moderne stadiëring zou namelijk ook deels moeten berusten op 
de behandelingsgerelateerde prognostische factoren. In dit tijdperk van neoadjuvante 
behandeling is de waarde van de CRM voor de stadiering van rectum tumoren belan-
grijker dan klassieke tumor gerelateerde factoren zoals het T stadium die de mate van 
tumor invasie aangeeft.
In hoofdstuk 2 staan de analyses uit de TME trial beschreven die aantonen dat de CRM 
een belangrijke rol zou moeten spelen in de stadiëring van het rectum carcinoom. Het 
stadiëren van rectum tumoren berust op het zogenaamde “Tumor Node Metastasis” 
(TNM) systeem. Dit systeem is opgebouwd uit tumorgerelateerde prognostische fac-
toren. Univariabele en multivariabele analyses met betrekking tot de overleving van 
patiënten uit de TME trial tonen aan dat de combinatie van het lymfeklier (N) stadium 
en de CRM, resulterend in de NCRM classificatie, leidt tot een betere voorspelling van 
de overleving dan het klassieke TNM systeem. Dit geldt voor zowel de patiënten die niet 
bestraald zijn als de patiënten die wel RT hebben ontvangen (5X5 Gy). Deze bevinding 
werd gevalideerd in een onafhankelijke data set bestaande uit patiënten die hadden 
deelgenomen aan een andere prospectief gerandomiseerde trial. Dit hoofdstuk sluit af 
met de conclusie dat de combinatie van een tumorgerelateerde met een behandelings-
gerelateerde factor meer prognostische informatie geeft dan een classificatie die enkel 
berust op tumor gerelateerde factoren.
In hoofdstuk 3 wordt de prognostische waarde van de CRM voor patiënten met een 
lokaal voortgeschreden rectum carcinoom (LARC) beschreven. Alle LARC patiënten die 
beschreven worden in dit hoofdstuk hebben een bedreigde CRM (kleiner dan 2 mm op 
“magnetische resonantie” (MR) beeldvorming) en hebben radio(chemo)therapie (RCT) 
gehad om de lokale controle te vergroten. In dit hoofdstuk wordt onderzocht welke fac-
toren de beste indicatoren zijn voor de voorspelling van overleving of het optreden van 
een lokaal recidief na dit uitgebreide RCT schema. Histopathologische factoren en vier 
verschillende tumor regressie systemen worden onderzocht. Uit de analyses blijkt dat de 
bepaling van de CRM de belangrijkste prognostische factor is na RCT. De prognostische 
rol van histologische tumor regressie is ondergeschikt aan de CRM, echter een hogere 
mate van tumor regressie resulteert significant vaker in een negatieve CRM. Een goede 
tumor respons op de radiochemotherapie draagt dus wel degelijk bij een het verhogen 
van de lokale controle, mits een vrije CRM verkregen wordt. 
10
Na de pathologische aspecten omtrent de behandeling van rectum tumoren te hebben 
beschreven in hoofdstuk 1 t/m 3 komen de biologische aspecten aan bod in hoofdstuk 
4 t/m 7. hoofdstuk 4 beschrijft het “Epitheliaal Cel Adhesie Molecuul” (Ep-CAM) aan 
het invasieve tumor front van colorectale tumoren. Met behulp van immunohistoche-
mie, waarbij gebruik is gemaakt van drie verschillende anti Ep-CAM antilichamen met 
verschillende epitopen, hebben we aangetoond dat tumor cellen waarbij het extracel-
lulaire deel van het eiwit vermindert aanwezig is een verhoogde invasieve capaciteit 
hebben en zich vaker afsplitsen van ander tumor cellen (tumor budding). Analyses van 
patiënten van de TME trial laten zien dat afname van het extracellulaire Ep-CAM sig-
nificant vaker gepaard gaat met het optreden van tumor budding en een lokaal recidief. 
Verder wordt in dit hoofdstuk beschreven dat er klieving van het Ep-CAM molecuul lijkt 
plaats te vinden aan het invasieve tumor front onder invloed van β-catenine waardoor 
het extracellulaire deel van het eiwit afgesplitst wordt en de rest van het eiwit wordt 
geïnternaliseerd.
In hoofdstuk 5 worden de klinische relevantie en onderliggende biologische mecha-
nismen van de aanwezigheid van zegelringcellen in mucineuze rectum carcinomen be-
schreven. De aanwezigheid van zegelringcellen in mucineuze tumoren is vrij zeldzaam 
en ddaarmee gepaard gaande moleculaire mechanismen zijn nog onbekend. Cellijnen 
met verschillende fenotype zijn onderzocht met behulp van de Multiplex Ligation-de-
pendent Probe Amplification (MPLA) techniek. Uit de resultaten blijkt dat het Bcl-2 gen 
is geamplificeerd in de cellijnen met zegelringcellen en mucineuze fenotypen en niet in 
de cellijnen met het niet-mucineuze fenotype. Veder is met behulp van immunohisto-
chemie aangetoond dat E-cadherine en β-catenine in verminderde mate aanwezig zijn 
in zegelringcellen en dat deze cellen sterk positief zijn voor ITF en MUC2. veder blijkt 
dat de aanwezigheid van zegelringcellen gepaard gaat met een slechtere prognose.
In hoofdstuk 6 wordt de prognostische waarde van het enzym “cyclooxygenase 2” 
(Cox-2), dat betrokken is bij het ontstaan van colorectale tumoren en de productie van 
prostaglandines, voor het rectum carcinoom onderzocht. Hiertoe is patiënten materiaal 
uit de TME trial onderzocht met behulp van immunohistochemische kleuringen tegen 
Cox-2. Hieruit blijkt dat Cox-2 vaker verhoogd aanwezig is in bestraalde patiënten dan 
in onbestraalde patiënten. In tumoren met een verhoogde aanwezigheid van Cox-2 is 
het niveau van apoptose significant lager dan in tumoren met een lagere Cox-2 expres-
sie. Verder blijkt dat een verhoogde aanwezigheid van het Cox-2 enzym geassocieerd 
is met een slechtere prognose (overleving en metastase vrije overleving). Dit is echter 
alleen het geval als patiënten preoperatief bestraald waren. Dit hoofdstuk eindigt met 
de suggestie dat het toedienen van Cox-2 remmers tijdens radiotherapie zou kunnen 
bijdragen aan het voorkomen van het optreden van metastasen en het verlengen van 
de overleving.
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In hoofdstuk 7 wordt de predictieve waarde van Thymidylaat Synthase (TS) bij patiënt-
en met een stadium III colon carcinoom onderzocht op DNA en op eiwit niveau. TS is 
het doelwitenzym van 5-Fluorouracil (5-FU), de belangrijkste component van de ad-
juvante chemotherapie die al de bestudeerde patiënten hebben ontvangen. TS gen 
amplificatie en de verschillende functionele polymorfismen zijn met behulp van PCR 
in kaart gebracht en onderzoek naar TS op eiwit niveau werd met behulp van immu-
nohistochemie uitgevoerd. Uit de analyses blijkt dat het variabele aantal tandem re-
peats (VNTR) polymorfisme in normaal weefsel voorspellend is voor het optreden van 
metastasen en kankerspecifieke overleving. Patiënten die homozygoot zijn voor twee 
herhalingen in de VNTR regio (2R/2R) hebben een gunstige prognose. Uit de analyses 
op eiwit niveau blijkt dat deze niet zijn geassocieerd met overleving of metastase vrije 
overleving. Analyse van TS op DNA niveau lijkt van grotere predictieve waarde te zijn 
dan analyse op eiwit niveau. 
hoofdstuk 8 beschrijft de prognostische waarde van apoptose en vijf apoptose gere-
lateerde eiwitten (p53, Bcl-2, Bax, Cox-2 en maspine) in patiënten met LARC die neo-
adjuvante radiochemotherpapie hebben ontvangen. Onbehandelde biopten en post-
therapie resectie preparaten zijn onderzocht met behulp van immunohistochemie. 
Apoptose is geëvalueerd met behulp van het M30 antilichaam. Uit de resultaten valt 
af te leiden dat zowel apoptose als de apoptose gerelateerde eiwitten (p53, Bcl-2, Bax 
en Cox-2) niet gerelateerd zijn met overleving of het optreden van een lokaal recidief 
in deze populatie. Een sterke cytoplasmatische aankleuring van het maspine eiwit in 
de biopten was significant gecorreleerd met een hoger risico op het optreden van een 
lokaal recidief maar niet met overleving. Hieruit kan geconcludeerd worden dat het suc-
ces van radiochemotherapie in patiënten met LARC niet bepaald wordt door het intrin-
sieke niveau van apoptose of van een van de apoptose gerelateerde eiwitten.
conclusies en toekomstig onderzoek
In dit proefschrift zijn verschillende studies beschreven die betrekking hebben met de 
behandeling van colorectale tumoren. De studies aangaande de pathologische aspecten 
zijn uitgevoerd op verschillende patiënten populaties met een rectum carcinoom. Deze 
studies wijzen uit dat de CRM een grote prognostische waarde heeft. Dit geldt zowel 
voor patiënten met een mobiel rectum carcinoom als patiënten met een voortgeschre-
den rectum carcinoom (LARC). Derhalve zou de CRM als behandelingsgerelateerde 
factor opgenomen moeten worden in de moderne stadiëring van rectum tumoren. De 
waarde van stadiëring die mede berust op de CRM zal in toekomstige gerandomiseerde 
trials gevalideerd moeten worden alvorens deze daadwerkelijk opgenomen zal worden 
in de kliniek.
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De biologische aspecten die in dit proefschrift beschreven zijn geven aan dat adhesie 
moleculen zoals Ep-CAM en E-cadherine een rol spelen bij respectievelijk tumor bud-
ding en het ontstaan van zegelringcellen in mucineuze tumoren. De studie naar Ep-CAM 
(hoofdstuk 4) geeft aanwijzingen voor klieving van het eiwit maar additionele studies 
met bijvoorbeeld cellijnen zouden dit, en met name het tijdgebonden aspect, verder 
kunnen verhelderen. De studie naar Cox-2 (hoofdstuk 6) geeft aan dat de toevoeging 
van Cox-2 remmers tijdens kortdurende radiotherapie een gunstige invloed zou kunnen 
hebben op de overleving en metastasevrije overleving van patiënten met een rectum 
carcinoom. Om dit te bestuderen zou een prospectieve studie opgezet moeten worden 
waarbij gerandomiseerd wordt tussen wel of geen toediening van deze remmers. Ech-
ter, het toedienen van Cox-2 remmers is redelijk omstreden geraakt vanwege de vrij 
ernstige cadiovasculaire bijwerkingen van de selectieve Cox-2 remmer rofecoxib. 
Een belangrijk actueel onderzoeksgebied heeft als doel om prognostische biomarkers 
en voorspellend biomarkers voor de respons op therapie te vinden. Veel studies hebben 
getracht om deze voorspellende markers in tumor weefsel te vinden maar het aantal 
markers wat heden ten dagen in de kliniek wordt gebruikt voor colorectale tumoren is 
teleurstellend laag. Onderzoek naar TS, microsatelliet instabiliteit (MSI), p53, K-ras en 
deleted in colon cancer (DCC) gaf aan dat er onvoldoende bewijs is voor routinematig 
gebruik van deze makers als predicatieve en prognostische handvaten. De studies be-
schreven in dit proefschrift hebben onderzocht in hoeverre TS (hoofdstuk 7) en apop-
tose (hoofdstuk 8) een predictieve waarde hebben voor respectievelijk patiënten met 
een stadium III colon carcinoom en patiënten met LARC. De waarde van voorspellende 
waarde van intrinsieke apoptose bij patiënten met LARC lijkt zeer gering te zijn, de tu-
mor respons op radiochemotherapie is onafhankelijk van deze parameter . Analyses 
van het VNTR polymorfisme van het TS gen wijzen uit dat dit een interessante marker 
lijkt te zijn maar omdat deze conclusie is gebaseerd op een kleine groep patiënten is het 
een aanbeveling om deze analyse in toekomstige trials zeker niet buiten beschouwing 
te laten.
Summary/Samenvatting
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behaalde zij haar Gymnasium diploma aan het Theresia Lyceum te Tilburg en in 
datzelfde jaar startte zij met haar studie Medische Biologie aan de Radboud Universiteit 
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onderzoek in dienstverband van het Catharina ziekenhuis te Eindhoven. Een groot deel 
van de werkzaamheden zijn uitgevoerd op de Stichting voor Pathologische Anatomie 
en Medische Microbiologie (PAMM) te Eindhoven. Vanaf augustus 2007 t/m juli 2008 
combineerde ze deze werkzaamheden met een baan als docent op Fontys Hogescholen 
te Eindhoven (Instituut voor Toegepaste Natuurwetenschappen). Vanaf augustus 2008 
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dankWoord
10-9-8 
Tien september 2008, zo mijn promotie datum is geprikt. Als je er zo naar kijkt is het 
eigenlijk best een mooie datum, het is namelijk net aftellen. 10, 9, 8……7, 6, 5, 4, 3, 2, 
1, en dan…..gepromoveerd! 
Maar voor het zover is wil ik eerst natuurlijk een aantal mensen bedanken, die 
een belangrijke rol in de totstandkoming van dit proefschrift hebben gespeeld. 
Een proefschrift schrijf je natuurlijk niet alleen! Allereerst wil ik mijn promotor, 
professor Van Krieken bedanken. Beste Han, ik wil je bedanken voor de plezierige 
samenwerking. Jij hebt me laten inzien dat een “negatieve” bevinding in de juiste 
context toch een erg belangrijk resultaat kan zijn. Mijn co-promotor, dr. Rutten ben 
ik ook veel dank verschuldigd. Beste Harm, ik heb grote bewondering voor je visie, 
je doortastendheid en je vakmanschap. Je bent een van de weinige mensen die me, 
hoewel ik je al jaren ken, nog steeds kan verbazen met zijn scherpzinnigheid. Dr. 
Nagtegaal, beste Iris, ik heb het erg getroffen met jou als co-promotor. Jouw kritische 
blik en wetenschappelijke talent zijn onmisbaar geweest voor dit proefschrift. Jij 
hebt me laten zien dat het credo “less is more” mijn concept artikelen vaak sterk 
verbeterde. Tevens wil ik mijn co-promotor dr. Van den Brule niet ongenoemd laten. 
Beste Adriaan, ik wil je bedanken voor het feit jouw deur altijd voor mij open stond . Ik 
heb bewondering voor jouw oog voor detail, iets waar ik zelf af en toe te ongeduldig 
voor ben.
Tijdens mijn promotieonderzoek ben ik op verschillende locaties werkzaam geweest. 
Het leeuwendeel van het werk heb ik uitgevoerd op het laboratorium voor pathologie 
van de stichting PAMM te Eindhoven. Op de afdeling speciale technieken heb ik 
dan ook heel wat uurtjes doorgebracht om onder andere coupes te kleuren en om 
PCR’s uit te voeren. Ik heb altijd met heel veel plezier met jullie op het lab gewerkt 
en gepauzeerd in de koffiekamer! Rens, je bent een echte goeroe op het gebeid van 
de immunohistochemie! Elna, ik heb veel van je geleerd dankzij je grote expertise 
op het gebied van de moleculaire biologie en diagnostiek. Verder wil ik Ingrid, Willy, 
Antje, Marlies, Boudewijn, Mireille, Hanneke, Henk, Mark, Maurice en Toine natuurlijk 
ook bedanken voor hun hulp, interesse in mijn werk en de leuke gesprekken die we 
samen in de loop der jaren hebben gevoerd. Lisette en Elisabeth, ik heb jullie met veel 
plezier begeleid tijdens jullie wetenschappelijke stage, succes met jullie toekomstige 
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loopbaan als arts! Arantza, ik wens je veel succes met je promotie onderzoek. We 
zullen elkaar, hoop ik, nog regelmatig tegenkomen op Fontys! Het gevaar van namen 
noemen is natuurlijk dat je mensen vergeet….. Ik wil naast de afdeling speciale 
technieken ook de medewerkers van de afdelingen histologie, cytologie en het 
secretariaat bedanken voor de prettige samenwerking. Tenslotte wil ik de pathologen 
van het PAMM en in het bijzonder Ivonne, Ineke en Shaira bedanken voor hun hulp. 
Ook Grard en Ignace, chirurgen van het Catharina ziekenhuis, wil ik bedanken 
voor hun medewerking en samenwerking. In Leiden had ik ook mijn “contactjes” 
namelijk Pieter en Elza. Pieter, samen hebben we in hoofdstuk 6 een mooi stuk 
werk afgeleverd. Elza, ik vond het altijd leuk om je tegen te komen op congressen, 
tijdens onze gesprekken kwam dan de “bioloog in ons” vaak naar boven, iets wat 
tussen de artsen minder vaak gebeurt. Valery Lemmens, werkzaam bij het Integraal 
Kankercentrum Zuid (IKZ), wil ik bedanken voor zijn enthousiaste medewerking aan 
hoofdstuk 7.
Voor ik op het Catrien en PAMM terecht kwam heb ik eerst een jaar in Nijmegen 
gewerkt op de afdeling pathologie. Ik heb hier altijd met heel veel plezier gewerkt 
en dit kwam voor een belangrijk deel door de mensen die er werkzaam zijn. 
Bedankt daarvoor! Ik heb “in de wandelgangen” veel leuke gesprekken gevoerd 
met verschillende mensen. Ik denk dan in het bijzonder aan Henry, Marcel, Hans, 
Anita, Kristof, Harold, Léon, Patricia, Bart, Corine, Margit, Elke, Marleen en Miriam 
maar dat wil natuurlijk niet zeggen dat ik dan niemand vergeten ben. Ook op mijn 
kamer was het gezellig en dat kwam voor een groot deel door mijn kamergenoten 
Micha en Jeroen. Beste Micha, ik heb altijd goed met je op kunnen schieten en vaak 
reisden samen weer af naar het Brabantse land. Deze reis werd dan geïnitieerd door 
jouw legendarische woorden: “kom Gosens, hora est!”en dan vertrokken we richting 
het station waar Willem en Robert zich vaak bij ons voegden. Ook mijn andere ex-
kamergenoot Jeroen wil ik noemen. Jeroen, ik heb erg veel van je geleerd, variërend 
van handigheidjes voor de pc tot Jeff Buckley. Hopelijk denk je straks nog aan me als 
Chaam weer eens in het wereldnieuws is. Elisa, bedankt voor je gezelligheid! Zonder 
jouw inspanningen tijdens je stage, had hoofdstuk 5, met zijn prachtige figuren, niet 
in dit boekje gestaan. Cathy, jij hebt me de beginselen van het “kleuren” bijgebracht 
maar ik heb naar mijn idee nog veel meer van je geleerd.
Mijn paranimf Marloes was als het ware mijn “maatje” bij de pathologie. We zaten 
allebei in het GE onderzoek en we konden goed met elkaar opschieten. Ik ben erg blij 
dat jij mijn paranimf bent! Ook nu hebben we nog regelmatig contact, om even bij 
te kletsen of als ik weer eens gebruik wilde maken van jou als “ervaringsdeskundige” 
op promotie-gebied. Mijn andere paranimf, Elleke is mijn “maatje” In Eindhoven. We 
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hebben vanaf het begin af aan erg intensief samen gewerkt en ik mis je wel een beetje 
nu ik ook steeds minder op het Catrien en het PAMM werk. We hebben veel lol gehad 
samen in St. Gallen en in Berlijn! Ik vind het dan ook heel leuk dat jij mijn paranimf wilt 
zijn! Ik sta straks als brunette tussen 2 geweldige blondines! Ik hoop met jullie allebei 
in de toekomst nog contact te houden.
Ik vond het erg leuk dat mijn vrienden erg betrokken waren bij mijn promotie traject 
en daar wil ik ze ook graag voor bedanken. Het laatste half jaar begonnen ze echter 
wel een beetje ongeduldig te worden; ”hé, dr. Goos weet je nu al wanneer ik vrij moet 
nemen voor die promotie!” Mijn ouders wil ik bedanken voor hun onvoorwaardelijke 
steun en hun vertrouwen in mij. Als laatste wil ik Joris, mijn aanstaande, natuurlijk niet 
ongenoemd laten. Lieve Joris, dank je voor je niet aflatende steun en begrip. Als geen 
ander kon je me gerust stellen met de woorden: “het komt allemaal goed schatje”.
Dus toch……
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Chapter 4, Figure 3        
Immunofluoresence 
double staining of the 
invasive margin. A, Ber-
EP4 immunoreactivity. 
B, staining with tumor 
marker cytokeratin 8. C, 
merge, Ber-EP4 staining is 
depicted in red, cytokeratin 
in green. Arrows indicate 
that infiltrating tumor cells 
show a loss of Ber-EP4 
immunoreactivity (original 
magnifications: 100X).
Color figures
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Chapter 4, Figure 4 
Double staining of Ep-CAM (Ber-EP4 epitope) and β-catenin of tumor masses with sprouting tumor 
cells. The Ber-EP4 epitope was visualized with DAB (brown) and β-catenin was displayed with fast blue 
staining (blue); nuclei were counterstained with Nuclear Fast Red. A, Tumor nodule with distinct budding 
of tumor cells which show a nuclear staining pattern of β-catenin and decreased staining of the Ber-
EP4 epitope, arrows (original magnification 100X). This staining pattern of β-catenin was not observed 
centrally in the tumor nodule. B, Budding tumor cells spreading into the mesorectal fat. Isolated tumor 
cells exhibit loss of the Ber-EP4 epitope and nuclear β-catenin, arrow (original magnifications: 100X).
Figure 5: Ep-CAM mRNA in situ hybridization (ISH) and Ber-EP4 immunohistochemistry on serial 
sections. A, Ep-CAM mRNA ISH. B, Ber-EP4 staining of clusters of tumors cells at the tumor front of the 
same tumor area. Tumor cells with decreased Ber-EP4 staining do not present to have lower amounts of 
Ep-CAM mRNA (arrows, original magnifications: 100X).
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Chapter 4, Figure 5 
Ep-CAM mRNA in situ hybridization (ISH) and Ber-EP4 immunohistochemistry on serial sections. A, 
Ep-CAM mRNA ISH. B, Ber-EP4 staining of clusters of tumors cells at the tumor front of the same tumor 
area. Tumor cells with decreased Ber-EP4 staining do not present to have lower amounts of Ep-CAM 
mRNA (arrows, original magnifications: 100X).
Color figures
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Chapter 4, Figure 6                                                                                                         
Immunofluorescence double staining of Ep-CAM with both monoclonal Ber- EP4 and polyclonal 
antibody. A, Normal mucosa of the colon shows a membranous staining pattern with Ber-EP4. B, The 
polyclonal antibody also presents a membranous staining pattern in normal colon mucosa. C. Merge 
Ber-EP4 is visualized in green and the polyclonal antibodies in red, nuclei are counterstained wit DAPI 
(blue). D, An isolated tumor cluster (arrow head) next to a tumor gland (arrow), immunohistochemistry 
was performed with the Ber-EP4 antibody. E, immunohistochemical expression of Ep-CAM evaluated 
with the polyclonal antibody. F, Merge Ber-EP4 is visualized in green and the polyclonal antibody in 
red, nuclei are counterstained wit DAPI (blue). Loss of Ber-EP4 staining intensity is associated with 
a cytoplasmic staining pattern with the polyclonal anti Ep-CAM antibody (original magnifications: 
400X).
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Chapter 5, Figure 1  
Illustration of amplifications 
and deletions of 41 genes 
(divided into four graphs). 
Normal range is between 
0.8 and 1.2 (dotted line). 
Some cell lines showed an 
amplification of more than 2 
in certain genes (*). Genes 
described in results (MYC, 
CDH1, Bcl2) are marked.
Color figures
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Chapter 5, Figure 2                                                                                                                  Illustration 
Illustration of E-cadherin by immunofluorescence staining. The nuclei are represented by the blue 
colour. Subtype clone 36 (transmembrane) is represented by the green colour, subtype HECD-
1 (extracellular) is represented by the red colour. The yellow colour of the normal mucosa (A) 
indicates that both epitopes are still present. (B) A signet ring cell at high magnification (100x), the 
transmembranal epitope is still available, while the extracellular epitope was partly not detected. 
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Chapter 5, Figure 3                                                                                                
 Immunofluorescence illustration of a normal mucosa (A) with goblet cells (arrows) secreting ITF 
(red, arrowheads) into the lumen; (B) signet ring cell showing a strong membranous and cytoplasmic 
staining of β-catenin (green) and weak cytoplasmic staining of ITF; and (C) a signet ring cell showing 
a weak membranous staining of β-catenin and strong cytoplasmic staining of ITF, while β-catenin 
has moved to the nucleus (D).
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Chapter 5, Figure 4                                                                                                                           
    ITF distribution in clustered signet ring cells (A) and solitary signet ring cells (B). Signet ring cells 
were positive for ITF mRNA (C, dark purple) and negative using the sense probe (D, negative control), 
indicating that signet ring cells can produce their own ITF. Expression of MUC2 in normal mucosa (E) 
and solitary signet ring cells (F).
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Chapter 6, Figure 1       
Representative stainings of Cox-2 expression in tissue microarray cores from the 1231 rectal cancer 
specimens evaluated in this study. Figure 1A: Cox-2 negative tumor (score 0). Figure 1B: weak 
diffuse cytoplasmic staining (score 1). Figure 1C: moderate to strong granular cytoplasmic staining 
(score 2). Figure 1D: strong intensity of the staining (score 3). 
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Chapter 7, Figure 1                                                             
Different staining intensities observed after TS IHC with monoclonal antibody TS-106 
(DakoCytomation) in tumor tissue (B, D, F and H) and normal tissue (A, C, E and G), original 
magnifications: 200X. Arrows depict intensely stained immature lymphocytes. Staining intensities of 
0, 1, 2 and 3 are respectively indicated by panel A and B, C and D, E and F and G and H. 
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Chapter 8, Figure 1                                                               
Examples of immunohisto-chemical staining patterns observed after staining with M30 CytoDEATH (A), 
p53 (B), Bcl-2 (C), Bax (D), Cox-2 (E) and maspin (F). The arrows in panel A depict examples of apoptotic 
tumour cells that demonstrate intense staining with the M30 antibody. Original magnifications B-F: 
200X, A: 400X.
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